Original Article
Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
N Engl J Med 1998; 339:1485-1492November 19, 1998
- Abstract
Background
Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of interferon alfa-2b and ribavirin for the initial treatment of patients with chronic hepatitis C.
Methods
We randomly assigned 912 patients with chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribavirin (1000 or 1200 mg orally per day, depending on body weight) for 24 or 48 weeks. Efficacy was assessed by measurements of serum hepatitis C virus (HCV) RNA and serum aminotransferases and by liver biopsy.
Results
The rate of sustained virologic response (defined as an undetectable serum HCV RNA level 24 weeks after treatment was completed) was higher among patients who received combination therapy for either 24 weeks (70 of 228 patients, 31 percent) or 48 weeks (87 of 228 patients, 38 percent) than among patients who received interferon alone for either 24 weeks (13 of 231 patients, 6 percent) or 48 weeks (29 of 225 patients, 13 percent) (P<0.001 for the comparison of interferon alone with both 24 weeks and 48 weeks of combination treatment). Among patients with HCV genotype 1 infection, the best response occurred in those who were treated for 48 weeks with interferon and ribavirin. Histologic improvement was more common in patients who were treated with combination therapy for either 24 weeks (57 percent) or 48 weeks (61 percent) than in those who were treated with interferon alone for either 24 weeks (44 percent) or 48 weeks (41 percent). The drug doses had to be reduced and treatment discontinued more often in patients who were treated with combination therapy.
Conclusions
In patients with chronic hepatitis C, initial therapy with interferon and ribavirin was more effective than treatment with interferon alone.
Media in This Article
Table 1
Base-Line Characteristics of the Patients.Table 2
Virologic and Biochemical Responses at the End of Treatment and Follow-up.Article Activity
- Article
Chronic hepatitis C infection is now recognized as an important health care problem.1 Nearly 4 million Americans are estimated to be infected, and cirrhosis will eventually develop in at least 15 to 20 percent of them.2-5 In the United States, infection with hepatitis C virus (HCV) is a leading cause of chronic liver disease and the most common indication for liver transplantation.1,6
Until recently, interferon alfa was the only therapy available for patients with chronic hepatitis C. However, after 48 weeks of treatment, serum HCV RNA levels are undetectable in only 15 to 20 percent of patients.7-12 Pilot studies of patients who have relapsed and of previously untreated patients suggest that combining interferon with ribavirin is more effective than using interferon alone,13,14 and in a small, placebo-controlled study of previously untreated patients, treatment with interferon and ribavirin for six months was more effective than interferon alone.15
The aims of this study were to compare the safety and efficacy of interferon alone and in combination with ribavirin for the initial treatment of chronic hepatitis C and to determine the optimal duration of combination therapy.
Methods
Selection of Patients
Adult patients were eligible for the study if they were seropositive for HCV RNA on testing with the polymerase chain reaction, had undergone a liver biopsy within one year before entry whose results were consistent with a diagnosis of chronic hepatitis, and had had elevated serum alanine aminotransferase values (more than the upper limit of normal values) for at least six months. Patients with decompensated cirrhosis,16 serum alpha-fetoprotein concentrations of more than 50 ng per milliliter, anemia (hemoglobin concentration, less than 12 g per deciliter in women and less than 13 g per deciliter in men), human immunodeficiency virus infection, psychiatric conditions, seizure disorders, cardiovascular disease, hemophilia, poorly controlled diabetes mellitus, or autoimmune diseases were excluded, as were those who had undergone organ transplantation and those who were unable to practice contraception.
Study Design and Organization
This double-blind, placebo-controlled trial was conducted at 44 centers in the United States. The study was approved by the institutional review board at each center, and all the patients provided written informed consent. We screened 1337 patients, of whom 404 did not meet the inclusion criteria. The remaining 933 patients were randomly assigned to one of four treatment groups, which were balanced for the presence or absence of cirrhosis, pretreatment serum HCV RNA level, and HCV genotype. The analysis was based on the 912 patients who received at least one dose of medicine (21 patients were randomly assigned to a treatment group but did not receive therapy: 13 did not wish to continue, 5 did not meet the entry criteria, and 3 had adverse events before the initiation of therapy). Enrollment began in April 1996, and the trial was completed in March 1998.
The patients were randomly assigned to a treatment group as follows: recombinant interferon alfa-2b (Intron A, Schering-Plough, Kenilworth, N.J.) plus placebo for 24 weeks in the case of 231 patients and for 48 weeks in the case of 225 patients, and the combination of interferon alfa-2b and ribavirin (Rebetron, Schering-Plough) for 24 weeks in the case of 228 patients and for 48 weeks in the case of 228 patients. Interferon alfa-2b was given subcutaneously in a dose of 3 million units three times per week, and ribavirin (or matched placebo) was administered orally twice a day at a total daily dose of 1000 mg for patients who weighed 75 kg or less and 1200 mg for those who weighed more than 75 kg. Both drugs were started and stopped at the same time.
The severity of adverse events was graded as mild, moderate, severe, or life-threatening17; therapy was discontinued after life-threatening events. For severe adverse events other than anemia, the dose of interferon alfa-2b was reduced to 1.5 million units three times a week and the dose of ribavirin was reduced to 600 mg per day. The full dose could be resumed after the event or discontinued if the effect persisted. The dose of ribavirin was reduced to 600 mg per day in patients whose hemoglobin concentrations fell below 10 g per deciliter, and it was discontinued if the concentration fell below 8.5 g per deciliter.
The patients were evaluated as outpatients at weeks 1, 2, 4, 6, and 8 and then every 4 weeks during treatment and 4, 8, 12, and 24 weeks after therapy. Biochemical and hematologic testing was performed by a central laboratory. Serum HCV RNA levels were determined before treatment; during treatment at weeks 4, 12, and 24; at 36 and 48 weeks in the patients who were treated for 48 weeks; and after therapy at weeks 12 and 24. Serum HCV RNA was measured by a reverse-transcription–polymerase-chain-reaction assay with a sensitivity of 100 copies per milliliter (National Genetics Institute, Los Angeles).18 HCV genotyping was performed as previously described.19 Liver biopsy was performed 24 weeks after the end of treatment, and the specimens were analyzed by a single pathologist who was unaware of the patients' identification, treatment regimen, and response and of the timing of the biopsy in relation to treatment.
Assessment of Efficacy
The primary end point was a sustained virologic response, defined as the absence of serum HCV RNA 24 weeks after treatment was completed. Secondary end points were normalization of the serum alanine aminotransferase concentration and histologic improvement. The degree of hepatic inflammation and fibrosis was graded with a modified Knodell Histologic Activity Index.20 The inflammation score was obtained by combining the scores for the first three components of this index: portal, periportal, and lobular inflammation. The scores could range from 0 to 18, with higher scores indicating more severe abnormalities. The degree of fibrosis was graded as 0, no fibrosis; 1, portal fibrosis; 3, bridging fibrosis; or 4, cirrhosis. Histologic improvement was defined as a decrease of at least two points in the inflammation score, as compared with the score for the pretreatment biopsy specimen. The biochemical response and the sustained combined biochemical and virologic response were also assessed.1
Statistical Analysis
The study was designed to have 220 patients per group in order to have a power of 89 percent to detect a difference of 15 percentage points between the rates of sustained virologic response (30 percent vs. 45 percent), at a 5 percent level of significance (with two-sided tests). The treatment responses were compared with the use of Fisher's exact test.21 Changes in the liver-biopsy score within each group were compared with the use of Student's t-tests.21 The relation between pretreatment variables and treatment response was examined by stepwise logistic-regression analysis.22 All P values are two-tailed.
Results
Characteristics of the Patients
The base-line characteristics of the patients in the four groups were similar (Table 1Table 1
Base-Line Characteristics of the Patients.). The proportion of patients with HCV genotype 1 (72 percent) was similar to the proportions in prior reports from the United States.23,24 Virologic Response
At the end of follow-up, the rates of virologic response were higher among the patients who had been treated with interferon and ribavirin for 24 weeks (31 percent) or 48 weeks (38 percent) than among those who had received interferon alone for 48 weeks (13 percent, P<0.001) (Table 2Table 2
Virologic and Biochemical Responses at the End of Treatment and Follow-up.). Increasing the duration of combination therapy from 24 weeks to 48 weeks increased the rate of virologic response from 31 percent to 38 percent (P=0.05). The rates of response at the completion of 24 weeks of therapy were almost twice as high in the combination-therapy group as in the interferon-alone group (53 percent vs. 29 percent, P<0.001), and the respective rates after 48 weeks of therapy were more than twice as high (50 percent vs. 24 percent, P<0.001). Relapse after therapy was less frequent with combination therapy (42 percent at 24 weeks and 24 percent at 48 weeks) than with interferon alone (80 percent at 24 weeks and 46 percent at 48 weeks).In patients who were treated with interferon alone, viral clearance at week 4 was associated with a sustained virologic response, as reported previously.25-27 However, among 51 of the 87 patients (59 percent) who were treated with combination therapy for 48 weeks and who eventually had sustained responses, HCV RNA remained detectable in serum until week 12 or 24 of therapy. Late viral clearance with a subsequent sustained response was also observed in 50 percent of patients (35 of 70 patients) who were treated with interferon and ribavirin for 24 weeks, 23 percent of those (3 of 13 patients) who received interferon alone for 24 weeks, and 52 percent of those (15 of 29 patients) who received interferon alone for 48 weeks.
Biochemical Response
The rate of sustained biochemical response was higher among patients who received interferon and ribavirin for 24 or 48 weeks than among those who received interferon alone for 24 or 48 weeks (Table 2).
The combined rates of sustained biochemical and virologic responses in the groups given interferon and ribavirin were 26 percent (60 of 228 patients) in the group treated for 24 weeks and 34 percent (77 of 228 patients) in the group treated for 48 weeks, as compared with 5 percent (12 of 231 patients, P<0.001) in the group treated with interferon for 24 weeks and 12 percent (27 of 225 patients, P<0.001) in the group treated with interferon for 48 weeks.
Normalization of serum alanine aminotransferase values was associated with undetectable levels of serum HCV RNA in most patients who had sustained virologic responses. Of 199 patients who had a sustained virologic response, 176 (88 percent) had persistently normal serum alanine aminotransferase concentrations. The mean (±SD) elevations of serum alanine aminotransferase after therapy in the remaining 23 patients (12 percent) was 1.6±0.1 times the upper limit of the normal value. Eighteen percent of patients (39 of 215) with a sustained biochemical response had persistently detectable serum HCV RNA. The proportion of patients who had sustained virologic responses among those with a sustained biochemical response was higher in the combination-therapy group as a whole (137 of 155 patients, 88 percent) than in the interferon group as a whole (39 of 60 patients, 65 percent).
Histologic Response
Pretreatment and post-treatment liver-biopsy specimens were available from 670 patients (73 percent). Histologic improvement occurred in all four groups, but it was more common in either combination-therapy group than in the interferon group that was treated for 48 weeks (P<0.001) (Table 3Table 3
Rates of Histologic Response.). The degree of histologic improvement, defined as a decrease in the inflammatory score of at least two points, was greatest in the group given interferon and ribavirin for 48 weeks. Of the 165 patients who had a sustained virologic response and who had pretreatment and post-treatment biopsy specimens available, 142 (86 percent) had a decrease in hepatic inflammation regardless of the treatment regimen. Inflammation also decreased in 194 of 497 patients (39 percent) who had persistent viremia at follow-up. Treatment had no effect on fibrosis.Variables Associated with a Response
Treatment with interferon and ribavirin was the strongest predictor of a response. Sustained virologic response was unrelated to age, sex, body weight, or the estimated duration of disease. The response rates for pretreatment variables known to influence the response to treatment are shown in Table 4Table 4
Rates of Sustained Virologic Response According to Pretreatment Variables and Treatment Group.. Among patients with HCV genotype 1 infection who were treated for 48 weeks, the rate of sustained response for patients who were treated with interferon and ribavirin was four times as high as that in patients who were treated with interferon alone for 48 weeks. Among patients with this genotype, 48 weeks of combination therapy was more beneficial than 24 weeks of combination therapy (46 of 166 patients [28 percent] had a response, as compared with 26 of 164 patients [16 percent]; P=0.01). The response rates for patients with HCV genotype 1a infections and those with genotype 1b infections were similar. Among patients with other HCV genotypes who were treated with combination therapy, the response rates did not vary significantly as a function of the duration of therapy. The results in patients with HCV genotype 2 were similar to those in patients with HCV genotype 3.Regardless of the viral load at base line or the presence of cirrhosis or bridging fibrosis at base line, the response was better in patients who were treated with interferon and ribavirin. Among patients with a high viral load or fibrosis at base line, the response rates were two to five times as high in those who were treated with interferon and ribavirin for either 24 or 48 weeks as in those who were treated with interferon alone for 48 weeks. The response of patients with HCV genotypes other than 1 who were treated with 24 or 48 weeks of combination therapy were similar irrespective of the base-line viral load, whereas the response of patients with HCV genotype 1 and high pretreatment viral loads was better among those who received 48 weeks of combination therapy than among those who received 24 weeks of therapy.
Stepwise logistic-regression analyses revealed that greater efficacy was associated with HCV genotypes other than 1 (P<0.001), a base-line viral load of 2×106 copies per milliliter or less (P<0.001), the absence of cirrhosis at base line (P=0.04), and female sex (P=0.05), in addition to combination treatment (P<0.001) and 48 weeks of therapy (P=0.002).
Safety
Hemoglobin concentrations decreased to less than 10 g per deciliter, necessitating a reduction in the dose of ribavirin, in 8 percent of the patients who were treated with combination therapy (Table 5Table 5
Rates of Discontinuation of Treatment, Dose Reductions, and Other Adverse Events during Treatment.). The mean maximal decrease from base line was 3.1 g per deciliter (range of changes, –7.0 to +0.2) after four weeks of therapy, and this was associated with compensatory reticulocytosis. A reduction in the dose resulted in an increase in hemoglobin concentrations of 1 to 1.5 g per deciliter, and the concentrations were subsequently stable throughout treatment. Both hemoglobin concentrations and reticulocyte counts returned to base line within 4 to 8 weeks after treatment was discontinued at 24 or 48 weeks. The longer duration of therapy was not associated with a significantly higher incidence of reductions in the dose of ribavirin due to anemia. Discontinuation of therapy and transfusion were necessary in one patient with a hemoglobin concentration of less than 10 g per deciliter. Reductions in the dose of ribavirin and subsequent completion of treatment did not affect the rate of sustained response. Leukocyte counts decreased in all groups during therapy, but the mean value remained within the normal range. The mean platelet counts were similar at base line and during therapy, remaining above 100×103 per cubic millimeter in 95 to 98 percent of all patients.Dyspnea, pharyngitis, pruritus, rash, nausea, insomnia, and anorexia were more common with combination therapy than with interferon alone (Table 5). The incidence of side effects was higher after 48 weeks of treatment than after 24 weeks of treatment, regardless of the type of therapy.
The drug doses were reduced because of adverse events other than anemia in 13 percent of patients who were given interferon and ribavirin for 24 weeks and in 17 percent of those who were treated for 48 weeks. Among the patients who were given interferon alone, the dose was reduced in 12 percent of those who were treated for 24 weeks and in 9 percent of those who were treated for 48 weeks. The most frequent reason for the discontinuation of therapy in all groups was emotional disturbance — mainly depression; the frequency of cessation of treatment for depression ranged from 2 to 9 percent in the four groups.
Discussion
The currently approved initial therapy for patients with chronic HCV infection consists of treatment with interferon for at least 48 weeks. The rates of sustained virologic response with this regimen are approximately 15 to 20 percent.7-12 Our results confirm this low response rate.
We found that combination therapy with interferon and ribavirin for either 24 or 48 weeks was superior to therapy with interferon alone with respect to virologic, biochemical, and histologic end points. The higher rates of sustained virologic response were the result of higher rates of response at the end of treatment and, subsequently, lower rates of relapse. Recent reports suggest that similar sustained virologic responses are usually long-lasting (5 to 10 years) and are accompanied by progressive histologic improvement.28,29 In our study, late clearance of HCV RNA from serum during combination therapy was also frequently associated with a sustained response. This phenomenon is uncommon in patients who are treated with interferon alone, which suggests that stopping therapy at week 12 because of persistent viremia, as recently suggested,1,18,30 may not be appropriate in the case of therapy with interferon and ribavirin.
The beneficial effect of combination therapy also extended to subgroups of patients in whom treatment has historically been unsuccessful, such as patients with HCV genotype 1 infection, high pretreatment viral burdens, or advanced fibrosis or cirrhosis. Approximately 70 percent of U.S. patients with chronic HCV have genotype 1 infection, and such patients derived the greatest benefit from combination therapy for 48 weeks, suggesting that HCV genotyping should be considered before treatment is initiated.
Ribavirin, a synthetic guanosine analogue, has actions in vitro against a range of RNA and DNA viruses.31 When given alone to patients with chronic hepatitis C, ribavirin decreases serum aminotransferase concentrations but has no antiviral effect.32-34 Ribavirin has been postulated to inhibit viral-dependent RNA polymerase, the capping structure of viral messenger RNA, and inosine monophosphate dehydrogenase.31 Other immunomodulatory actions may also contribute to the drug's beneficial effects.35 Despite these potential actions, the exact mechanism responsible for the improved response that occurs when ribavirin is combined with interferon is unknown.
Combination therapy was relatively safe, but modifications in the dose and discontinuation of treatment were required more often in patients who received interferon and ribavirin than in those who were treated with interferon alone. Reversible, hemolytic anemia due to ribavirin occurred, as has been previously reported when this drug was given alone.32-34 Patients who are treated with ribavirin should therefore be monitored closely (hemoglobin should be measured two and four weeks after therapy is begun and then as clinically indicated). The symptoms related to treatment with interferon and ribavirin have been reported previously, and there were no synergistic effects. Cough, pruritus, rash, and insomnia, all of which have been associated with the use of other, similar nucleoside analogues, were more common in the patients who received combination therapy.
In summary, in patients with chronic hepatitis C, therapy with interferon and ribavirin is more effective than interferon alone in inducing virologic and histologic improvement, and the combination may therefore be indicated as initial therapy in such patients.
Supported in part by research grants from Schering-Plough Research Institute, Kenilworth, N.J., and Clinical Research Center grants from Massachusetts General Hospital (MO1-RR01066), Scripps Clinic (MO1-RR00833), and the University of Florida (5MO1-RR00082).
Drs. McHutchison, Gordon, Schiff, Shiffman, Lee, Rustgi, and Goodman have served as consultants to Schering-Plough or have been members of the speakers' bureau of this corporation, and Drs. Rustgi, Cort, and Albrecht own stock in the corporation.
Source Information
From the Division of Gastroenterology–Hepatology, Scripps Clinic and Research Foundation, La Jolla, Calif. (J.G.M.); William Beaumont Hospital, Royal Oak, Mich. (S.C.G.); University of Miami, Miami (E.R.S.); Medical College of Virginia, Richmond (M.L.S.); University of Texas Southwestern Medical Center, Dallas (W.M.L.); Georgetown University, Washington, D.C. (V.K.R.); Armed Forces Institute of Pathology, Washington, D.C. (Z.D.G.); and Schering-Plough Research Institute, Kenilworth, N.J. (M.-H.L., S.C., J.K.A.).
Address reprint requests to Dr. McHutchison at Scripps Clinic and Research Foundation, Division of Gastroenterology–Hepatology (203N), 10666 N. Torrey Pines Rd., La Jolla, CA 92037.
The other members of the Hepatitis Interventional Therapy Group are listed in the Appendix.
Appendix
In addition to the authors, the members of the Hepatitis Interventional Therapy Group include the following: L. Balart, Center for Digestive Diseases, New Orleans; K. Benner, Oregon Health Sciences University, Portland; M. Black, Temple University, Philadelphia; S. Caldwell, University of Virginia, Charlottesville; R. Carithers, Jr., University of Washington, Seattle; W. Carey, Cleveland Clinic Foundation, Cleveland; H. Conjeevaram, University of Chicago, Chicago; G. Davis, University of Florida, Gainesville; A. DiBisceglie and B. Bacon, Saint Louis University, St. Louis; J. Dienstag, Massachusetts General Hospital, Boston; D. Dietrich, New York; J. Donovan, University of Nebraska, Omaha; G. Everson, University of Colorado, Denver; R. Gish, California Pacific Medical Center, San Francisco; N. Gitlin, Emory University, Atlanta; J. Gross, Jr., Mayo Clinic, Rochester, Minn.; J. Hoefs, University of California at Irvine, Orange; I. Jacobson, New York; D. Jensen, Rush–Presbyterian–St. Luke's Medical Center, Chicago; P. King, University of Missouri, Columbia; R. Koff, Metro West Medical Center, Framingham, Mass.; E. Krawitt, University of Vermont, Burlington; D. LaBrecque, University of Iowa Hospital and Clinic, Iowa City; K. Lindsay, University of Southern California, Los Angeles; A. Lok, University of Michigan, Ann Arbor; P. Martin, University of California at Los Angeles, Los Angeles; T. Morgan, Veterans Affairs Medical Center, Long Beach, Calif.; R. Perrillo, Ochsner Clinic, New Orleans; J. Rakela, University of Pittsburgh, Pittsburgh; R. Reindollar, Charlotte Clinic for Gastrointestinal and Liver Diseases, Charlotte, N.C.; L. Rossaro, University of New Mexico, Albuquerque; L. Seeff, Veterans Affairs Medical Center, Washington, D.C.; L. Smith, St. Michael's Hospital, Newark, N.J.; C. Smith, Minnesota Clinical Research Center, St. Paul; C. Tamburro, University of Louisville, Louisville, Ky.; J. Vierling, Cedars–Sinai Medical Center, Los Angeles; T. Wright, University of California at San Francisco, San Francisco.
- References
References
1
National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C
CrossRef | Web of Science | Medline2
Alter MJ . Epidemiology of hepatitis C. Hepatology 1997;26:Suppl 1:62S-65S
CrossRef | Web of Science | Medline3
Seeff LB ,Buskell-Bales Z ,Wright EC , et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911
Full Text | Web of Science | Medline4
Tong MJ ,El-Farra NS ,Reikes AR ,Co RL . Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466
Full Text | Web of Science | Medline5
Darby SC ,Ewart DW ,Giangrande PLF , et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431
CrossRef | Web of Science | Medline6
Detre KM ,Belle SH ,Lombardero M . Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996;2:219-2287
Hoofnagle JH ,Di Bisceglie AM . The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356
Full Text | Web of Science | Medline8
Tine F ,Magrin S ,Craxi A ,Pagliaro L . Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991;13:192-199
CrossRef | Web of Science | Medline9
Poynard T ,Bedossa P ,Chevallier M , et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-1462[Erratum, N Engl J Med 1996;334:1143.]
Full Text | Web of Science | Medline10
Poynard T ,Leroy V ,Cohard M , et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-789
CrossRef | Web of Science | Medline11
Lin R ,Roach E ,Zimmerman M ,Strasser S ,Farrell GC . Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: results of the first multicentre Australian trial. J Hepatol 1995;23:487-496
CrossRef | Web of Science | Medline12
Carithers RL Jr ,Emerson SS . Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997;26:Suppl 1:83S-88S
CrossRef | Web of Science | Medline13
Schvarcz R ,Yun ZB ,Sonnerborg A ,Weiland O . Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995;46:43-47
CrossRef | Web of Science | Medline14
Schalm SW ,Hansen BE ,Chemello L , et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-966
CrossRef | Web of Science | Medline15
Reichard O ,Norkrans G ,Fryden A ,Braconier JH ,Sonnerborg A ,Weiland O . Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-87
CrossRef | Web of Science | Medline16
Lindsay KL ,Davis GL ,Schiff ER , et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996;24:1034-1040
Web of Science | Medline17
Miller AB ,Hoogstraten B ,Staquet M ,Winkler A . Reporting results of cancer treatment. Cancer 1981;47:207-214
CrossRef | Web of Science | Medline18
Tong MJ ,Blatt LM ,McHutchison JG ,Co RL ,Conrad A . Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997;26:1640-1645
CrossRef | Web of Science | Medline19
Stuyver L ,Rossau R ,Wyseur A , et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102
CrossRef | Web of Science | Medline20
Goodman ZD ,Ishak KG . Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15:70-81
CrossRef | Web of Science | Medline21
Fleiss JL. The design and analysis of clinical experiments. New York: John Wiley, 1986.
22
Agresti A. Categorical data analysis. New York: John Wiley, 1990.
23
Mutchnick M ,Tamburro C ,Hassanein T , et al. Analysis of HCV RNA concentrations by a multi-cycle RT-PCR assay in 3538 untreated chronic HCV patients: assessment of RNA titer by HCV genotype. Hepatology 1997;26:Suppl:186A-186A abstract.24
Bukh J ,Miller RH ,Purcell RH . Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63
CrossRef | Web of Science | Medline25
Hino K ,Okuda M ,Konishi T ,Ishiko H ,Okita K . Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy. Dig Dis Sci 1995;40:14-20
CrossRef | Web of Science | Medline26
Kleter GE ,Brouwer JT ,Heijtink RA ,Schalm SW ,Quint WG . Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob Agents Chemother 1993;37:595-597
Web of Science | Medline27
Orito E ,Mizokami M ,Suzuki K , et al. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995;46:109-115
CrossRef | Web of Science | Medline28
Marcellin P ,Boyer N ,Gervais A , et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881
Web of Science | Medline29
Lau DT-Y ,Kleiner DE ,Ghany MG ,Schmid P ,Hoofnagle JH . Sustained virologic response to interferon alpha (IFN-α) in chronic hepatitis C is associated with long-term histologic improvement and lack of hepatic HCV RNA. Gastroenterology 1998;114:Suppl:A1284-A1284 abstract.
CrossRef | Web of Science30
McHutchison J ,Blatt L ,Sedghi-Vaziri A ,Russell J ,Schmid P ,Conrad A . Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? J Hepatol 1998;29:362-368
CrossRef | Web of Science | Medline31
Patterson JL ,Fernandez-Larsson R . Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1132-114632
Di Bisceglie AM ,Conjeevaram HS ,Fried MW , et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903
Web of Science | Medline33
Dusheiko G ,Main J ,Thomas H , et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-598
CrossRef | Web of Science | Medline34
Bodenheimer HC Jr ,Lindsay KL ,Davis GL ,Lewis JH ,Thung SN ,Seeff LB . Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-477
CrossRef | Web of Science | Medline35
Ning Q ,Brown D ,Parodo J , et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487-3493
Web of Science | Medline
- Citing Articles (1303)
Citing Articles
1
Virginia Clark, David R. Nelson. (2012) The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver International 32, 103-107
CrossRef2
Ching-Chih Hu, Cheng-Hao Weng, Chih-Lang Lin, Hui-Ching Tien, Yen-Lin Kuo, Cheng-Hung Chien, Cho-Li Yen, Chun-Yen Lin, Rong-Nan Chien. (2012) Predictors of Changes in Hemoglobin Levels in Patients with Chronic Hepatitis C Treated with Ribavirin Plus Pegylated Interferon-α. Renal Failure1-6
CrossRef3
Alison Jazwinski, Andrew Muir. (2012) IL28B: Implications for Clinical Practice. Current Hepatitis Reports
CrossRef4
M. Rumi, A. Aghemo, G. M. Prati. (2012) Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C. Journal of Viral Hepatitis 19, 37-41
CrossRef5
Anita Arora, Natalia Mendoza, Stephen K. Tyring. 2011. Antiviral Market Overview. .
CrossRef6
N. I. Rallon, J. Morello, P. Labarga, J. M. Benito, S. Rodriguez-Novoa, E. Vispo, P. Barreiro, M. A. Castro, K. Aguirrebengoa, J. A. Pineda, P. Miralles, M. J. Tellez, J. Portu, C. Miralles, A. Ocampo, V. Soriano, . (2011) Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C. Clinical Infectious Diseases 53:12, 1291-1295
CrossRef7
Mohammad A. B. Al-Freah, Zeino Zeino, Michael A. Heneghan. (2011) Management of Hepatitis C in Patients with Chronic Kidney Disease. Current Gastroenterology Reports
CrossRef8
H. E. HARRIS, A. COSTELLA, G. AMIRTHALINGAM, G. ALEXANDER, M. E. B. RAMSAY, N. ANDREWS, . (2011) Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study. Epidemiology and Infection1-8
CrossRef9
Kathleen B. Schwarz. 2011. HCV and the Pediatric Population. , 190-195.
CrossRef10
Fred Poordad, Grace M. Chee. 2011. Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs. , 36-42.
CrossRef11
Fred Poordad, Grace M. Chee. (2011) Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era. Current Gastroenterology Reports
CrossRef12
Moon Young Kim, Mee Yon Cho, Soon Koo Baik, Hong Jun Park, Hyo Keun Jeon, Chong Kun Im, Chan Sik Won, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Min Seob Eom, Seung Hwan Cha, Young Ju Kim, Sei Jin Chang, Samuel S. Lee. (2011) Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. Journal of Hepatology 55:5, 1004-1009
CrossRef13
Donna M. Evon, Denise A. Esserman, Darmendra Ramcharran, Jason E. Bonner, Michael W. Fried. (2011) Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. Journal of Psychosomatic Research 71:5, 349-356
CrossRef14
J. E. Bonner, D. Esserman, D. M. Evon. (2011) Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens. Journal of Viral Hepatitisno-no
CrossRef15
Maria Buti, Maria Homs. (2011) Nuevos agentes para el tratamiento de la hepatitis C. Enfermedades Infecciosas y Microbiología Clínica
CrossRef16
Chung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu. (2011) Chronic hepatitis C infection in the elderly. The Kaohsiung Journal of Medical Sciences
CrossRef17
Jan Paeshuyse, Kai Dallmeier, Johan Neyts. (2011) Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology
CrossRef18
Ahmad Amanzada, Armin Goralczyk, Federico Moriconi, Martina Blaschke, Inga-Marie Schaefer, David Thiel, Sabine Mihm, Giuliano Ramadori. (2011) Ultra-Rapid Virological Response, Young Age, Low γ-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-α2a Monotherapy. Digestive Diseases and Sciences
CrossRef19
Timothy Goh, Rohan Dhillon, Tarun Bastiampillai. (2011) Manic induction with interferon alpha therapy. Australian and New Zealand Journal of Psychiatry1-1
CrossRef20
T. Karamitros, A. Kakkanas, A. Katsoulidou, V. Sypsa, G. Dalagiorgou, P. Mavromara, A. Hatzakis. (2011) Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin. Journal of Viral Hepatitisno-no
CrossRef21
S. Wang, X. Wu, T. Pan, W. Song, Y. Wang, F. Zhang, z. yuan. (2011) Viperin inhibits Hepatitis C Virus replication by interfering with the binding of NS5A to host protein hVAP-33. Journal of General Virology
CrossRef22
Nobuhiko Hiraga, Hiromi Abe, Michio Imamura, Masataka Tsuge, Shoichi Takahashi, C. Nelson Hayes, Hidenori Ochi, Chise Tateno, Katsutoshi Yoshizato, Yusuke Nakamura, Naoyuki Kamatani, Kazuaki Chayama. (2011) Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology 54:3, 764-771
CrossRef23
Maria Ripoli, Valerio Pazienza. (2011) Impact of HCV genetic differences on pathobiology of disease. Expert Review of Anti-infective Therapy 9:9, 747-759
CrossRef24
Joerg-Patrick Stübgen. (2011) Neuromuscular Diseases Associated With Chronic Hepatitis C Virus Infection. Journal of Clinical Neuromuscular Disease 13:1, 14-25
CrossRef25
Chalermrat Bunchorntavakul, K. Rajender Reddy. (2011) Ribavirin: How Does it Work and is it Still Needed?. Current Hepatitis Reports 10:3, 168-178
CrossRef26
Aarthi Chary, Mark Holodniy. (2011) Interferon combination therapy for HIV/hepatitis C virus coinfection. Immunotherapy 3:9, 1087-1102
CrossRef27
Raymond P. Donnelly, Harold Dickensheets, Thomas R. O’Brien. (2011) Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends in Immunology 32:9, 443-450
CrossRef28
Christopher M. Moore, Magdalena George, David H. Thiel. (2011) Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin. Digestive Diseases and Sciences
CrossRef29
Jee-Fu Huang, Chao-Kuan Huang, Ming-Lung Yu, Chia-Yen Dai, Chung-Feng Huang, Wei-Wen Hung, Ming-Lun Yeh, Meng-Hsuan Hsieh, Jeng-Fu Yang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Chern Chen, Shun-Sheng Wu, Wan-Long Chuang. (2011) Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. Hepatology International
CrossRef30
Srikanth Venkatraman, F. George Njoroge. 2011. Intervention of Hepatitis C Replication through NS3-4A, the Protease Inhibitor Boceprevir. , 239-255.
CrossRef31
Christian M. Lange, Simone Susser, Eva Herrmann, Ursula Karey, Tara L. Kieffer, Ann D. Kwong, Janke Schinkel, Henk W. Reesink, Stefan Zeuzem, Christoph Sarrazin. (2011) HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a. Scandinavian Journal of Gastroenterology1-7
CrossRef32
Tohru Noguchi, Akihiro Tamori, Naoki Ogura, Yuji Hori, Satoru Ikeda, Shuhei Nishiguchi. (2011) Investigation of Interferon-α Response by a Single Amino Acid Substitution of Nonstructural Protein 5A in Hepatitis C Virus-Infected Patients. Journal of Interferon & Cytokine Research 31:8, 589-599
CrossRef33
Christian M. Lange, Darius Moradpour, Alexandra Doehring, Hans-Anton Lehr, Beat Müllhaupt, Stephanie Bibert, Pierre-Yves Bochud, Anca T. Antonino, Manuel Pascual, Harald Farnik, Ying Shi, Wolf Otto Bechstein, Christian Moench, Martin-Leo Hansmann, Christoph Sarrazin, Jörn Lötsch, Stefan Zeuzem, Wolf-Peter Hofmann. (2011) Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. Journal of Hepatology 55:2, 322-327
CrossRef34
Maria Buti, Rafael Esteban. (2011) 1990–2010: Two Decades of Interferon-Based Therapy. Clinics in Liver Disease 15:3, 473-482
CrossRef35
S. K. Tohra, S. Taneja, S. Ghosh, B. K. Sharma, A. Duseja, R. K. Dhiman, A. Das, Y. K. Chawla. (2011) Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C. Digestive Diseases and Sciences 56:8, 2449-2455
CrossRef36
Mitchell L. Shiffman. (2011) Interferon-Free Regimens: The Near Future, the Likely and the Not So Likely. Clinics in Liver Disease 15:3, 665-675
CrossRef37
Elisabetta Cariani, Erica Villa, Cristina Rota, Rosina Critelli, Tommaso Trenti. (2011) Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection. Clinical Chemistry and Laboratory Medicine 49:8, 1247-1256
CrossRef38
Andres Duarte-Rojo, Elizabeth Jenny Heathcote, Jordan Jay Feld. (2011) ‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?. Journal of Hepatology 55:2, 466-473
CrossRef39
Jacinta A. Holmes, Paul V. Desmond, Alexander J. Thompson. (2011) Redefining Baseline Demographics: The Role of Genetic Testing in Hepatitis C Virus Infection. Clinics in Liver Disease 15:3, 497-513
CrossRef40
Jawad A. Ilyas, John M. Vierling. (2011) An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C. Clinics in Liver Disease 15:3, 515-536
CrossRef41
Hendrik Jan Thibaut, Armando M. De Palma, Johan Neyts. (2011) Combating enterovirus replication: State-of-the-art on antiviral research. Biochemical Pharmacology
CrossRef42
Shahriar Tavakoli-Tabasi, Ameena Bagree. (2011) A Longitudinal Cohort Study of Mucocutaneous Drug Eruptions During Interferon and Ribavirin Treatment of Hepatitis C. Journal of Clinical Gastroenterology1
CrossRef43
Renato Bonardi, Marco Tabone, Aldo Manca, Rinaldo Pellicano, Alessia Ciancio, Mario Rizzetto. (2011) Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Biomedicine & Pharmacotherapy 65:4, 303-306
CrossRef44
Ajit Kumar. (2011) MicroRNA in HCV infection and liver cancer. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
CrossRef45
C. Krueger, K. Hawkins, S. Wong, M. W. Enns, G. Minuk, J. D. Rempel. (2011) Persistent pro-inflammatory cytokines following the initiation of pegylated IFN therapy in hepatitis C infection is associated with treatment-induced depression. Journal of Viral Hepatitis 18:7, e284-e291
CrossRef46
Adam J. Morgan, Sophia Nguyen, Vinita Uttamsingh, Gary Bridson, Scott Harbeson, Roger Tung, Craig E. Masse. (2011) Design and synthesis of deuterated boceprevir analogs with enhanced pharmacokinetic properties. Journal of Labelled Compounds and Radiopharmaceuticals 54:9, 613-624
CrossRef47
Peter Ferenci. (2011) Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future. Expert Opinion on Drug Safety 10:4, 529-544
CrossRef48
Yoshisato Tanimoto, Hirotaka Tashiro, Hiroshi Aikata, Hironobu Amano, Akihiko Oshita, Tsuyoshi Kobayashi, Shintaro Kuroda, Hirofumi Tazawa, Shoichi Takahashi, Toshiyuki Itamoto, Kazuaki Chayama, Hideki Ohdan. (2011) Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection. Annals of Surgical Oncology
CrossRef49
Teerapol Srichana, Tan Suwandecha. 2011. Polyethylene Glycol in Clinical Application and PEGylated Drugs. , 451-493.
CrossRef50
Gabriel A. Cook, Stanley J. Opella. (2011) Secondary structure, dynamics, and architecture of the p7 membrane protein from hepatitis C virus by NMR spectroscopy. Biochimica et Biophysica Acta (BBA) - Biomembranes 1808:6, 1448-1453
CrossRef51
Stephane Chevaliez, Tarik Asselah. (2011) Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clinics and Research in Hepatology and Gastroenterology 35, S31-S41
CrossRef52
Stefano Brillanti, Giuseppe Mazzella, Enrico Roda. (2011) Ribavirin for chronic hepatitis C: And the mystery goes on. Digestive and Liver Disease 43:6, 425-430
CrossRef53
Riham Salah El Dine, Azza R. Abdel Monem, Ali M. El-Halawany, Masao Hattori, Essam Abdel-Sattar. (2011) HCV-NS3/4A Protease Inhibitory Iridoid Glucosides and Dimeric Foliamenthoic Acid Derivatives from Anarrhinum orientale. Journal of Natural Products 74:5, 943-948
CrossRef54
Chao-Hung Hung, Chuan-Mo Lee, Jing-Houng Wang, Tsung-Hui Hu, Chien-Hung Chen, Chih-Yun Lin, Sheng-Nan Lu. (2011) Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. International Journal of Cancer 128:10, 2344-2352
CrossRef55
Natalie Bzowej, David R. Nelson, Norah A. Terrault, Gregory T. Everson, Lichen L. Teng, Avinash Prabhakar, Michael R. Charlton, . (2011) PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transplantation 17:5, 528-538
CrossRef56
Tesfay Abreha, Yimtubezinash Woldeamanuel, Corinna Pietsch, Melanie Maier, Daniel Asrat, Almaz Abebe, Bereket Hailegiorgis, Abraham Aseffa, Uwe Gerd Liebert. (2011) Genotypes and viral load of hepatitis C virus among persons attending a voluntary counseling and testing center in Ethiopia. Journal of Medical Virology 83:5, 776-782
CrossRef57
Andreas J. Kesel. (2011) Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. European Journal of Medicinal Chemistry 46:5, 1656-1664
CrossRef58
Christian Markus Lange, Jörg Bojunga, Elizabeth Ramos-Lopez, Michael von Wagner, Angela Hassler, Johannes Vermehren, Eva Herrmann, Klaus Badenhoop, Stefan Zeuzem, Christoph Sarrazin. (2011) Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. Journal of Hepatology 54:5, 887-893
CrossRef59
Saba Khaliq, Shah Jahan, Sajida Hassan. (2011) Hepatitis C virus p7: molecular function and importance in hepatitis C virus life cycle and potential antiviral target. Liver International 31:5, 606-617
CrossRef60
F. Cao, M. J. Donlin, K. Turner, X. Cheng, J. E. Tavis. (2011) Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapy. Journal of Viral Hepatitis 18:5, 349-357
CrossRef61
Hiroaki Ikezaki, Norihiro Furusyo, Takeshi Ihara, Takeo Hayashi, Eiichi Ogawa, Kazuhiro Toyoda, Hiroaki Taniai, Mosaburo Kainuma, Masayuki Murata, Jun Hayashi. (2011) Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. Journal of Infection and Chemotherapy
CrossRef62
Hiroshi Aoyama, Kazuyuki Sugita, Masahiko Nakamura, Atsushi Aoyama, Mohammed T.A. Salim, Mika Okamoto, Masanori Baba, Yuichi Hashimoto. (2011) Fused heterocyclic amido compounds as anti-hepatitis C virus agents. Bioorganic & Medicinal Chemistry 19:8, 2675-2687
CrossRef63
Ingrid Imhof, Peter Simmonds. (2011) Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 53:4, 1090-1099
CrossRef64
Hafsa Aziz, Muzaffar Latif Gil, Yasir Waheed, Uzama Adeeb, Abida Raza, Iram Bilal, Muhammad Amin Athar. (2011) Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Infection, Genetics and Evolution 11:3, 640-645
CrossRef65
Mark S. Sulkowski, Curtis Cooper, Bela Hunyady, Jidong Jia, Pavel Ogurtsov, Markus Peck-Radosavljevic, Mitchell L. Shiffman, Cihan Yurdaydin, Olav Dalgard. (2011) Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nature Reviews Gastroenterology & Hepatology 8:4, 212-223
CrossRef66
Elena Vezali, Alessio Aghemo, Massimo Colombo. (2011) Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opinion on Biological Therapy 11:3, 301-313
CrossRef67
Hubert Sung, Michael Chang, Sammy Saab. (2011) Management of Hepatitis C Antiviral Therapy Adverse Effects. Current Hepatitis Reports 10:1, 33-40
CrossRef68
Kimberly A. Forde, K. Rajender Reddy. (2011) Hormones: A Potential Explanation for Differences in Response Rates to Therapy for Chronic Hepatitis C Infection. Gastroenterology 140:3, 776-779
CrossRef69
S. M. Gadalla, L. R. Preiss, M. E. Eyster, J. J. Goedert. (2011) Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia. Journal of Viral Hepatitis 18:3, 161-169
CrossRef70
Nancy Reau, Rohit Satoskar, Helen Te, Amanda DeVoss, Carolyn Elsen, Gautham Reddy, Smruti Mohanty, Donald Jensen. (2011) Evaluation of Early Null Response to Pegylated Interferon and Ribavirin as a Predictor of Therapeutic Nonresponse in Patients Undergoing Treatment for Chronic Hepatitis C. The American Journal of Gastroenterology 106:3, 452-458
CrossRef71
Joshua T Schiffer, John Scott, Lawrence Corey. (2011) A siege of hepatitis: Fighting a defiant virus. Nature Medicine 17:3, 253-254
CrossRef72
Kazuhisa Muraishi, Yuko Sasaki, Tomoko Kato, Chizuko Inada, Yuji Tajiri, Kentaro Yamada. (2011) Classification and characteristics of interferon-related diabetes mellitus in Japan. Hepatology Research 41:2, 184-188
CrossRef73
Chen-Hua Liu, Jia-Horng Kao. (2011) Treatment of hepatitis C virus infection in patients with end-stage renal disease. Journal of Gastroenterology and Hepatology 26:2, 228-239
CrossRef74
Serena Slavenburg, Hanneke W H A Huntjens-Fleuren, Ton S M Dofferhoff, Clemens Richter, Peter P Koopmans, Corrien P W G M Verwey-Van Wissen, Joost P H Drenth, David M Burger. (2011) Ribavirin Plasma Concentration Measurements in Patients With Hepatitis C: Early Ribavirin Concentrations Predict Steady-State Concentrations. Therapeutic Drug Monitoring 33:1, 40-44
CrossRef75
Fred Poordad. (2011) Big Changes Are Coming in Hepatitis C. Current Gastroenterology Reports 13:1, 72-77
CrossRef76
Kathleen B. Schwarz, Regino P. Gonzalez–Peralta, Karen F. Murray, Jean P. Molleston, Barbara A. Haber, Maureen M. Jonas, Philip Rosenthal, Parvathi Mohan, William F. Balistreri, Michael R. Narkewicz, Lesley Smith, Steven J. Lobritto, Stephen Rossi, Alexandra Valsamakis, Zachary Goodman, Patricia R. Robuck, Bruce A. Barton. (2011) The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C. Gastroenterology 140:2, 450-458.e1
CrossRef77
Hao-Zhe Yang, Mei-Ying Pan, Da-Wei Jiang, Yang He. (2011) Synthesis of Janus type nucleoside analogues and their preliminary bioactivity. Organic & Biomolecular Chemistry 9:5, 1516
CrossRef78
Ignatius Y. S. Tang, Natasha Walzer, Nidhi Aggarwal, Ivo Tzvetanov, Scott Cotler, Enrico Benedetti. (2011) Management of the Kidney Transplant Patient with Chronic Hepatitis C Infection. International Journal of Nephrology 2011, 1-10
CrossRef79
Jang Eun Lee, Na Ri Yoon, Jin Dong Kim, Myeong Jun Song, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Sung Won Jeong, Seung Kew Yoon. (2011) Durability of Sustained Virologic Response in Chronic Hepatitis C: Analysis of Factors Related to Relapse after Sustained Virologic Response with Peginterferon Plus Ribavirin Combination Therapy. The Korean Journal of Gastroenterology 57:3, 173
CrossRef80
Marco Carbone, Paul Cockwell, James Neuberger. (2011) Hepatitis C and Kidney Transplantation. International Journal of Nephrology 2011, 1-17
CrossRef81
Sibnarayan Datta, Sidhartha Hazari, Partha K Chandra, Maria Samara¹, Bret Poat, Feyza Gunduz, William C Wimley, Hansjorg Hauser, Mario Koster, Christophe Lamaze, Luis A Balart, Robert F Garry, Srikanta Dash. (2011) Mechanism of HCV's resistance to IFN-α in cell culture involves expression of functional IFN-α receptor 1. Virology Journal 8:1, 351
CrossRef82
Salvatore Petta, Antonio Craxì. (2011) Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. Liver International 31, 36-44
CrossRef83
Rebekah G. Gross, Ira M. Jacobson. 2011. , 65.
CrossRef84
Sajid Ali, Ijaz Ali, Sadiq Azam, Bashir Ahmad. (2011) Frequency distribution of HCV genotypes among chronic hepatitis C patients of Khyber Pakhtunkhwa. Virology Journal 8:1, 193
CrossRef85
Seiji Ishiguro, Manami Inoue, Yasuhito Tanaka, Masashi Mizokami, Motoki Iwasaki, Shoichiro Tsugane. (2011) Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: A population-based cohort study (JPHC Study). Cancer Letters 300:2, 173-179
CrossRef86
Paulo Dias, Judith A Hahn, Eric Delwart, Brian Edlin, Jeff Martin, Paula Lum, Jennifer Evans, Alex Kral, Steve Deeks, Michael P Busch, Kimberly Page. (2011) Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infectious Diseases 11:1, 208
CrossRef87
Usman Ashfaq, Tariq Javed, Sidra Rehman, Zafar Nawaz, Sheikh Riazuddin. (2011) Inhibition of HCV 3a core gene through Silymarin and its fractions. Virology Journal 8:1, 153
CrossRef88
Ed Gane. 2011. , 140.
CrossRef89
Usman A Ashfaq, Muhammad S Masoud, Zafar Nawaz, Sheikh Riazuddin. (2011) Glycyrrhizin as antiviral agent against Hepatitis C Virus. Journal of Translational Medicine 9:1, 112
CrossRef90
L. Arnaud, G. Gorochov, F. Charlotte, V. Lvovschi, C. Parizot, M. Larsen, P. Ghillani-Dalbin, B. Hervier, J.-E. Kahn, C. Deback, L. Musset, Z. Amoura, J. Haroche. (2011) Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 117:10, 2783
CrossRef91
Akio Miyasaka, Juichi Sakamoto, Shinsaku Fukuda, Takashi Goto, Hirohide Ohnishi, Yoshiyuki Ueno, Tooru Shimosegawa, Takafumi Saito, Sumio Kawata, Hiromasa Ohira, Masafumi Komatsu, Koich Abe, Kazuyuki Suzuki, Tohoku Viral Hepatitis Therapy and. (2011) Efficacy of combination therapy of pegylated interferon alfa-2b plus ribavirin for 48 weeks in chronic hepatitis C patients with serotype 1 high viral load: Results of multicenter trial in Tohoku area of Japan. Kanzo 52:10, 652-661
CrossRef92
Jama M. Darling, Stanley M. Lemon, Michael W. Fried. 2011. , 582.
CrossRef93
Maria Guido. 2011. Chronic Hepatitis. , 201-213.
CrossRef94
Dipankar Bhattacharya, Molly A Accola, Israr H Ansari, Rob Striker, William M Rehrauer. (2011) Naturally occurring genotype 2b/1a hepatitis C virus in the United States. Virology Journal 8:1, 458
CrossRef95
Marcello Persico, Savino Bruno, Andrea Costantino, Marta Mazza, Piero Luigi Almasio. (2011) The Impact of Antiviral Therapy and the Influence of Metabolic Cofactors on the Outcome of Chronic HCV Infection. International Journal of Hepatology 2011, 1-8
CrossRef96
Susie H. Park. (2011) Completion of Chronic Hepatitis C Virus Treatment in Interferon-Induced Major Depressive Disorder with Psychotic Features. Psychiatry Investigation 8:4, 381
CrossRef97
Kenneth Kar-Lung Yan, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan. (2010) Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital. Digestive Diseases and Sciences 55:12, 3541-3547
CrossRef98
Magdalena Figlerowicz, Paulina Jackowiak, Piotr Formanowicz, Paweł Kędziora, Magdalena Alejska, Nelli Malinowska, Jacek Błażewicz, Marek Figlerowicz. (2010) Hepatitis C virus quasispecies in chronically infected children subjected to interferon–ribavirin therapy. Archives of Virology 155:12, 1977-1987
CrossRef99
Nitin Nigam, Joshua Hedaya, W R. Freeman. (2010) INTERFERON INDUCED SARCOID UVEITIS WITH PAPILLITIS AND MACULAR EDEMA. Retinal Cases & Brief Reports 3:1, 102-104
CrossRef100
Elena Vezali, Alessio Aghemo, Massimo Colombo. (2010) A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clinical Therapeutics 32:13, 2117-2138
CrossRef101
Abeer Elkady, Yasuhito Tanaka, Fuat Kurbanov, Fuminaka Sugauchi, Masaya Sugiyama, Anis Khan, Elsayed Mostafa Ali, Layla Mouhamed, Sahar Abou el-fetouh, AbdEl-Rahaman AbdEl-Hameed, Masashi Mizokami. (2010) Performance of two Real-Time RT-PCR assays for quantitation of hepatitis C virus RNA: Evaluation on HCV genotypes 1-4. Journal of Medical Virology 82:11, 1878-1888
CrossRef102
Ankur Patel, Allan Siegel, Steven S. Zalcman. (2010) Lack of aggression and anxiolytic-like behavior in TNF receptor (TNF-R1 and TNF-R2) deficient mice. Brain, Behavior, and Immunity 24:8, 1276-1280
CrossRef103
Mario Furlanut, Giorgio Soardo, Debora Donnini, Leonardo Sechi, Loretta Franceschi. (2010) Fluoxetine Disposition in Patients with Chronic Hepatitis C Treated with Interferon-α. Clinical Pharmacokinetics 49:11, 767-772
CrossRef104
Seyed-Moayed Alavian, Bita Behnava, Seyed Vahid Tabatabaei. (2010) Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis. European Journal of Clinical Pharmacology 66:11, 1071-1079
CrossRef105
M. Isabel Fiel. (2010) Pathology of Chronic Hepatitis B and Chronic Hepatitis C. Clinics in Liver Disease 14:4, 555-575
CrossRef106
Naoya Sakamoto, Yasuhito Tanaka, Mina Nakagawa, Hiroshi Yatsuhashi, Shuhei Nishiguchi, Nobuyuki Enomoto, Seishin Azuma, Yuki Nishimura-Sakurai, Sei Kakinuma, Nao Nishida, Katsushi Tokunaga, Masao Honda, Kiyoaki Ito, Masashi Mizokami, Mamoru Watanabe. (2010) ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatology Research 40:11, 1063-1071
CrossRef107
Christian M. Lange, Michael von Wagner, Jörg Bojunga, Thomas Berg, Harald Farnik, Angela Hassler, Christoph Sarrazin, Eva Herrmann, Stefan Zeuzem. (2010) Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin. European Journal of Gastroenterology & Hepatology 22:11, 1303-1307
CrossRef108
Alexandre Pariente, Pierre Lahmek, Christel Duprat, Jacques Denis, Roger Faroux, Christophe Renou, Bernard Nalet, Thierry Morin, Jean-François Cadranel. (2010) Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in ‘true life’. European Journal of Gastroenterology & Hepatology 22:11, 1297-1302
CrossRef109
Tarik Asselah, Emilie Estrabaud, Ivan Bieche, Martine Lapalus, Simon De Muynck, Michel Vidaud, David Saadoun, Vassili Soumelis, Patrick Marcellin. (2010) Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver International 30:9, 1259-1269
CrossRef110
Fred Poordad, Eric Lawitz, Mitchell L. Shiffman, Tarek Hassanein, Andrew J. Muir, Bruce R. Bacon, Jamie Heise, Deanine Halliman, Eric Chun, Janet Hammond. (2010) Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 52:4, 1208-1215
CrossRef111
Marcos V. Carneiro, Fernanda F. Souza, Andreza C. Teixeira, José F.C. Figueiredo, Marcia G. Villanova, Marie Secaf, Afonso Passos, Leandra N.Z. Ramalho, Fabiana P. Carneiro, Sérgio Zucoloto, Ana L. Candolo Martinelli. (2010) The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C. European Journal of Gastroenterology & Hepatology 22:10, 1204-1210
CrossRef112
Debika Bhattacharya, T Umbleja, F Carrat, R T Chung, M G Peters, F Torriani, J Andersen, J S Currier. (2010) Women Experience Higher Rates of Adverse Events During Hepatitis C Virus Therapy in HIV Infection: A Meta-Analysis. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:2, 170-175
CrossRef113
Harald Farnik, Christian M. Lange, Christoph Sarrazin, Bernd Kronenberger, Stefan Zeuzem, Eva Herrmann. (2010) Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clinical Gastroenterology and Hepatology 8:10, 884-890
CrossRef114
N. H. Nguyen, P. VuTien, R. T. Garcia, H. Trinh, H. Nguyen, K. Nguyen, B. Levitt, M. H. Nguyen. (2010) Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6. Journal of Viral Hepatitis 17:10, 691-697
CrossRef115
Catherine François, Véronique Descamps, Etienne Brochot, Isabelle Bernard, Valérie Canva, Philippe Mathurin, Sandrine Castelain, Gilles Duverlie. (2010) Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy. Journal of Medical Virology 82:10, 1640-1646
CrossRef116
Emma Devitt, Matthew W. Lawless, Denise Sadlier, John A. Browne, Caroline Walsh, John Crowe. (2010) Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h. European Journal of Gastroenterology & Hepatology 22:10, 1211-1220
CrossRef117
Paul J. Pockros, Fayez M. Hamzeh, Paul Martin, Ellen Lentz, Xiaolei Zhou, Sugantha Govindarajan, Anna S. Lok. (2010) Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology 52:4, 1193-1200
CrossRef118
Bloom Jonathan, Zapf Christoph, Levin Jeremy, Flint Michael. 2010. Recent Advances in Hepatitis C Therapies. .
CrossRef119
Stanley S. Liu, Terry D. Schneekloth, Jayant A. Talwalkar, W. Ray Kim, John J. Poterucha, Michael R. Charlton, Russell H. Wiesner, John B. Gross. (2010) Impact of Depressive Symptoms and Their Treatment on Completing Antiviral Treatment in Patients With Chronic Hepatitis C. Journal of Clinical Gastroenterology 44:8, e178-e185
CrossRef120
Seyed-Moayed Alavian, Seyed Vahid Tabatabaei, Maryam Keshvari, Bita Behnava, Seyyed Mohammad Miri, Pegah Karimi Elizee, Kamran Bagheri Lankarani. (2010) Peginterferon α-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver International 30:8, 1173-1180
CrossRef121
Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo. (2010) Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C. Nature Reviews Gastroenterology & Hepatology 7:9, 485-494
CrossRef122
Iou-Jiun Kang, Li-Wen Wang, Teng-Kuang Yeh, Chung-Chi Lee, Yen-Chun Lee, Sheng-Ju Hsu, Yen-Shian Wu, Jing-Chyi Wang, Yu-Sheng Chao, Andrew Yueh, Jyh-Haur Chern. (2010) Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors. Bioorganic & Medicinal Chemistry 18:17, 6414-6421
CrossRef123
Mazen Noureddin, Marc G. Ghany. (2010) Pharmacokinetics and Pharmacodynamics of Peginterferon and Ribavirin: Implications for Clinical Efficacy in the Treatment of Chronic Hepatitis C. Gastroenterology Clinics of North America 39:3, 649-658
CrossRef124
Edward J. Gane, Frank Weilert, David W. Orr, Geraldine F. Keogh, Michael Gibson, Michelle M. Lockhart, Christopher M. Frampton, Kenneth M. Taylor, Robin A. J. Smith, Michael P. Murphy. (2010) The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver International 30:7, 1019-1026
CrossRef125
Diana Koletzki, Stéphanie Dumont, Hans Vermeiren, Bart Fevery, Pieter De Smet, Lieven J. Stuyver. (2010) Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay. Clinical Chemistry and Laboratory Medicine 48:8, 1095-1102
CrossRef126
F. Dammacco, F. A. Tucci, G. Lauletta, P. Gatti, V. De Re, V. Conteduca, S. Sansonno, S. Russi, M. A. Mariggio, M. Chironna, D. Sansonno. (2010) Pegylated interferon- , ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 116:3, 343-353
CrossRef127
Francis E. Lotrich, Robert E. Ferrell, Mordechai Rabinovitz, Bruce G. Pollock. (2010) Labile Anger During Interferon Alfa Treatment is Associated With a Polymorphism in Tumor Necrosis Factor α. Clinical Neuropharmacology 33:4, 191-197
CrossRef128
Jordan J. Feld, Glen A. Lutchman, Theo Heller, Koji Hara, Julie K. Pfeiffer, Richard D. Leff, Claudia Meek, Maria Rivera, Myung Ko, Christopher Koh, Yaron Rotman, Marc G. Ghany, Vanessa Haynes–Williams, Avidan U. Neumann, T. Jake Liang, Jay H. Hoofnagle. (2010) Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling. Gastroenterology 139:1, 154-162.e4
CrossRef129
C. M. Lange, C. Sarrazin, S. Zeuzem. (2010) Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Alimentary Pharmacology & Therapeutics 32:1, 14-28
CrossRef130
Erinn S. Kellner, Pui Y. Lee, Yi Li, Juliana Switanek, Haoyang Zhuang, Mark S. Segal, Eric S. Sobel, Minoru Satoh, Westley H. Reeves. (2010) Endogenous type-I interferon activity is not associated with depression or fatigue in systemic lupus erythematosus. Journal of Neuroimmunology 223:1-2, 13-19
CrossRef131
Mina Nakagawa, Naoya Sakamoto, Mayumi Ueyama, Kaoru Mogushi, Satoshi Nagaie, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Hiroshi Tanaka, Nobuyuki Enomoto, Mamoru Watanabe. (2010) Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. Journal of Gastroenterology 45:6, 656-665
CrossRef132
Gabriel A. Cook, Stanley J. Opella. (2010) NMR studies of p7 protein from hepatitis C virus. European Biophysics Journal 39:7, 1097-1104
CrossRef133
Nghia H. Nguyen, Philip VuTien, Huy N. Trinh, Ruel T. Garcia, Long H. Nguyen, Huy A. Nguyen, Khanh K. Nguyen, Mindie H. Nguyen. (2010) Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatology International 4:2, 523-529
CrossRef134
Nazish Bostan, Tariq Mahmood. (2010) An overview about hepatitis C: A devastating virus. Critical Reviews in Microbiology 36:2, 91-133
CrossRef135
Ana-Carolina Cardoso, Rami Moucari, Claudio Figueiredo-Mendes, Marie-Pierre Ripault, Nathalie Giuily, Corinne Castelnau, Nathalie Boyer, Tarik Asselah, Michelle Martinot-Peignoux, Sarah Maylin, Roberto J. Carvalho-Filho, Dominique Valla, Pierre Bedossa, Patrick Marcellin. (2010) Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. Journal of Hepatology 52:5, 652-657
CrossRef136
Yuanfeng Jin, Jinxi Jiang, Tinghuai Ma. (2010) An Agei Method for Solving Four-Order Diffusion Equations. Information Technology Journal 9:5, 1044-1048
CrossRef137
Fabrizio Fabrizi, Vivek Dixit, Piergiorgio Messa, Paul Martin. (2010) Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials. Journal of Medical Virology 82:5, 768-775
CrossRef138
E. Lukasiewicz, M. Gorfine, L. S. Freedman, J.-M. Pawlotsky, S. W. Schalm, C. Ferrari, S. Zeuzem, A. U. Neumann, . (2010) Prediction of nonSVR to therapy with pegylated interferon-α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. Journal of Viral Hepatitis 17:5, 345-351
CrossRef139
Peter L. Franzen, Daniel J. Buysse, Mordechai Rabinovitz, Bruce G. Pollock, Francis E. Lotrich. (2010) Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Research 177:1-2, 240-245
CrossRef140
Kenneth E. Sherman. (2010) Thymosin α 1 for treatment of hepatitis C virus: promise and proof. Annals of the New York Academy of Sciences 1194:1, 136-140
CrossRef141
Su Rin Shin, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Cho, Joon Hyoek Lee, Kwang Cheol Koh, Byung Chul Yoo, Seung Woon Paik. (2010) Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. Journal of Gastroenterology and Hepatology 25:5, 957-963
CrossRef142
Bertram Bengsch, Robert Thimme. (2010) Ribavirin ante portas: Uptake transporters into hepatocytes dissected. Journal of Hepatology 52:4, 469-471
CrossRef143
Y. Miyake, A. Takaki, Y. Iwasaki, K. Yamamoto. (2010) Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Journal of Viral Hepatitis 17:4, 287-292
CrossRef144
Michelle Martinot-Peignoux, Christiane Stern, Sarah Maylin, Marie-Pierre Ripault, Nathalie Boyer, Laurence Leclere, Corinne Castelnau, Nathalie Giuily, Ahmed El Ray, Ana-Carolina Cardoso, Rami Moucari, Tarik Asselah, Patrick Marcellin. (2010) Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51:4, 1122-1126
CrossRef145
Ni. Zhang, Zhengwen. Liu, Qunying. Han, Jinghong. Chen, Yi. Lv. (2010) Xanthohumol enhances antiviral effect of interferon α-2b against bovine viral diarrhea virus, a surrogate of hepatitis C virus. Phytomedicine 17:5, 310-316
CrossRef146
Masahiko Nakamura, Atsushi Aoyama, Mohammed T.A. Salim, Mika Okamoto, Masanori Baba, Hiroyuki Miyachi, Yuichi Hashimoto, Hiroshi Aoyama. (2010) Structural development studies of anti-hepatitis C virus agents with a phenanthridinone skeleton. Bioorganic & Medicinal Chemistry 18:7, 2402-2411
CrossRef147
A. Walker, G. Dunlevy, D. Rycroft, P. Topley, L. J. Holt, T. Herbert, M. Davies, F. Cook, S. Holmes, L. Jespers, C. Herring. (2010) Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Engineering Design and Selection 23:4, 271-278
CrossRef148
Owen T-Y Tsang, Jonpaul S-T Zee, Jacky M-C Chan, Reggie S-T Li, Yee-Man Kan, Francis T-W Li, Fu-Hang Lo, David A Chow, Kent W-L Cheung, Kam-Hon Chan, Yat-Wah Yeung, Fook-Hong Ng, Michael K-K Li, Wai-Keung Kwan, Thomas S-T Lai. (2010) Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. Journal of Gastroenterology and Hepatology 25:4, 766-771
CrossRef149
Srikanth Venkatraman, Francisco Velazquez, Wanli Wu, Melissa Blackman, Vincent Madison, F. George Njoroge. (2010) Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups. Bioorganic & Medicinal Chemistry Letters 20:7, 2151-2155
CrossRef150
Francesco Negro. (2010) Adverse effects of drugs in the treatment of viral hepatitis. Best Practice & Research Clinical Gastroenterology 24:2, 183-192
CrossRef151
Izumi Namiki, Shuhei Nishiguchi, Keisuke Hino, Fumitaka Suzuki, Hiromitsu Kumada, Yoshihito Itoh, Yusuhiro Asahina, Akihiro Tamori, Naoki Hiramatsu, Norio Hayashi, Masatoshi Kudo. (2010) Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatology Research 40:4, 347-368
CrossRef152
Mamta K Jain, Cindy Zoellner. (2010) Role of ribavirin in HCV treatment response: now and in the future. Expert Opinion on Pharmacotherapy 11:4, 673-683
CrossRef153
U. Mihm, W. P. Hofmann, C. Welsch, A. Polta, T. Lengauer, S. Zeuzem, C. Sarrazin, E. Herrmann. (2010) Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome. Journal of Viral Hepatitis 17:3, 217-221
CrossRef154
Brian Rha, David Kimberlin, Richard Whitley. 2010. Antiviral Therapy. , 210-225.
CrossRef155
Eiichi Tomita, Kazuki Ando, Jun-ichi Sugihara, Youichi Nishigaki, Tetsuya Yamada, Ryoko Ando, Masao Takemura, Mitsuru Seishima. (2010) Advantage of IFN-β/α2b same-day administration for ribavirin-intolerant patients with chronic hepatitis C. Hepatology Research 40:3, 261-268
CrossRef156
P. A. Revill, D. S. Bowden, P. A. White. 2010. Viral Genotyping and the Sequencing Revolution. , 40-58.
CrossRef157
Chia-Yen Dai, Chi-Kung Ho, Jee-Fu Huang, Ming-Yen Hsieh, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Ming-Lung Yu, Wan-Long Chuang. (2010) Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan. Journal of Hepatology 52:2, 160-166
CrossRef158
Neelam Mohan, Regino P González-Peralta, Tomoo Fujisawa, Mei-Hwei Chang, Solange Heller, Paloma Jara, Deirdre Kelly, Giorgina Mieli-Vergani, Uzma Shah, Karen F Murray. (2010) Chronic Hepatitis C Virus Infection in Children. Journal of Pediatric Gastroenterology and Nutrition 50:2, 123-131
CrossRef159
Jesper Brok, Lise Lotte Gluud, Christian Gluud, Jesper Brok. 2010. Ribavirin plus interferon versus interferon for chronic hepatitis C. .
CrossRef160
Hirokazu Takahashi, Yuichirou Eguchi, Haruko Uemura, Takuya Inoue, Noriko Oza, Takuya Kuwashiro, Yasunori Kawaguchi, Yasushi Ide, Toshihiko Mizuta, Iwata Ozaki, Shinichirou Soejima, Kazuma Fujimoto. (2010) The utility of natural human interferonβ in a case of chronic hepatitis C with a history of peg-interferonα2a related erythema multiforme. Kanzo 51:3, 112-118
CrossRef161
Makoto Numata, Tatehiro Kagawa, Sei-ichiro Kojima, Shunji Hirose, Naruhiko Nagata, Koichi Shiraishi, Norihito Watanabe, Hirokazu Shiozawa, Yasuhiro Nishizaki, Shigeyuki Motegi, Shinji Takashimizu, Jun-ichiro Kamochi, Mitsuru Wasada, Takashi Ohno, Yoshihiro Tei, Atsushi Nakano, Takuji Yamada, Kazuhiro Atsukawa, Tetsu Watanabe, Tetsuya Mine. (2010) Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C. Hepatitis Research and Treatment 2010, 1-6
CrossRef162
Nobuo Waguri, Koichi Furukawa, Haruo Ikeda, Masahiro Hayashi, Junji Kouhisa, Isamu Hama, Takeshi Yokoo, Tsuneo Aiba, Osamu Yoneyama, Kazuhito Sugimura, Kentaro Igarashi, Satoshi Tsukioka. (2010) A case of hepatitis C related cirrhosis with sustained virological response by a long-term, intermittent use of low-dose natural interferon-alpha. Kanzo 51:1, 6-12
CrossRef163
Maysaa El Sayed Zaki, Niveen Saudy, Amany El Diasty. (2010) Study of Nitric Oxide in Patients with Chronic Hepatitis C Genotype 4: Relationship to Viremia and Response to Antiviral Therapy. Immunological Investigations 39:6, 598-610
CrossRef164
Kazuyuki Sugita, Masanori Baba, Mohammed T. A. Salim, Mika Okamoto, Hiroshi Aoyama, Yuichi Hashimoto, Takashi Misawa. (2010) Synthesis and Anti-Hepatitis C Virus Activity of Morpholino Triazine Derivatives. HETEROCYCLES 81:6, 1419
CrossRef165
Hongju Mao, Honglian Zhang, Hua Zhang, Jianlong Zhao, Zhimeng Lu, Gendi Jin, Shimin Gu, Huimin Wang, Yongzhong Wang. (2010) Clinical evaluation of a colorimetric oligonucleotide chip for genotyping hepatitis C virus. Clinical Biochemistry 43:1-2, 214-219
CrossRef166
Daniel E. Brady, Dawn M. Torres, Jong W. An, John A. Ward, Eric Lawitz, Stephen A. Harrison. (2010) Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized, Multicenter, Open-Label Study. Clinical Gastroenterology and Hepatology 8:1, 66-71.e1
CrossRef167
Yasuhiro Itsui, Naoya Sakamoto, Sei Kakinuma, Mina Nakagawa, Yuko Sekine-Osajima, Megumi Tasaka-Fujita, Yuki Nishimura-Sakurai, Gouki Suda, Yuko Karakama, Kako Mishima, Machi Yamamoto, Takako Watanabe, Mayumi Ueyama, Yusuke Funaoka, Seishin Azuma, Mamoru Watanabe. (2009) Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein. Hepatology 50:6, 1727-1737
CrossRef168
Urtzi Garaigorta, Francis V. Chisari. (2009) Hepatitis C Virus Blocks Interferon Effector Function by Inducing Protein Kinase R Phosphorylation. Cell Host & Microbe 6:6, 513-522
CrossRef169
M. Sato, H. Sueki, M. Iijima. (2009) Repeated episodes of fixed eruption 3âmonths after discontinuing pegylated interferon-α-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Clinical and Experimental Dermatology 34:8, e814-e817
CrossRef170
Florence Legrand-Abravanel, Philippe Colson, Hélène Leguillou-Guillemette, Laurent Alric, Isabelle Ravaux, Françoise Lunel-Fabiani, Magali Bouviers-Alias, Pascale Trimoulet, Marie Laure Chaix, Christophe Hézode, Juliette Foucher, Hélène Fontaine, Anne-Marie Roque-Afonso, Michèle Gassin, Evelyne Schvoerer, Catherine Gaudy, Bruno Roche, Michel Doffoël, Louis D'Alteroche, Sophie Vallet, Yazid Baazia, Bruno Pozzetto, Vincent Thibault, Jean-Baptiste Nousbaum, Dominique Roulot, Henry Coppere, Thierry Poinard, Christopher Payan, Jacques Izopet. (2009) Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. Journal of Medical Virology 81:12, 2029-2035
CrossRef171
Catherine François, Sandrine Castelain, Gilles Duverlie, Dominique Capron, Eric Nguyen-Khac. (2009) Optimizing the treatment of chronic viral hepatitis C. Expert Review of Gastroenterology & Hepatology 3:6, 607-613
CrossRef172
Iou-Jiun Kang, Li-Wen Wang, Sheng-Ju Hsu, Chung-Chi Lee, Yen-Chun Lee, Yen-Shian Wu, Andrew Yueh, Jing-Chyi Wang, Tsu-An Hsu, Yu-Sheng Chao, Jyh-Haur Chern. (2009) Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors. Bioorganic & Medicinal Chemistry Letters 19:21, 6063-6068
CrossRef173
Sylvie Deuffic-Burban, Gérard Babany, Isabelle Lonjon-Domanec, Pierre Deltenre, Valérie Canva-Delcambre, Sébastien Dharancy, Alexandre Louvet, Françoise Roudot-Thoraval, Philippe Mathurin. (2009) Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology 50:5, 1351-1359
CrossRef174
Phillip A Furman, Angela M Lam, Eisuke Murakami. (2009) Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends. Future Medicinal Chemistry 1:8, 1429-1452
CrossRef175
Jesper Brok, Lise Lotte Gluud, Christian Gluud, Jesper Brok. 2009. Ribavirin monotherapy for chronic hepatitis C. .
CrossRef176
I. S. Elefsiniotis, C. Pavlidis, D. Dimitroulopoulos, E. Vezali, C. Mihas, T. Mariolis-Sapsakos, S. Koutsounas, E. Paraskevas, G. Saroglou. (2009) Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity. Journal of Viral Hepatitis 16:10, 738-742
CrossRef177
J. Vignau, O. Costisella, V. Canva, M. Imbenotte, A. Duhamel, M. Lhermitte. (2009) Impact du traitement par interféron α sur le métabolisme du tryptophane chez des patients porteurs d’hépatite C chroniqueRésultats de la phase d’étude pilote sur dix patients. L'Encéphale 35:5, 477-483
CrossRef178
Geoff McCaughan. (2009) Advances in viral hepatitis: 50âyears of Australian gastroenterology. Journal of Gastroenterology and Hepatology 24, S132-S135
CrossRef179
K. R. Reddy, D. Messinger, M. Popescu, S. J. Hadziyannis. (2009) Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. Journal of Viral Hepatitis 16:10, 724-731
CrossRef180
Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo. (2009) Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C. Expert Review of Anti-infective Therapy 7:8, 925-935
CrossRef181
Yasunori Kawaguchi, Toshihiko Mizuta. 2009. Supplementation With High Doses Of Vitamins E And C In Chronic Hepatitis C. , 259-269.
CrossRef182
M. RAHMANI, M. N. TOOSI, K. GHANNADI, G. R. LARI, M. JAZEBI, M. RASOULZADEGAN, F. ALA. (2009) Clinical outcome of interferon and ribavirin combination treatment in hepatitis C virus infected patients with congenital bleeding disorders in Iran. Haemophilia 15:5, 1097-1103
CrossRef183
Yoshiaki Iwasaki, Yasushi Shiratori, Shuhei Hige, Shuhei Nishiguchi, Hitoshi Takagi, Morikazu Onji, Haruhiko Yoshida, Namiki Izumi, Yutaka Kohgo, Kyosuke Yamamoto, Nobuhiro Sato, Akitaka Shibuya, Hidetsugu Saito, Michio Sata, Kazuyuki Suzuki, Shuichi Kaneko, Mitsuhiko Moriyama, Masao Omata. (2009) A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan. Hepatology International 3:3, 468-479
CrossRef184
Yi-Chun Cheng, Chun-Chih Chen, Ai-Sheng Ho, Nan-Ying Chiu. (2009) Prolonged Psychosis Associated With Interferon Therapy in a Patient With Hepatitis C: Case Study and Literature Review. Psychosomatics 50:5, 538-542
CrossRef185
Iou-Jiun Kang, Li-Wen Wang, Sheng-Ju Hsu, Chung-Chi Lee, Yen-Chun Lee, Yen-Shian Wu, Tsu-An Hsu, Andrew Yueh, Yu-Sheng Chao, Jyh-Haur Chern. (2009) Design and synthesis of indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives as novel HCV inhibitors. Bioorganic & Medicinal Chemistry Letters 19:15, 4134-4138
CrossRef186
Srikanth Venkatraman, Wanli Wu, Neng-Yang Shih, F. George Njoroge. (2009) Potent aza-peptide derived inhibitors of HCV NS3 protease. Bioorganic & Medicinal Chemistry Letters 19:16, 4760-4763
CrossRef187
Virginia Clark, David R. Nelson. (2009) Novel Interferons for Treatment of Hepatitis C Virus. Clinics in Liver Disease 13:3, 351-363
CrossRef188
Ilan S. Weisberg, Ira M. Jacobson. (2009) Telaprevir: Hope on the Horizon, Getting Closer. Clinics in Liver Disease 13:3, 441-452
CrossRef189
William W. Shields, Paul J. Pockros. (2009) Ribavirin Analogs. Clinics in Liver Disease 13:3, 419-427
CrossRef190
Hidenori Toyoda, Takashi Kumada, Seiki Kiriyama, Yasuhiro Sone, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Hiroyuki Atsumi, Makiko Takagi, Satoshi Nakano, Takahiro Arakawa, Masashi Fujimori. (2009) Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha. Journal of Medical Virology 81:8, 1354-1362
CrossRef191
N. A. Cannon, M. J. Donlin, L. M. Mayes, A. C. Lyra, A. M. Di Bisceglie, J. E. Tavis. (2009) Evidence for action of ribavirin through the hepatitis C virus RNA polymerase. Journal of Viral Hepatitis 16:8, 595-604
CrossRef192
N. Hiramatsu, T. Oze, T. Yakushijin, Y. Inoue, T. Igura, K. Mochizuki, K. Imanaka, A. Kaneko, M. Oshita, H. Hagiwara, E. Mita, T. Nagase, T. Ito, Y. Inui, T. Hijioka, K. Katayama, S. Tamura, H. Yoshihara, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi. (2009) Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. Journal of Viral Hepatitis 16:8, 586-594
CrossRef193
Philippe A. Gallay. (2009) Cyclophilin Inhibitors. Clinics in Liver Disease 13:3, 403-417
CrossRef194
T. Oze, N. Hiramatsu, T. Yakushijin, M. Kurokawa, T. Igura, K. Mochizuki, K. Imanaka, A. Yamada, M. Oshita, H. Hagiwara, E. Mita, T. Ito, Y. Inui, T. Hijioka, S. Tamura, H. Yoshihara, E. Hayashi, A. Inoue, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi. (2009) Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin. Journal of Viral Hepatitis 16:8, 578-585
CrossRef195
Srikanth Venkatraman, Mellissa Blackman, Wanli Wu, Latha Nair, Ashok Arasappan, Angela Padilla, Stéphane Bogen, Frank Bennett, Kevin Chen, John Pichardo, Xiao Tong, Andrew Prongay, Kuo-Chi Cheng, Viyyoor Girijavallabhan, F. George Njoroge. (2009) Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies. Bioorganic & Medicinal Chemistry 17:13, 4486-4495
CrossRef196
J. de Bruijne, C. J. Weegink, P. L. M. Jansen, H. W. Reesink. (2009) New developments in the antiviral treatment of hepatitis C. Vox Sanguinis 97:1, 1-12
CrossRef197
Naoya Sakamoto, Mamoru Watanabe. (2009) New therapeutic approaches to hepatitis C virus. Journal of Gastroenterology 44:7, 643-649
CrossRef198
C. Li, L. Lu, X. Zhang, D. Murphy. (2009) Entire genome sequences of two new HCV subtypes, 6r and 6s, and characterization of unique HVR1 variation patterns within genotype 6. Journal of Viral Hepatitis 16:6, 406-417
CrossRef199
M. Wada, H. Marusawa, R. Yamada, A. Nasu, Y. Osaki, M. Kudo, M. Nabeshima, Y. Fukuda, T. Chiba, F. Matsuda. (2009) Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. Journal of Viral Hepatitis 16:6, 388-396
CrossRef200
Elena Vezali, Ioannis Elefsiniotis, Constantinos Mihas, Evangelos Konstantinou, George Saroglou. (2009) Thyroid dysfunction in patients with chronic hepatitis C: Virus- or therapy-related?. Journal of Gastroenterology and Hepatology 24:6, 1024-1029
CrossRef201
Shinnosuke Hosoda, Hiroshi Aoyama, Yukinori Goto, Mohammed T.A. Salim, Mika Okamoto, Mariko Hashimoto, Masanori Baba, Yuichi Hashimoto. (2009) Discovery of diphenylmethane analogs as anti-bovine diarrhea viral agents. Bioorganic & Medicinal Chemistry Letters 19:12, 3157-3161
CrossRef202
Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yuzo Miyakawa, Hiromitsu Kumada. (2009) Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads. Digestive Diseases and Sciences 54:6, 1317-1324
CrossRef203
Mika Kurokawa, Naoki Hiramatsu, Tsugiko Oze, Kiyoshi Mochizuki, Takayuki Yakushijin, Nao Kurashige, Yuko Inoue, Takumi Igura, Kazuho Imanaka, Akira Yamada, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Taizo Hijioka, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Michio Kato, Shinichi Kiso, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Norio Hayashi. (2009) Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatology Research 39:5, 432-438
CrossRef204
Hui-Hui Tan, Thomas D. Schiano. (2009) Treatment of hepatitis C in the potential liver transplant recipient. Current Hepatitis Reports 8:2, 81-86
CrossRef205
J.-F. YANG, M.-Y. HSIEH, N.-J. HOU, C.-Y. DAI, J.-F. HUANG, Z.-Y. LIN, S.-C. CHEN, M.-Y. HSIEH, L.-Y. WANG, W.-L. CHUANG, M.-L. YU. (2009) Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. Alimentary Pharmacology & Therapeutics 29:9, 1000-1010
CrossRef206
Mohammad Irshad. (2009) Retracted: Genetic diversity in hepatitis C virus (HCV): A brief review. Reviews in Medical Virology 19:3, NA-NA
CrossRef207
Hoofnagle, Jay H., . (2009) A Step Forward in Therapy for Hepatitis C. New England Journal of Medicine 360:18, 1899-1901
Full Text208
Nina Ebner, Christian Wanner, Bernadette Winklbaur, Christian Matzenauer, Crispa Aeschbach Jachmann, Kenneth Thau, Gabriele Fischer. (2009) Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addiction Biology 14:2, 227-237
CrossRef209
Iou-Jiun Kang, Li-Wen Wang, Chung-Chi Lee, Yen-Chun Lee, Yu-Sheng Chao, Tsu-An Hsu, Jyh-Haur Chern. (2009) Design, synthesis, and anti-HCV activity of thiourea compounds. Bioorganic & Medicinal Chemistry Letters 19:7, 1950-1955
CrossRef210
Harel Dahari, Jennifer E. Layden–Almer, Eric Kallwitz, Ruy M. Ribeiro, Scott J. Cotler, Thomas J. Layden, Alan S. Perelson. (2009) A Mathematical Model of Hepatitis C Virus Dynamics in Patients With High Baseline Viral Loads or Advanced Liver Disease. Gastroenterology 136:4, 1402-1409
CrossRef211
Rubina Mondal, Gennadiy Koev, Tami Pilot-Matias, Yupeng He, Teresa Ng, Warren Kati, Akhteruzzaman Molla. (2009) Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well. Antiviral Research 82:1, 82-88
CrossRef212
Nami Mori, Michio Imamura, Yoshiiku Kawakami, Hiromi Saneto, Tomokazu Kawaoka, Shintaro Takaki, Hiroshi Aikata, Shoichi Takahashi, Kazuaki Chayama, . (2009) Randomized trial of high-dose interferon-α-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. Journal of Medical Virology 81:4, 640-649
CrossRef213
Kisun Ryu, Nam Doo Kim, Seong Il Choi, Cheol Kyu Han, Jeong Hyeok Yoon, Kyoung Tai No, Kyun-Hwan Kim, Baik L. Seong. (2009) Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorganic & Medicinal Chemistry 17:8, 2975-2982
CrossRef214
Jorge André de Segadas-Soares, Cristiane A. Villela-Nogueira, Renata M. Perez, Letícia C. Nabuco, Carlos Eduardo Brandão-Mello, Henrique Sérgio M. Coelho. (2009) Is the Rapid Virologic Response a Positive Predictive Factor of Sustained Virologic Response in all Pretreatment Status Genotype 1 Hepatitis C Patients Treated With Peginterferon-α2b and Ribavirin?. Journal of Clinical Gastroenterology 43:4, 362-366
CrossRef215
Tomokazu Kawaoka, Yoshiiku Kawakami, Keiji Tsuji, Hiroyuki Ito, Mikiya Kitamoto, Shiomi Aimitsu, Hiroiku Kawakami, Soo Cheol Jeong, Michio Imamura, Hiroshi Aikata, Shoichi Takahashi, Kazuaki Chayama. (2009) Dose comparison study of pegylated interferon-α-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial. Journal of Gastroenterology and Hepatology 24:3, 366-371
CrossRef216
Sumalee Thitinan, Jason T. McConville. (2009) Interferon alpha delivery systems for the treatment of hepatitis C. International Journal of Pharmaceutics 369:1-2, 121-135
CrossRef217
Ming-Lung Yu, Wan-Long Chuang. (2009) Treatment of chronic hepatitis C in Asia: When East meets West. Journal of Gastroenterology and Hepatology 24:3, 336-345
CrossRef218
Sarah L. George, Bruce R. Bacon, Elizabeth M. Brunt, Kusal L. Mihindukulasuriya, Joyce Hoffmann, Adrian M. Di Bisceglie. (2009) Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients. Hepatology 49:3, 729-738
CrossRef219
Yoshiki Murakami, Hussein H. Aly, Atsushi Tajima, Ituro Inoue, Kunitada Shimotohno. (2009) Regulation of the hepatitis C virus genome replication by miR-199a
. Journal of Hepatology 50:3, 453-460
CrossRef220
A. K. Silberbogen, E. W. Ulloa, E. A. Janke, D. L. Mori. (2009) Psychosocial Issues and Mental Health Treatment Recommendations for Patients With Hepatitis C. Psychosomatics 50:2, 114-122
CrossRef221
K. Rajender Reddy, David R. Nelson, Stefan Zeuzem. (2009) Ribavirin: Current role in the optimal clinical management of chronic hepatitis C. Journal of Hepatology 50:2, 402-411
CrossRef222
Lei Wan, Yung-Jen Kung, Ying-Ju Lin, Chiu-Chu Liao, Jim J.C. Sheu, Yuhsin Tsai, Hsueh-Chou Lai, Cheng-Yuan Peng, Fuu-Jen Tsai. (2009) Th1 and Th2 cytokines are elevated in HCV-infected SVR(−) patients treated with interferon-α. Biochemical and Biophysical Research Communications 379:4, 855-860
CrossRef223
Ayse L. Mindikoglu, Ram R. Miller. (2009) Hepatitis C in the Elderly: Epidemiology, Natural History, and Treatment. Clinical Gastroenterology and Hepatology 7:2, 128-134
CrossRef224
Daniel P Webster, Paul Klenerman, Jane Collier, Katie JM Jeffery. (2009) Development of novel treatments for hepatitis C. The Lancet Infectious Diseases 9:2, 108-117
CrossRef225
S. Zeuzem, T. Berg, B. Moeller, H. Hinrichsen, S. Mauss, H. Wedemeyer, C. Sarrazin, D. Hueppe, E. Zehnter, M. P. Manns. (2009) Expert opinion on the treatment of patients with chronic hepatitis C. Journal of Viral Hepatitis 16:2, 75-90
CrossRef226
Yasuji Arase, Fumitaka Suzuki, Hitomi Sezaki, Yusuke Kawamura, Yoshiyuki Suzuki, Masahiro Kobayashi, Norio Akuta, Tetsuya Hosaka, Hiromi Yatsuji, Miharu Hirakawa, Mariko Kobayashi, Satoshi Saitoh, Kenji Ikeda, Hiromitsu Kumada. (2009) The Efficacy of Interferon-beta Monotherapy for Elderly Patients with Type C Hepatitis of Genotype 2. Internal Medicine 48:16, 1337-1342
CrossRef227
Ioannis S. Elefsiniotis, Christos Pavlidis, Elena Vezali, Theodoros Mariolis-Sapsakos, Sotirios Koutsounas, George Saroglou. (2009) Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly Viremic Chronic Hepatitis C Patients. Gastroenterology Research and Practice 2009, 1-5
CrossRef228
Srikanth Venkatraman, Wanli Wu, Andrew Prongay, Viyyoor Girijavallabhan, F. George Njoroge. (2009) Potent inhibitors of HCV-NS3 protease derived from boronic acids. Bioorganic & Medicinal Chemistry Letters 19:1, 180-183
CrossRef229
C.-J. CHU, S.-D. LEE, T.-H. HUNG, H.-C. LIN, S.-J. HWANG, F.-Y. LEE, R.-H. LU, M.-I. YU, C.-Y. CHANG, P.-L. YANG, C.-Y. LEE, F.-Y. CHANG. (2009) Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon α-2b plus ribavirin. Alimentary Pharmacology & Therapeutics 29:1, 46-54
CrossRef230
Hiroshi Aoyama, Kumiko Sako, Shinichi Sato, Masahiko Nakamura, Hiroyuki Miyachi, Yukinori Goto, Mika Okamoto, Masanori Baba, Yuichi Hashimoto. (2009) Polymethylated γ-Carbolines with Potent Anti-Bovine Viral Diarrhea Virus (BVDV) Activity. HETEROCYCLES 77:2, 779
CrossRef231
H. Kerzman, M. S. Green, E. Shinar. (2009) Predictors for non-compliance of notified hepatitis C virus-positive blood donors with recommendation to seek medical counselling. Vox Sanguinis 96:1, 20-28
CrossRef232
Mi Na Kim, Ki Tae Yoon, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Chae Yoon Chon, Kwang-Hyub Han. (2009) A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C. The Korean Journal of Hepatology 15:4, 496
CrossRef233
Masato Homma, Hiroyuki Hosono, Yuichi Hasegawa, Yukinao Kohda. (2009) Morphological Transformation and Phosphatidylserine Exposure in Erythrocytes Treated with Ribavirin. Biological & Pharmaceutical Bulletin 32:11, 1940-1942
CrossRef234
Takehide Ogihara, Hideki Katagiri, Tetsuya Yamada, Hirohito Kudo, Junta Imai, Yasushi Ishigaki, Yoshinori Hinokio, Yoko Yamagiwa, Yoshiyuki Ueno, Tooru Shimosegawa, Yoshitomo Oka. (2009) Peginterferon (PEG-IFN) Plus Ribavirin Combination Therapy, but neither Interferon nor PGE-IFN Alone, Induced Type 1 Diabetes in a Patient with Chronic Hepatitis C. Internal Medicine 48:16, 1387-1390
CrossRef235
Natasha Walzer, Steven L Flamm. (2009) Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations. Expert Review of Clinical Pharmacology 2:1, 67-76
CrossRef236
Rajeev Aurora, Maureen J. Donlin, Nathan A. Cannon, John E. Tavis. (2008) Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. Journal of Clinical Investigation
CrossRef237
Wolf Peter Hofmann, Eva Herrmann, Christoph Sarrazin, Stefan Zeuzem. (2008) Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver International 28:10, 1332-1343
CrossRef238
Moisés Diago. (2008) Tratamiento de la infección por el virus de la hepatitis C. Estado actual y perspectivas. Gastroenterología y Hepatología 31:9, 596-605
CrossRef239
Marina Berenguer. (2008) Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 48:5, 1690-1699
CrossRef240
Kristin Johnson, Lisa A. Sargent, Christopher Galizio, Eroboghene E. Ubogu. (2008) Interferon-α-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient. European Journal of Gastroenterology & Hepatology 20:11, 1110-1114
CrossRef241
(2008) Hepatitis and reproduction. Fertility and Sterility 90:5, S226-S235
CrossRef242
Tomasz Pawelczyk, Agnieszka Pawelczyk, Dominik Strzelecki, Jolanta Rabe-Jablonska. (2008) Pegylated interferon α and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. General Hospital Psychiatry 30:6, 501-508
CrossRef243
E. A. Janke, S. McGraw, G. Garcia-Tsao, L. Fraenkel. (2008) Psychosocial Issues in Hepatitis C: A Qualitative Analysis. Psychosomatics 49:6, 494-501
CrossRef244
S GARATTINI. (2008) Is there discrimination in access to therapy for HCV patients?
CrossRef245
Gaetano Scotto, Vincenzina Fazio, Chiara Fornabaio, Alessandra Tartaglia, Rocco Di Tullio, Annalisa Saracino, Gioacchino Angarano. (2008) Peg-Interferon Alpha-2a versus Peg-Interferon Alpha-2b in Nonresponders with HCV Active Chronic Hepatitis: A Pilot Study. Journal of Interferon & Cytokine Research 28:10, 623-630
CrossRef246
Renee Pozza. (2008) Clinical management of HIV/hepatitis C virus coinfection. Journal of the American Academy of Nurse Practitioners 20:10, 496-505
CrossRef247
Jason P Smith. (2008) Treatment Options for Patients with Hepatitis C: Role of Pharmacists in Optimizing Treatment Response and Managing Adverse Events. Pharmacotherapy 28:9, 1151-1161
CrossRef248
M. Gambarin-Gelwan, I. M. Jacobson. (2008) Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C. Journal of Viral Hepatitis 15:9, 623-633
CrossRef249
Sarah Maylin, Michelle Martinot–Peignoux, Rami Moucari, Nathalie Boyer, Marie–Pierre Ripault, Dominique Cazals–Hatem, Nathalie Giuily, Corinne Castelnau, Ana Carolina Cardoso, Tarik Asselah, Cyrille Féray, Marie Hélène Nicolas–Chanoine, Pierre Bedossa, Patrick Marcellin. (2008) Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C. Gastroenterology 135:3, 821-829
CrossRef250
H. Toyoda, T. Kumada, S. Kiriyama, Y. Sone, M. Tanikawa, Y. Hisanaga, A. Kanamori, H. Atsumi, S. Nakano, T. Arakawa, T. Honda, K. Hayashi, Y. Katano, H. Goto. (2008) Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin. Journal of Viral Hepatitis 15:9, 651-658
CrossRef251
Krystle Lang, David B Weiner. (2008) Immunotherapy for HCV infection: next steps. Expert Review of Vaccines 7:7, 915-923
CrossRef252
Brendon Y. Chua, Emily M. Eriksson, Lorena E. Brown, Weiguang Zeng, Eric J. Gowans, Joseph Torresi, David C. Jackson. (2008) A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 26:37, 4866-4875
CrossRef253
Steven W. Ludmerer, Donald J. Graham, Mihir Patel, Kevin Gilbert, Mark Stahlhut, David B. Olsen. (2008) A transient cell-based phenotype assay for hepatitis C NS3/4A protease: Application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV. Journal of Virological Methods 151:2, 301-307
CrossRef254
Karen F Murray, Uzma Shah, Neelam Mohan, Solange Heller, Regino P González-Peralta, Deirdre Kelly, Mei-Hwei Chang, Giorgina Mieli-Vergani, Paloma Jara, Tomoo Fujisawa. (2008) Chronic Hepatitis. Journal of Pediatric Gastroenterology and Nutrition 47:2, 225-233
CrossRef255
Tomoko Fujimoto, Masahiko Tomimatsu, Daijiro Iga, Hitoshi Endo, Kuniaki Otsuka. (2008) Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 23:8pt2, e432-e437
CrossRef256
M SHIFFMAN. (2008) Optimizing the Current Therapy for Chronic Hepatitis C Virus: Peginterferon and Ribavirin Dosing and the Utility of Growth Factors. Clinics in Liver Disease 12:3, 487-505
CrossRef257
Nancy Reau, Stephanos J. Hadziyannis, Diethelm Messinger, Michael W. Fried, Donald M. Jensen. (2008) Early Predictors of Anemia in Patients With Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a (40KD) Plus Ribavirin. The American Journal of Gastroenterology 103:8, 1981-1988
CrossRef258
C. L. Ward, A. Dev, S. Rigby, W. T. Symonds, K. Patel, A. Zekry, J.-M. Pawlotsky, J. G. McHutchison. (2008) Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. Journal of Viral Hepatitis 15:8, 571-577
CrossRef259
S DEUFFICBURBAN, P DELTENRE, A LOUVET, V CANVA, S DHARANCY, A HOLLEBECQUE, J BOITARD, J HENRION, Y YAZDANPANAH, P MATHURIN. (2008) Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France
CrossRef260
Tomohito Hamazaki, Kei Hamazaki. (2008) Fish oils and aggression or hostility. Progress in Lipid Research 47:4, 221-232
CrossRef261
Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Akihide Masumoto, Toshihiro Maruyama, Makoto Nakamuta, Munechika Enjoji, Koichi Azuma, Junya Shimono, Hironori Sakai, Shinji Shimoda, Jun Hayashi, . (2008) Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group. Journal of Gastroenterology and Hepatology 23:7pt1, 1094-1104
CrossRef262
Peter Ferenci, Harald Brunner, Hermann Laferl, Thomas-Matthias Scherzer, Andreas Maieron, Michael Strasser, Gabriele Fischer, Harald Hofer, Martin Bischof, Rudolf Stauber, Michael Gschwantler, Petra Steindl-Munda, Katharina Staufer, Karin Löschenberger, . (2008) A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 47:6, 1816-1823
CrossRef263
M. KUMAR, S. K. SARIN. (2008) Systematic review: combination therapies for treatment-naïve chronic hepatitis B. Alimentary Pharmacology & Therapeutics 27:12, 1187-1209
CrossRef264
I ELEFSINIOTIS, C PAVLIDIS, I KETIKOGLOU, S KOUTSOUNAS, N SCARMEAS, K PANTAZIS, A MOULAKAKIS, E TSIANOS. (2008) Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin. European Journal of Internal Medicine 19:4, 266-270
CrossRef265
Tohru Noguchi, Tomoko Otsubaki, Izuru Ando, Naoki Ogura, Satoru Ikeda, Kunitada Shimotohno. (2008) Isolation and gene analysis of interferon α-resistant cell clones of the hepatitis C virus subgenome. Virology 375:2, 424-432
CrossRef266
Gustine Liu-Young, Michael J. Kozal. (2008) Review: Hepatitis C Protease and Polymerase Inhibitors in Development. AIDS Patient Care and STDs 22:6, 449-457
CrossRef267
Paul Martin, Donald M Jensen. (2008) Ribavirin in the treatment of chronic hepatitis C. Journal of Gastroenterology and Hepatology 23:6, 844-855
CrossRef268
Mindie H. Nguyen, Huy N. Trinh, Ruel Garcia, Gloria Nguyen, Khoa D. Lam, Emmet B. Keeffe. (2008) Higher Rate of Sustained Virologic Response in Chronic Hepatitis C Genotype 6 Treated With 48 Weeks Versus 24 Weeks of Peginterferon Plus Ribavirin. The American Journal of Gastroenterology 103:5, 1131-1135
CrossRef269
E. CHOLONGITAS, G. V. PAPATHEODORIDIS. (2008) Review article: novel therapeutic options for chronic hepatitis C. Alimentary Pharmacology & Therapeutics 27:10, 866-884
CrossRef270
Shintaro Abe, Ryoichi Narita, Toru Matsuhashi, Takeshi Oto, Akinari Tabaru, Makoto Otsuki. (2008) Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C. European Journal of Gastroenterology & Hepatology 20:5, 373-378
CrossRef271
Jee-Fu Huang, Chia-Yen Dai, Ya-Yun Lin, Ming-Lung Yu, Shu-Fen Liu, I-Ling Lin, Ming-Yen Hsieh, Li-Po Lee, Zu-Yau Lin, Shinn-Chern Chen, Ming-Yuh Hsieh, Wen-Yu Chang, Wan-Long Chuang. (2008) Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections. Clinical Chemistry and Laboratory Medicine 46:4, 475-480
CrossRef272
L. Ye, J. S. Peng, X. Wang, Y. J. Wang, G. X. Luo, W. Z. Ho. (2008) Methamphetamine enhances Hepatitis C virus replication in human hepatocytes. Journal of Viral Hepatitis 15:4, 261-270
CrossRef273
Narayan Dharel, Naoya Kato, Ryosuke Muroyama, Hiroyoshi Taniguchi, Motoyuki Otsuka, Yue Wang, Amarsanaa Jazag, Run-Xuan Shao, Jin-Hai Chang, Mark K. Adler, Takao Kawabe, Masao Omata. (2008) Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus. Hepatology 47:4, 1136-1149
CrossRef274
Deepak Kumar, Abdul Malik, Mohammad Asim, Anita Chakravarti, Rakha H. Das, Premashis Kar. (2008) Response of Combination Therapy on Viral Load and Disease Severity in Chronic Hepatitis C. Digestive Diseases and Sciences 53:4, 1107-1113
CrossRef275
P.-J. Chen, Y. Hwang, C. G.-J. Lin, Y.-J. Wu, L. S.-H. Wu. (2008) The genetic differences with whole genome linkage disequilibrium mapping between responder and non-responder in interferon-α and ribavirin combined therapy for chronic hepatitis C patients. International Journal of Immunogenetics 35:2, 153-157
CrossRef276
E.A. Gould, T. Solomon, J.S. Mackenzie. (2008) Does antiviral therapy have a role in the control of Japanese encephalitis?. Antiviral Research 78:1, 140-149
CrossRef277
Jann LÜBBE. (2008) Adverse skin reactions associated with hepatitis C treatment: Comment. The Journal of Dermatology 35:4, 250-250
CrossRef278
C. M. Rousseau, G. N. Ioannou, J. A. Todd-Stenberg, K. L. Sloan, M. F. Larson, C. W. Forsberg, J. A. Dominitz. (2008) Racial Differences in the Evaluation and Treatment of Hepatitis C Among Veterans: A Retrospective Cohort Study. American Journal of Public Health 98:5, 846-852
CrossRef279
M. H. Latka, H. Hagan, F. Kapadia, E. T. Golub, S. Bonner, J. V. Campbell, M. H. Coady, R. S. Garfein, M. Pu, D. L. Thomas, T. K. Thiel, S. A. Strathdee. (2008) A Randomized Intervention Trial to Reduce the Lending of Used Injection Equipment Among Injection Drug Users Infected With Hepatitis C. American Journal of Public Health 98:5, 853-861
CrossRef280
J MENG, Z YAN, Y WU, M GAO, W LI, F GAO, H WANG, W HAN, Y ZHANG. (2008) Preclinical safety evaluation of IFNα2a-NGR. Regulatory Toxicology and Pharmacology 50:3, 294-302
CrossRef281
Tatehiro Kagawa, Hirokazu Shiozawa, Sei-ichiro Kojima, Shinji Takashimizu, Naruhiko Nagata, Makoto Numata, Fumitoshi Morino, Yasuhiro Nishizaki, Kaori Mochizuki, Norihito Watanabe, Tetsu Watanabe, Shohei Matsuzaki, Tetsuya Mine. (2008) Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon α-2a in the treatment of chronic hepatitis C. Hepatology Research 38:3, 259-266
CrossRef282
Zachary D. Goodman, Hala R. Makhlouf, Lea Liu, William Balistreri, Regino P. Gonzalez-Peralta, Barbara Haber, Maureen M. Jonas, Parvathi Mohan, Jean P. Molleston, Karen F. Murray, Michael R. Narkewicz, Philip Rosenthal, Lesley J. Smith, Patricia R. Robuck, Kathleen B. Schwarz. (2008) Pathology of chronic hepatitis C in children: Liver biopsy findings in the Peds-C Trial. Hepatology 47:3, 836-843
CrossRef283
Edmond Vartany, Cary A. Caldwell, Terence K. Trow. (2008) Adult respiratory distress syndrome after treatment with pegylated interferon α-2a and ribavirin. Heart & Lung: The Journal of Acute and Critical Care 37:2, 153-156
CrossRef284
J FRANCISCOMARQUEZPEIRO. (2008) Efectividad del tratamiento de la hepatitis C con peginterferón alfa (2a o 2b) más ribavirina en pacientes naïve. Enfermedades Infecciosas y Microbiología Clínica 26:3, 135-140
CrossRef285
Seema Baid-Agrawal, Manuel Pascual, Darius Moradpour, Ulrich Frei, Nina Tolkoff-Rubin. (2008) Hepatitis C virus infection in haemodialysis and kidney transplant patients. Reviews in Medical Virology 18:2, 97-115
CrossRef286
Lucija Virovic Jukic, Marko Duvnjak, Catherine H. Wu, George Y. Wu. (2008) Human uridine-cytidine kinase phosphorylation of ribavirin: a convenient method for activation of ribavirin for conjugation to proteins. Journal of Biomedical Science 15:2, 205-213
CrossRef287
Yoshihiko Nagase, Hiroshi Yotsuyanagi, Chiaki Okuse, Kiyomi Yasuda, Tomohiro Kato, Kazuhiko Koike, Michihiro Suzuki, Kusuki Nishioka, Shiro Iino, Fumio Itoh. (2008) Effect of treatment with interferon α-2b and ribavirin in patients infected with genotype 2 hepatitis C virus. Hepatology Research 38:3, 252-258
CrossRef288
Le-Ning Zhang, Sharlene Velichko, Jon Vincelette, Richard M. Fitch, Ronald Vergona, Mark E. Sullivan, Ed Croze, Yi-Xin Wang. (2008) Interferon-beta attenuates angiotensin II-accelerated atherosclerosis and vascular remodeling in apolipoprotein E deficient mice. Atherosclerosis 197:1, 204-211
CrossRef289
Hongju Mao, Zhimeng Lu, Honglian Zhang, Kangdong Liu, Jianlong Zhao, Gendi Jin, Shimin Gu, Mengsu Yang. (2008) Colorimetric oligonucleotide array for genotyping of hepatitis C virus based on the 5′ non-coding region. Clinica Chimica Acta 388:1-2, 22-27
CrossRef290
Antonio Craxì, Giacomo Laffi, Anna Linda Zignego. (2008) Hepatitis C virus (HCV) infection: A systemic disease. Molecular Aspects of Medicine 29:1-2, 85-95
CrossRef291
Leo G.J. De Leede, John E. Humphries, Anne C. Bechet, Ewoud J. Van Hoogdalem, Ruud Verrijk, David G. Spencer. (2008) Novel Controlled-Release Lemna -Derived IFN- α 2b (Locteron): Pharmacokinetics, Pharmacodynamics, and Tolerability in a Phase I Clinical Trial. Journal of Interferon & Cytokine Research 28:2, 113-122
CrossRef292
C GORDON, K UHLIG, J LAU, C SCHMID, A LEVEY, J WONG. (2008) Interferon Treatment in Hemodialysis Patients With Chronic Hepatitis C Virus Infection: A Systematic Review of the Literature and Meta-analysis of Treatment Efficacy and Harms. American Journal of Kidney Diseases 51:2, 263-277
CrossRef293
R. MARTÍN-SANTOS, C. DÍEZ-QUEVEDO, P. CASTELLVÍ, R. NAVINÉS, M. MIQUEL, H. MASNOU, A. SOLER, M. ARDEVOL, F. GARCÍA, J. A. GALERAS, R. PLANAS, R. SOLÀ. (2008) De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Alimentary Pharmacology & Therapeutics 27:3, 257-265
CrossRef294
John W. Steinke, Gabor Illei, Gülbû Uzel, JoAnn M. Mican. 2008. Cytokine therapy. , 1393-1404.
CrossRef295
He-Jun Yuan, William M Lee. (2008) Nonresponse to Treatment for Hepatitis C. Drugs 68:1, 27-42
CrossRef296
Suzanne M Davison, Deirdre A Kelly. (2008) Management Strategies for Hepatitis C Virus Infection in Children. Pediatric Drugs 10:6, 357-365
CrossRef297
Eric Snoeck, Stephanos J. Hadziyannis, Claudio Puoti, Mark G. Swain, Thomas Berg, Patrick Marcellin, Jean-Pierre Zarski, Karin Jorga, Stefan Zeuzem. (2008) Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon α-2a (40KD) plus ribavirin. Liver International 28:1, 61-71
CrossRef298
Yusuke Kawamura, Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Masahiro Kobayashi, Norio Akuta, Tetsuya Hosaka, Hitomi Sezaki, Hiromi Yatsuji, Mariko Kobayashi, Hiromitsu Kumada. (2008) The Efficacy of Short-term Interferon-beta Therapy for Chronic Hepatitis C Patients with Low Virus Load. Internal Medicine 47:5, 355-360
CrossRef299
Patrice Cacoub, Philippe Halfon, Eric Rosenthal, Gilles Pialoux, Yves Benhamou, Christian Perronne, Stanislas Pol. (2008) Treatment of hepatitis C virus in human immunodeficiency virus infected patients in “real life”: Modifications in two large surveys between 2004 and 2006. Journal of Hepatology 48:1, 35-42
CrossRef300
Miki Nagashima, Masatoshi Kudo, Hobyung Chung, Emi Ishikawa, Tatsuo Inoue, Tatsuya Nakatani, Kensaku Dote. (2008) Elevated Serum ALT Levels during Pegylated Interferon Monotherapy May Be Caused by Hepatic Iron Overload. Intervirology 51:1, 76-85
CrossRef301
T. Thévenot, C. Regimbeau, V. Ratziu, V. Leroy, P. Opolon, T. Poynard. (2008) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update. Journal of Viral Hepatitis 8:1, 48
CrossRef302
Koichi WATASHI. (2008) Chemical biology for revealing a life cycle of hepatitis C virus. Uirusu 58:1, 73-80
CrossRef303
Hojun Lee, Yoo-Kyung Cho, Heung Up Kim, Eun Kwang Choi, Soyoung Hyun, Donggu Kang, Seung Uk Jeong, Hyun Ju Kim, Kwang Sik Kim, Byung-Cheol Song. (2008) Distribution of hepatitis C virus genotypes in Jeju Island. The Korean Journal of Hepatology 14:1, 28
CrossRef304
Yasuji Arase, Fumitaka Suzuki, Hitomi Sezaki, Yusuke Kawamura, Yoshiyuki Suzuki, Masahiro Kobayashi, Norio Akuta, Tetsuya Hosaka, Hiromi Yatsuji, Mariko Kobayashi, Satoshi Saitoh, Kenji Ikeda, Hiromitsu Kumada. (2008) The Efficacy of Short-Term Interferon-Beta Therapy for Type C Cirrhotic Patients with Genotype 2a and Low Virus Load. Internal Medicine 47:12, 1085-1090
CrossRef305
Gaetano Scotto, Vincenzina Fazio, Chiara Fornabaio, Alessandra Tartaglia, Rocco Di Tullio, Annalisa Saracino, Gioacchino Angarano. (2008) Early and Sustained Virological Response in Non-Responders with Chronic Hepatitis C. Drugs 68:6, 791-801
CrossRef306
Heon Ju Lee, Jong Ryul Eun, Jae Won Choi, Kyung Ok Kim, Hee Jung Moon. (2008) Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C. The Korean Journal of Hepatology 14:1, 46
CrossRef307
Myoung Joo Kang, Eun Uk Jung, Sang Won Park, Paul Choi, Ji Hyun Kim, Sung Jae Park, Eun Taek Park, Youn Jae Lee, Sang Hyuk Lee, Sang Yong Seol. (2008) Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection. The Korean Journal of Hepatology 14:3, 318
CrossRef308
Kyoung-Tae Kim, Sang-Young Han, Jong-Han Kim, Hyun-Ah Yoon, Yang-Hyun Baek, Min-Ji Kim, Sung-Wook Lee, Jin-Seok Jang, Jong-Hun Lee, Myung-Hwan Roh. (2008) Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. The Korean Journal of Hepatology 14:1, 36
CrossRef309
Naoki Hiramatsu, Nao Kurashige, Tsugiko Oze, Tetsuo Takehara, Shinji Tamura, Akinori Kasahara, Masahide Oshita, Kazuhiro Katayama, Harumasa Yoshihara, Yasuharu Imai, Michio Kato, Sumio Kawata, Hirohito Tsubouchi, Hiromitsu Kumada, Takeshi Okanoue, Shinichi Kakumu, Norio Hayashi. (2008) Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. Hepatology Research 38:1, 52-59
CrossRef310
M. Makris, T. Baglin, G. Dusheiko, P. L. F. Giangrande, C. A. Lee, C. A. Ludlam, F. E. Preston, H. G. Watson, J. T. Wilde, M. Winter. (2008) Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 7:4, 339
CrossRef311
Jeong Il Kim, Seok Hyun Kim, Byung Seok Lee, Heon Young Lee, Tae Hee Lee, Young Woo Kang, Hyang Ie Lee, An Na Kim, Soon Woo Nam, Byeong Chool Park, Hee Bok Chae, Seok Bae Kim, Il Han Song, Ji Young Park, Hong Su Kim. (2008) Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study. The Korean Journal of Hepatology 14:4, 493
CrossRef312
Vandana Tayal, Bhupinder Singh Kalra. (2008) Cytokines and anti-cytokines as therapeutics — An update. European Journal of Pharmacology 579:1-3, 1-12
CrossRef313
Ke-Qin Hu, John M. Vierling, Allan G. Redeker. (2008) Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. Journal of Viral Hepatitis 8:1, 1
CrossRef314
C. Aguilar, J. F. Lucia, M. A. SimÓn. (2008) An emerging role for interferon in haemophiliacs with chronic hepatitis C?. Haemophilia 7:1, 6
CrossRef315
Marie-Christine Woronoff-Lemsi, Mehdi Medjoub, Rémy Contreras, Marie-Christine Woronoff-Lemsi, Jean-Philippe Miguet. 2008. Traitement des hépatites virales. , 309-332.
CrossRef316
Nyingi Kemmer, Guy W. Neff. (2007) Managing chronic hepatitis C in the difficult-to-treat patient. Liver International 27:10, 1297-1310
CrossRef317
Jonathan Shepherd, Jeremy Jones. (2007) A systematic review of the cost–effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, 577-595
CrossRef318
Arne Schäfer, Hans-Ulrich Wittchen, Jochen Seufert, Michael R. Kraus. (2007) Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C – a critical review. International Journal of Methods in Psychiatric Research 16:4, 186-201
CrossRef319
Christopher L. Washenberger, Jian-Qiu Han, Katherina J. Kechris, Babal Kant Jha, Robert H. Silverman, David J. Barton. (2007) Hepatitis C virus RNA: Dinucleotide frequencies and cleavage by RNase L. Virus Research 130:1-2, 85-95
CrossRef320
Michael P. Manns, Graham R. Foster, Jürgen K. Rockstroh, Stefan Zeuzem, Fabien Zoulim, Michael Houghton. (2007) The way forward in HCV treatment — finding the right path. Nature Reviews Drug Discovery 6:12, 991-1000
CrossRef321
Lei Kang, Jing Hu, Xue-shan Xia, Jian-guo Wu. (2007) HIV and HCV: from Co-infection to epidemiology, transmission, pathogenesis, and treatment. Virologica Sinica 22:6, 443-450
CrossRef322
Olivia McKenna, Catherine Blake. (2007) Management of hepatitis C: the potential benefits of exercise. Physical Therapy Reviews 12:4, 271-276
CrossRef323
Thomas R. Riley, Mohammad R. Taheri. (2007) Long-Term Treatment with the Combination of Amantadine and Ribavirin in Hepatitis C Nonresponders. A Case Series. Digestive Diseases and Sciences 52:12, 3418-3422
CrossRef324
Eric Nguyen-Khac, Dominique Capron, Sandrine Castelain, Catherine François, Alain Braillon. (2007) Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype?. European Journal of Internal Medicine 18:7, 510-515
CrossRef325
W. Jessner, T. Watkins-Riedel, C. Müller, E. Formann, M. Gschwantler, P. Ferenci. (2007) Comparison of the Bayer VERSANT HCV RNA 3.0 and the Roche COBAS Amplicor HCV Monitor, Version 2.0, assays in HCV genotype 4 infection. Journal of Viral Hepatitis 14:11, 775-781
CrossRef326
Th. Witthöft, B. Möller, K. H. Wiedmann, St. Mauss, R. Link, J. Lohmeyer, M. Lafrenz, C. M. Gelbmann, D. Hüppe, C. Niederau, U. Alshuth. (2007) Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. Journal of Viral Hepatitis 14:11, 788-796
CrossRef327
Chuanlai Shen, Ting Hu, Ling Shen, Lei Gao, Wei Xie, Jianqiong Zhang. (2007) Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection. Journal of Gastroenterology and Hepatology 22:11, 1898-1903
CrossRef328
Marc S. Itskowitz. (2007) Hepatitis C: Epidemiology, Diagnosis, and Management. Comprehensive Therapy 33:2, 87-93
CrossRef329
Frank Yeh, Fredric D Gordon. (2007) Peginterferon alfa-2b and ribavirin combination therapy for chronic hepatitis C. Future Virology 2:6, 553-563
CrossRef330
Antoine Jakiche, Edward C. Paredez, Pawan K. Tannan, Cynthia Geppert, Vicki L. Sontag, Clifford R. Qualls, David A. Blair, Elizabeth L. Dettmer. (2007) Trend of Depression and the Use of Psychiatric Medications in U.S. Veterans With Hepatitis C During Interferon-Based Therapy. The American Journal of Gastroenterology 102:11, 2426-2433
CrossRef331
Ira M. Jacobson, Robert S. Brown, Jonathan McCone, Martin Black, Clive Albert, Michael S. Dragutsky, Firdous A. Siddiqui, Thomas Hargrave, Paul Y. Kwo, Louis Lambiase, Greg W. Galler, Victor Araya, Bradley Freilich, Joann Harvey, Louis H. Griffel, Clifford A. Brass, . (2007) Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1. Hepatology 46:4, 982-990
CrossRef332
G JENSEN, J TROTTER. (2007) Treatment of chronic HCV in advanced liver disease: Unmet challenges, reason for optimism
CrossRef333
Lucas C. Quarantini, Rodrigo A. Bressan, Amanda Galvão, Susana Batista-Neves, Raymundo Paraná, Ângela Miranda-Scippa. (2007) Incidence of psychiatric side effects during pegylated interferon- ? retreatment in nonresponder hepatitis C virus-infected patients. Liver International 27:8, 1098-1102
CrossRef334
Ira M. Jacobson, Robert S. Brown, Bradley Freilich, Nezam Afdhal, Paul Y. Kwo, John Santoro, Scott Becker, Adil E. Wakil, David Pound, Eliot Godofsky, Robert Strauss, David Bernstein, Steven Flamm, Mary Pat Pauly, Pabak Mukhopadhyay, Louis H. Griffel, Clifford A. Brass, . (2007) Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. Hepatology 46:4, 971-981
CrossRef335
Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Masahiro Kobayashi, Norio Akuta, Tetsuya Hosaka, Hitomi Sezaki, Hiromi Yatsuji, Yusuke Kawamura, Mariko Kobayashi, Hiromitsu Kumada. (2007) Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. Journal of Medical Virology 79:10, 1485-1490
CrossRef336
Arleta Kowala-Piaskowska, Iwona Mozer-Lisewska, Magdalena Figlerowicz, Wojciech Służewski. (2007) Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Pharmacoepidemiology and Drug Safety 16:10, 1095-1103
CrossRef337
Zachary D. Goodman. (2007) Grading and staging systems for inflammation and fibrosis in chronic liver diseases. Journal of Hepatology 47:4, 598-607
CrossRef338
Stéphane Chevaliez, Jean-Michel Pawlotsky. (2007) Interferon-based therapy of hepatitis C. Advanced Drug Delivery Reviews 59:12, 1222-1241
CrossRef339
Martin Schaefer, Axel Hinzpeter, Ariane Mohmand, Gesa Janssen, Maurice Pich, Markus Schwaiger, Rahul Sarkar, Astrid Friebe, Andreas Heinz, Michael Kluschke, Marlene Ziemer, Juri Gutsche, Viola Weich, Juliane Halangk, Thomas Berg. (2007) Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology 46:4, 991-998
CrossRef340
Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada. (2007) Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load. Hepatology Research 37:10, 787-792
CrossRef341
Jason Grebely, Krista Genoway, Milan Khara, Fiona Duncan, Mark Viljoen, Doug Elliott, Jesse D. Raffa, Stanley DeVlaming, Brian Conway. (2007) Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. International Journal of Drug Policy 18:5, 437-443
CrossRef342
Sharif Missiha, Jenny Heathcote, Tamara Arenovich, Kamran Khan, . (2007) Impact of Asian Race on Response to Combination Therapy With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C. The American Journal of Gastroenterology 102:10, 2181-2188
CrossRef343
Mark S. Sulkowski. (2007) Hepatitis C virus infection in HIV-infected patients. Current Infectious Disease Reports 3:5, 469-476
CrossRef344
A. Sagir, T. Heintges, Z. Akyazi, M. Oette, A. Erhardt, D. Häussinger. (2007) Therapy outcome in patients with chronic hepatitis C: role of therapy supervision by expert hepatologists. Journal of Viral Hepatitis 14:9, 633-638
CrossRef345
Shotaro Enomoto, Hideyuki Tamai, Masashi Oka, Naoki Shingaki, Tatsuya Shiraki, Machiko Takeuchi, Hisanobu Deguchi, Hirohito Magari, Izumi Inoue, Mikitaka Iguchi, Kimihiko Yanaoka, Kenji Arii, Mitsuhiro Fujishiro, Naohisa Yahagi, Hiroshi Yotsuyanagi, Masao Ichinose. (2007) Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level. Hepatology Research 37:9, 692-700
CrossRef346
Diana L. Sylvestre, Barry J. Clements. (2007) Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. European Journal of Gastroenterology & Hepatology 19:9, 741-747
CrossRef347
Vicki M. Park, Barbara C. Mason, Julia Krushkal, Rongling Li, Caroline Riely, Jaquelyn Fleckenstein. (2007) Hepatitis C Hypervariable Region 1: Association of Reduced Selection Pressure in African Americans with Treatment Failure. Digestive Diseases and Sciences 52:10, 2540-2549
CrossRef348
Abdurrahman Sagir, Tobias Heintges, Zübeyde Akyazi, Mark Oette, Andreas Erhardt, Dieter Häussinger. (2007) Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection. Liver International 27:7, 954-959
CrossRef349
Jason Grebely, Jesse D Raffa, Caite Meagher, Fiona Duncan, Krista A Genoway, Milan Khara, Mark McLean, Annabel Mead, Mark Viljoen, Stanley deVlaming, Chris Fraser, Brian Conway. (2007) Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. Journal of Gastroenterology and Hepatology 22:9, 1519-1525
CrossRef350
Felice Piccinino, Nicola Coppola. (2007) Antiviral treatment of HCV-related cirrhosis. Digestive and Liver Disease 39, S96-S101
CrossRef351
J. Powis, K. M. Peltekian, S. S. Lee, M. Sherman, V. G. Bain, C. Cooper, M. Krajden, M. Deschenes, R. F. Balshaw, E. Jenny Heathcote, E. M. Yoshida, . (2007) Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. Journal of Viral Hepatitis 0:0, 070901052026007-???
CrossRef352
Michal Cohen, Larisa Bachmatov, Ziv Ben-Ari, Yaron Rotman, Ran Tur-Kaspa, Romy Zemel. (2007) Development of Specific Antibodies to an ARF Protein in Treated Patients with Chronic HCV Infection. Digestive Diseases and Sciences 52:9, 2427-2432
CrossRef353
Supriya Joshi, Magdalena Kuczynski, E. Jenny Heathcote. (2007) Symptomatic and Virological Response to Antiviral Therapy in Hepatitis C Associated with Extrahepatic Complications of Cryoglobulimia. Digestive Diseases and Sciences 52:9, 2410-2417
CrossRef354
Henry L. Y. Chan, Hong Ren, Wan C. Chow, Theodore Wee, . (2007) Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. Hepatology 46:2, 315-323
CrossRef355
Yuki HASHIMOTO, Hiromi KANTO, Masatoshi ITOH. (2007) Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. The Journal of Dermatology 34:8, 577-582
CrossRef356
Juan Cristina, María del Pilar Moreno, Gonzalo Moratorio. (2007) Hepatitis C virus genetic variability in patients undergoing antiviral therapy. Virus Research 127:2, 185-194
CrossRef357
D. POSTHOUWER, T. T. YEE, M. MAKRIS, K. FISCHER, A. GRIFFIOEN, J. J. VAN VEEN, E. P. MAUSER-BUNSCHOTEN. (2007) Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study. Journal of Thrombosis and Haemostasis 5:8, 1624-1629
CrossRef358
Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Masahiro Kobayashi, Norio Akuta, Tetsuya Hosaka, Hitomi Sezaki, Hiromi Yatsuji, Yusuke Kawamura, Mariko Kobayashi, Hiromitsu Kumada. (2007) Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. Journal of Medical Virology 79:8, 1095-1102
CrossRef359
Yintang Jia, Lai Wei, Dong Jiang, Jianghua Wang, Xu Cong, Ran Fei. (2007) Antiviral action of interferon-? against hepatitis C virus replicon and its modulation by interferon-? and interleukin-8. Journal of Gastroenterology and Hepatology 22:8, 1278-1285
CrossRef360
Mitchell L. Shiffman, Jennifer Salvatore, Sarah Hubbard, Angie Price, Richard K. Sterling, R. Todd Stravitz, Velimir A. Luketic, Arun J. Sanyal. (2007) Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 46:2, 371-379
CrossRef361
Gabor Butora, David B. Olsen, Steven S. Carroll, Daniel R. McMasters, Christoph Schmitt, Joseph F. Leone, Mark Stahlhut, Christine Burlein, Malcolm MacCoss. (2007) Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2′-C-methyladenosine. Bioorganic & Medicinal Chemistry 15:15, 5219-5229
CrossRef362
A. A. Butt, U. A. Khan, K. A. McGinnis, M. Skanderson, C. Kent Kwoh. (2007) Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. Journal of Viral Hepatitis 0:0, 070729180316002-???
CrossRef363
Władysław SUŁOWICZ, Andrzej RADZISZEWSKI, Eve CHOWANIEC. (2007) Hepatitis C virus infection in dialysis patients. Hemodialysis International 11:3, 286-295
CrossRef364
Harel Dahari, Ruy M. Ribeiro, Alan S. Perelson. (2007) Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 46:1, 16-21
CrossRef365
Takashi Honda, Yoshiaki Katano, Fumihiro Urano, Mutsumi Murayama, Kazuhiko Hayashi, Masatoshi Ishigami, Isao Nakano, Kentaro Yoshioka, Hidenori Toyoda, Takashi Kumada, Hidemi Goto. (2007) Efficacy of ribavirin plus interferon-? in patients aged ?60
years with chronic hepatitis C. Journal of Gastroenterology and Hepatology 22:7, 989-995
CrossRef366
Naoya Sakamoto, Mika Yoshimura, Tomomi Kimura, Keisuke Toyama, Yuko Sekine-Osajima, Mamoru Watanabe, Masaaki Muramatsu. (2007) Bone morphogenetic protein-7 and interferon-alpha synergistically suppress hepatitis C virus replicon. Biochemical and Biophysical Research Communications 357:2, 467-473
CrossRef367
Isabelle Desombere, Hans Van Vlierberghe, Ola Weiland, Catharina Hultgren, Matti Sällberg, Juan Quiroga, Vicente Carreño, Geert Leroux-Roels. (2007) Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. Journal of Medical Virology 79:6, 701-713
CrossRef368
István Tornai, János Mátyus. (2007) Treatment of Hepatitis C Virus Infection in Patients before and after Renal Transplantation. Hungarian Medical Journal 1:2, 225-234
CrossRef369
E. B. Devine, J. T. Cross, K. V. Kowdley, S. D. Sullivan. (2007) The cost of treating ribavirin-induced anemia in hepatitis C:the impact of using recombinant human erythropoietin*. Current Medical Research and Opinion 23:6, 1463-1472
CrossRef370
M. S. Sulkowski, Y. Benhamou. (2007) Therapeutic issues in HIV/HCV-coinfected patients. Journal of Viral Hepatitis 14:6, 371-386
CrossRef371
Claude Souvignet, Olivier Lejeune, Christian Trepo. (2007) Interferon-based treatment of chronic hepatitis C. Biochimie 89:6-7, 894-898
CrossRef372
Annagiulia Gramenzi, Pietro Andreone, Carmela Cursaro, Gabriella Verucchi, Sergio Boccia, Pier Luigi Giacomoni, Silvia Galli, Giuliano Furlini, Maurizio Biselli, Stefania Lorenzini, Luciano Attard, Fiorenza Bonvicini, Mauro Bernardi. (2007) A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. Journal of Gastroenterology 42:5, 362-367
CrossRef373
C. M. Behler, E. Vittinghoff, F. Lin, R. T. Chung, M. G. Peters, G. K. Robbins, P. A. Volberding. (2007) Hematologic Toxicity Associated with Interferon-Based Hepatitis C Therapy in HIV Type 1-Coinfected Subjects. Clinical Infectious Diseases 44:10, 1375-1383
CrossRef374
Juan Cristina. (2007) Hepatitis C virus: quasispecies dynamics, virus persistance and antiviral therapy. Expert Opinion on Therapeutic Patents 17:5, 499-510
CrossRef375
Christoph Sarrazin, Tara L. Kieffer, Doug Bartels, Brian Hanzelka, Ute Müh, Martin Welker, Dennis Wincheringer, Yi Zhou, Hui–May Chu, Chao Lin, Christine Weegink, Henk Reesink, Stefan Zeuzem, Ann D. Kwong. (2007) Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir. Gastroenterology 132:5, 1767-1777
CrossRef376
Ichiro Konishi, Norio Horiike, Yoichi Hiasa, Yoshio Tokumoto, Toshie Mashiba, Kojiro Michitaka, Yasuyuki Miyake, Suguru Nonaka, Kouji Joukou, Bunzo Matsuura, Morikazu Onji. (2007) Diabetes mellitus reduces the therapeutic effectiveness of interferon-?2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatology Research 37:5, 331-336
CrossRef377
J.-F. HUANG, M.-L. YU, C.-M. LEE, C.-Y. DAI, N.-J. HOU, M.-Y. HSIEH, J.-H. WANG, S.-N. LU, I.-S. SHEEN, S.-M. LIN, W.-L. CHUANG, Y.-F. LIAW. (2007) Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386-patient study from Taiwan. Alimentary Pharmacology & Therapeutics 25:9, 1029-1037
CrossRef378
Yasunori Kawaguchi, Toshihiko Mizuta, Kazuhiro Takahashi, Shinji Iwane, Keisuke Ario, Hiroaki Kawasoe, Kazuhiro Hamaoka, Yuichiro Eguchi, Tsutomu Yasutake, Hironao Shigematsu, Seiji Kawazoe, Noriko Fukushima, Iwata Ozaki, Kazuma Fujimoto. (2007) High-dose vitamins E and C supplementation prevents ribavirin-induced hemolytic anemia in patients with chronic hepatitis C. Hepatology Research 37:5, 317-324
CrossRef379
Ilan S. Weisberg, Samuel H. Sigal, Ira M. Jacobson. (2007) New treatments for hepatitis C: Life cycle lessons. Current Hepatitis Reports 6:2, 75-82
CrossRef380
A. Mallat. (2007) Traitement de la cirrhose virale C. Journal Africain d’Hépato-Gastroentérologie 1:1, 59-62
CrossRef381
Michael S. Economou, Spyridon Filis, Helen Vienna, Dimitrios Christodoulou, Leonidas Christou, Epameinondas V. Tsianos. (2007) Treatment and retreatment in patients with chronic hepatitis C: 10 years clinical practice in a single centre. Liver International 27:3, 340-346
CrossRef382
John G. McHutchison, Michael P. Manns, Robert S. Brown, K. Rajender Reddy, Mitchell L. Shiffman, John B. Wong. (2007) Strategies for Managing Anemia in Hepatitis C Patients Undergoing Antiviral Therapy. The American Journal of Gastroenterology 102:4, 880-889
CrossRef383
Lennox J. Jeffers. (2007) Treating hepatitis C in African Americans. Liver International 27:3, 313-322
CrossRef384
Joseph Torresi, Owen M. Stock, Alexandra E. Fischer, Lara Grollo, Heidi Drummer, Irene Boo, Weiguang Zeng, Linda Earnest-Silveira, David C. Jackson. (2007) A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology 45:4, 911-920
CrossRef385
Kazuaki Inoue, Takuya Umehara, Urs T. Ruegg, Fumihiko Yasui, Tsunamasa Watanabe, Hiroshi Yasuda, Jean-Maurice Dumont, Pietro Scalfaro, Makoto Yoshiba, Michinori Kohara. (2007) Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 45:4, 921-928
CrossRef386
Mitchell L. Shiffman, Anastasios A. Mihas, Farida Millwala, Richard K. Sterling, Velimir A. Luketic, R. Todd Stravitz, Arun J. Sanyal. (2007) Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2 and 3. CME. The American Journal of Gastroenterology 102:4, 761-766
CrossRef387
Stephen D Shafran. (2007) Early Initiation of Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:5, 551-556
CrossRef388
A. Mangia. (2007) Short-duration therapy for hepatitis C: suitable for all?. Journal of Viral Hepatitis 14:4, 221-227
CrossRef389
Wolf Peter Hofmann, Andreas Polta, Eva Herrmann, Ulrike Mihm, Bernd Kronenberger, Tanja Sonntag, Volker Lohmann, Barbara Schönberger, Stefan Zeuzem, Christoph Sarrazin. (2007) Mutagenic Effect of Ribavirin on Hepatitis C Nonstructural 5B Quasispecies In Vitro and During Antiviral Therapy. Gastroenterology 132:3, 921-930
CrossRef390
Eduardo Vilar Gomez, Bienvenido Gra Oramas, Enrique Arus Soler, Raimundo Llanio Navarro, Caridad Ruenes Domech. (2007) Viusid, a nutritional supplement, in combination with interferon ?-2b and ribavirin in patients with chronic hepatitis C. Liver International 27:2, 247-259
CrossRef391
István Tornai, János Mátyus. (2007) A hepatitis C-vírusfertőzés terápiája vesepótló kezelésben részesülő betegekben. Orvosi Hetilap 148:11, 489-494
CrossRef392
M. Motazakker, P. Preikschat, J. Elliott, C.A. Smith, P.R. Mills, K. Oien, E. Spence, R.M. Elliott, E.A.B. McCruden. (2007) Translation efficiencies of the 5′-untranslated region of genotypes 1a and 3a in hepatitis C infected patients. Journal of Medical Virology 79:3, 259-269
CrossRef393
Mohammad Saeid Hejazi ., Reza Ghotaslou ., Majid Farshdoosty Hagh ., Yashar Mohammadzadeh Sadigh .. (2007) Genotyping of Hepatitis C Virus in Northwest of Iran. Biotechnology(Faisalabad) 6:3, 302-308
CrossRef394
Zobair Younossi, Jillian Kallman, John Kincaid. (2007) The effects of HCV infection and management on health-related quality of life. Hepatology 45:3, 806-816
CrossRef395
Vincenzo Guadagnino, Maria Paola Trotta, Franco Montesano, Sergio Babudieri, Benedetto Caroleo, Orlando Armignacco, Jessica Carioti, Giuseppe Maio, Roberto Monarca, Andrea Antinori, . (2007) Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 102:3, 423-431
CrossRef396
Mireen Friedrich-Rust, Stefan Zeuzem, Christoph Sarrazin. (2007) Current therapy for hepatitis C. International Journal of Colorectal Disease 22:4, 341-349
CrossRef397
Pingfei Li, Qi Wan, Yong Feng, Min Liu, Jianguo Wu, Xinwen Chen, Xiao-Lian Zhang. (2007) Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization. Vaccine 25:8, 1544-1551
CrossRef398
Wenkui Li, Suyi Luo, Shaoyong Li, Lawrence Athill, Amy Wu, Tapan Ray, Wei Zhou, June Ke, Harold T. Smith, Francis L.S. Tse. (2007) Simultaneous determination of ribavirin and ribavirin base in monkey plasma by high performance liquid chromatography with tandem mass spectrometry. Journal of Chromatography B 846:1-2, 57-68
CrossRef399
David R. Berk, Susan Bayliss Mallory, Emmet B. Keeffe, Aijaz Ahmed. (2007) Dermatologic Disorders Associated With Chronic Hepatitis C: Effect of Interferon Therapy. Clinical Gastroenterology and Hepatology 5:2, 142-151
CrossRef400
Cristina M. Rocha, Renata M. Perez, Jana??na L. Narciso, Adalgisa P. Ferreira, Lara B. Lemos, Jos?? O. Medina-Pestana, Antonio Eduardo B. Silva, Maria Lucia G. Ferraz. (2007) Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance. European Journal of Gastroenterology & Hepatology 19:2, 119-123
CrossRef401
Karen H. Seal, Sue L. Currie, Hui Shen, Bhupinderjit S. Anand, Edmund J. Bini, Norbert Brau, Lennox Jeffers, Teresa L. Wright. (2007) Hepatitis C Treatment Candidacy and Outcomes Among 4318 US Veterans With Chronic Hepatitis C Virus Infection. Journal of Clinical Gastroenterology 41:2, 199-205
CrossRef402
Shin-ichiro Nakagawa, Takuya Umehara, Chiho Matsuda, Shusuke Kuge, Masayuki Sudoh, Michinori Kohara. (2007) Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochemical and Biophysical Research Communications 353:4, 882-888
CrossRef403
Saburo Sone, Akiko Izawa, Hideki Narumi, Akemi Kajita, Junichi Tanabe, Fumihiro Taguchi. (2007) The combination of type I interferon and ribavirin has an inhibitory effect on mouse hepatitis virus infection. Hepatology Research 37:2, 121-126
CrossRef404
Ke-Qin Hu, Sue L. Currie, Hui Shen, Ramsey C. Cheung, Samuel B. Ho, Edmund J. Bini, John D. McCracken, Tim Morgan, Norbert Bräu, Warren N. Schmidt, Lennox Jeffers, Teresa L. Wright, . (2007) Clinical Implications of Hepatic Steatosis in Patients with Chronic Hepatitis C: A Multicenter Study of U.S. Veterans. Digestive Diseases and Sciences 52:2, 570-578
CrossRef405
Ankur Goyal, Wolf P. Hofmann, Eva Hermann, Stella Traver, Syed S. Hissar, Naveen Arora, Hubert E. Blum, Stefan Zeuzem, Christoph Sarrazin, Shiv K. Sarin. (2007) The hepatitis C virus NS5A protein and response to interferon α: mutational analyses in patients with chronic HCV genotype 3a infection from India. Medical Microbiology and Immunology 196:1, 11-21
CrossRef406
Shintaro Takaki, Yoshiiku Kawakami, Michio Imamura, Hiroshi Aikata, Shoichi Takahashi, Hiroto Ishihara, Keiji Tsuji, Shiomi Aimitsu, Hiroiku Kawakami, Toshio Nakanishi, Mikiya Kitamoto, Takashi Moriya, Kenichi Satoh, Kazuaki Chayama. (2007) Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin. Intervirology 50:6, 439-446
CrossRef407
K. Rajender Reddy, Mitchell L. Shiffman, Timothy R. Morgan, Stefan Zeuzem, Stephanos Hadziyannis, Fayez M. Hamzeh, Teresa L. Wright, Michael Fried. (2007) Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment. Clinical Gastroenterology and Hepatology 5:1, 124-129
CrossRef408
T. Umemura, H. Muto, E. Tanaka, A. Matsumoto, T. Ichijo, K. Yoshizawa, T. Akamatsu, K. Kiyosawa, . (2007) Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C. Journal of Viral Hepatitis 14:1, 48-54
CrossRef409
Gennadiy Koev, Tatyana Dekhtyar, Lixin Han, Ping Yan, Teresa I. Ng, C. Thomas Lin, Hongmei Mo, Akhteruzzaman Molla. (2007) Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antiviral Research 73:1, 78-83
CrossRef410
Aleksandar Sikole, Pavlina Dzekova, Nexhmi Selja, Magdalena Gaseva, Igor G. Nikolov, Mustafa Zabzun, Sheriat Muharemi, Arben Asani, Vili Amitov, Sami Mena, Violeta Grunevska, Ljubomir Ivanovski, Momir Polenakovic. (2007) Treatment of Hepatitis C in Hemodialysis Patients with Pegylated Interferon α-2a as Monotherapy. Renal Failure 29:8, 961-966
CrossRef411
Mitchell L. Shiffman, Marc G. Ghany, Timothy R. Morgan, Elizabeth C. Wright, Gregory T. Everson, Karen L. Lindsay, Anna S.F. Lok, Herbert L. Bonkovsky, Adrian M. Di Bisceglie, William M. Lee, Jules L. Dienstag, David R. Gretch. (2007) Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. Gastroenterology 132:1, 103-112
CrossRef412
M. Basso, F. Torre, A. Grasso, G. Percario, E. Azzola, S. Artioli, S. Blanchi, N. Pelli, A. Picciotto. (2007) Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Digestive and Liver Disease 39:1, 47-51
CrossRef413
Mutsumi Murayama, Yoshiaki Katano, Isao Nakano, Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Yoshiki Hirooka, Akihiro Itoh, Hidemi Goto. (2007) A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1b. Journal of Medical Virology 79:1, 35-40
CrossRef414
Lisa N. Boggio, Craig M. Kessler. 2007. Hemophilia A and B. , 43-59.
CrossRef415
Hoofnagle, Jay H., Seeff, Leonard B., . (2006) Peginterferon and Ribavirin for Chronic Hepatitis C. New England Journal of Medicine 355:23, 2444-2451
Full Text416
A. Chakravarti, V. Verma. (2006) Distribution of hepatitis C virus genotypes in beta-thalassaemic patients from Northern India. Transfusion Medicine 16:6, 433-438
CrossRef417
Sheng-Shun Yang, Lin-Shien Fu, Chi-Sen Chang, Hong-Zen Yeh, Gran-Hum Chen, Jia-Horng Kao. (2006) Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 21:12, 1789-1793
CrossRef418
Ming-Lung Yu, Chia-Yen Dai, Li-Po Lee, Nei-Jen Hou, Ming-Yen Hsieh, Jee-Fu Huang, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang. (2006) A 24-week course of high-dose interferon-? plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Liver International 26:10, 1187-1195
CrossRef419
Adam N. Elwi, Vijaya L. Damaraju, Stephen A. Baldwin, James D. Young, Michael B. Sawyer, Carol E. Cass. (2006) Renal nucleoside transporters: physiological and clinical implicationsThis paper is one of a selection of papers published in this Special Issue, entitled CSBMCB — Membrane Proteins in Health and Disease.. Biochemistry and Cell Biology 84:6, 844-858
CrossRef420
Vincenzo Mazzaferro, Raffaele Romito, Marcello Schiavo, Luigi Mariani, Tiziana Camerini, Sherrie Bhoori, Lorenzo Capussotti, Fulvio Calise, Riccardo Pellicci, Giulio Belli, Alessandro Tagger, Massimo Colombo, Ferruccio Bonino, Pietro Majno, Josep M. Llovet, . (2006) Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44:6, 1543-1554
CrossRef421
A. Mathew, L. P. Peiffer, K. Rhoades, T. McGarrity. (2006) Sustained Viral Response to Pegylated Interferon α-2b and Ribavirin in Chronic Hepatitis C Refractory to Prior Treatment. Digestive Diseases and Sciences 51:11, 1956-1961
CrossRef422
R.K. Sharma, S.B. Bansal, A. Gupta, S. Gulati, A. Kumar, N. Prasad. (2006) Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clinical Transplantation 20:6, 677-683
CrossRef423
Pablo Saiz de la Hoya-Zamácola, Andrés Marco-Mouriño, Gerardo Clemente-Ricote, Joaquín Portilla-Sogorb, Vicente Boix-Martínez, Óscar Núñez-Martínez, Sergio Reus-Bañuls, Nuria Teixidó i Pérez. (2006) Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario. Gastroenterología y Hepatología 29:9, 551-559
CrossRef424
Ming-Lung Yu, Shi-Ming Lin, Chuan-Mo Lee, Chia-Yen Dai, Wen-Yu Chang, Shinn-Cherng Chen, Li-Po Lee, Zu-Yau Lin, Ming-Yuh Hsieh, Liang-Yen Wang, Wan-Long Chuang, Yun-Fan Liaw. (2006) A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 44:5, 1086-1097
CrossRef425
Zeid Kayali, Douglas R. LaBrecque, Warren N. Schmidt. (2006) Treatment of hepatitis C cryoglobulinemia: Mission and challenges. Current Treatment Options in Gastroenterology 9:6, 497-507
CrossRef426
W.-A. LIN, Y.-H. TARN, S.-L. TANG. (2006) Cost?utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for na
CrossRef427
Sergey Akimov, Oluwatoyin M Adeyemi. (2006) Peginterferon-α 2a in the treatment of chronic hepatitis C. Future Virology 1:6, 689-701
CrossRef428
Pablo Saiz De La Hoya-Zamácola, Andrés Marco-Mouriño, Gerardo Clemente-Ricote, Joaquín Portilla-Sogorb, Vicente Boix-Martínez, Óscar Núñez-Martínez, Sergio Reus-Bañuls, Nuria Teixidó i Pérez. (2006) Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario. Enfermedades Infecciosas y Microbiología Clínica 24:9, 568-575
CrossRef429
N URGANCI, S GULEC, S DOGAN, A NUHOGLU. (2006) Interferon and ribavirin treatment results of patients with HBV–HCV co-infection cured of childhood malignancies. International Journal of Infectious Diseases 10:6, 453-457
CrossRef430
Steven S. Zalcman, Allan Siegel. (2006) The neurobiology of aggression and rage: Role of cytokines. Brain, Behavior, and Immunity 20:6, 507-514
CrossRef431
Tsugiko Oze, Naoki Hiramatsu, Nao Kurashige, Natsuko Tsuda, Takayuki Yakushijin, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Michio Kato, Harumasa Yoshihara, Kazuhiro Katayama, Shinji Kubota, Taizo Hijioka, Kazunobu Ishibashi, Masahide Oshita, Hideki Hagiwara, Yoshimichi Haruna, Eiji Mita, Shinji Tamura, Norio Hayashi. (2006) Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Journal of Gastroenterology 41:9, 862-872
CrossRef432
Sean E. Doyle, Heidi Schreckhise, Kien Khuu-Duong, Katherine Henderson, Robert Rosler, Harold Storey, Lena Yao, Hong Liu, Fariba Barahmand-pour, Pallavur Sivakumar, Chung Chan, Carl Birks, Don Foster, Christopher H. Clegg, Perdita Wietzke-Braun, Sabine Mihm, Kevin M. Klucher. (2006) Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44:4, 896-906
CrossRef433
Armando Sánchez-Quijano, Eduardo Lissen-Otero. (2006) Tratamiento de las hepatitis víricas (II). Tratamiento de la hepatitis crónica C. Enfermedades Infecciosas y Microbiología Clínica 24:8, 518-526
CrossRef434
A. CIANCIO, A. PICCIOTTO, C. GIORDANINO, A. SMEDILE, M. TABONE, A. MANCA, G. MARENCO, P. GARBAGNOLI, M. ANDREONI, G. CARITI, G. CALLERI, M. SARTORI, S. CUSUMANO, A. GRASSO, R. RIZZI, M. GALLO, M. BASSO, M. ANSELMO, G. PERCARIO, G. CICCONE, M. RIZZETTO, G. SARACCO. (2006) A randomized trial of pegylated-interferon-?2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Alimentary Pharmacology and Therapeutics 24:7, 1079-1086
CrossRef435
Mitchell L. Shiffman, Vinod K. Rustgi. (2006) Use of Ribavirin in Patients With Chronic HCV Genotype 1: When Enough Is Really Enough. Gastroenterology 131:4, 1339-1341
CrossRef436
Pierluigi Toniutto, Carlo Fabris, Mario Pirisi. (2006) Antiviral treatment of hepatitis C. Expert Opinion on Pharmacotherapy 7:15, 2025-2035
CrossRef437
M. K. CHAPKO, J. A. DOMINITZ. (2006) Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Alimentary Pharmacology and Therapeutics 24:7, 1067-1077
CrossRef438
P. Cacoub, E. Rosenthal, P. Halfon, D. Sene, C. Perronne, S. Pol. (2006) Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. Journal of Viral Hepatitis 13:10, 678-682
CrossRef439
D. Alvarez, D. T. Dieterich, N. Brau, L. Moorehead, L. Ball, M. S. Sulkowski. (2006) Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. Journal of Viral Hepatitis 13:10, 683-689
CrossRef440
Y. Itsui, N. Sakamoto, M. Kurosaki, N. Kanazawa, Y. Tanabe, T. Koyama, Y. Takeda, M. Nakagawa, S. Kakinuma, Y. Sekine, S. Maekawa, N. Enomoto, M. Watanabe. (2006) Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. Journal of Viral Hepatitis 13:10, 690-700
CrossRef441
Jean–Pierre Bronowicki, Denis Ouzan, Tarik Asselah, Hervé Desmorat, Jean–Pierre Zarski, Juliette Foucher, Marc Bourlière, Christophe Renou, Albert Tran, Pascal Melin, Christophe Hézode, Michelle Chevalier, Magali Bouvier–Alias, Stéphane Chevaliez, François Montestruc, Isabelle Lonjon–Domanec, Jean–Michel Pawlotsky. (2006) Effect of Ribavirin in Genotype 1 Patients With Hepatitis C Responding to Pegylated Interferon Alfa-2a Plus Ribavirin. Gastroenterology 131:4, 1040-1048
CrossRef442
M. Martinot-Peignoux, L. Comanor, J. M. Minor, M. P. Ripault, B.-N. Pham, N. Boyer, C. Castelnau, N. Giuily, D. Hendricks, Patrick Marcellin. (2006) Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C. Journal of Viral Hepatitis 13:10, 701-707
CrossRef443
Nassim Kamar, David Ribes, Jacques Izopet, Lionel Rostaing. (2006) Treatment of Hepatitis C Virus Infection (HCV) After Renal Transplantation: Implications for HCV-Positive Dialysis Patients Awaiting a Kidney Transplant. Transplantation 82:7, 853-856
CrossRef444
J SANCHEZTAPIAS. (2006) Pacientes naïve con genotipo 1. Gastroenterología y Hepatología 29, 135-138
CrossRef445
J SALMERONESCOBAR. (2006) Ribavirina y análogos. Gastroenterología y Hepatología 29, 129-134
CrossRef446
Massimo Franchini, Nicoletta Nicolini, Franco Capra. (2006) Treatment of hepatitis C in hemophiliacs. American Journal of Hematology 81:9, 696-702
CrossRef447
N. Kabbaj, M.M. Guedira, H. El Atmani, M. El Alaoui, M. Mohammadi, K. Benabed, H. Lachkar, A. Benaïssa. (2006) Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Annales d'Endocrinologie 67:4, 343-347
CrossRef448
D. POSTHOUWER, E. P. MAUSER-BUNSCHOTEN, K. FISCHER, M. MAKRIS. (2006) Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. Haemophilia 12:5, 473-478
CrossRef449
Ming-Lung Yu, Wan-Long Chuang, Chia-Yen Dai, Li-Po Lee, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Sun-Lung Tsai, Hsing-Tao Kuo. (2006) Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Translational Research 148:3, 120-127
CrossRef450
Metin Basaranoglu, Selman Celebi, Hayri Karaaslan, Ali Demir. (2006) Case study on drug-related adverse effects of hepatitis C therapy. Advances in Therapy 23:5, 769-771
CrossRef451
Stanislas Pol, Vincent O Mallet. (2006) Improving anti-hepatitis C virus therapy. Expert Opinion on Biological Therapy 6:9, 923-933
CrossRef452
Winita Hardikar, Kathleen B Schwarz. (2006) Treatment options for chronic hepatitis B and C infection in children. Expert Review of Anti-infective Therapy 4:4, 583-591
CrossRef453
José M. Sánchez–Tapias, Moisés Diago, Pedro Escartín, Jaime Enríquez, Manuel Romero–Gómez, Rafael Bárcena, Javier Crespo, Raúl Andrade, Eva Martínez–Bauer, Ramón Pérez, Milagros Testillano, Ramón Planas, Ricard Solá, Manuel García–Bengoechea, Javier Garcia–Samaniego, Miguel Muñoz–Sánchez, Ricardo Moreno–Otero. (2006) Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. Gastroenterology 131:2, 451-460
CrossRef454
Carla W. Brady, Andrew J. Muir. (2006) The impact of race and ethnicity on the treatment of hepatitis C disease. Current Hepatitis Reports 5:3, 79-85
CrossRef455
J. Dumortier, E. Ducos, J.-Y. Scoazec, P. Chevallier, O. Boillot, M.-C. Gagnieu. (2006) Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon α-2b and ribavirin combination after liver transplantation. Journal of Viral Hepatitis 13:8, 538-543
CrossRef456
C. Brandao, A. Barone, F. Carrilho, A. Silva, M. Patelli, C. Caramori, R. Focaccia, L. Pereira, M. Pedroso, F. Tatsch, M. Pessoa, . (2006) The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. Journal of Viral Hepatitis 13:8, 552-559
CrossRef457
Keisuke Hino, Yasuko Murakami, Ayako Nagai, Akira Kitase, Yuichi Hara, Takakazu Furutani, Fenyu Ren, Yuhki Yamaguchi, Kohki Yutoku, Satoyoshi Yamashita, Michiari Okuda, Misako Okita, Kiwamu Okita. (2006) 417–2α-Tocopherol and ascorbic acid attenuates the ribavirin-induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. Journal of Gastroenterology and Hepatology 21:8, 1269-1275
CrossRef458
Omana V. Nainan, Miriam J. Alter, Deanna Kruszon-Moran, Feng-Xiang Gao, Guoliang Xia, Geraldine McQuillan, Harold S. Margolis. (2006) Hepatitis C Virus Genotypes and Viral Concentrations in Participants of a General Population Survey in the United States. Gastroenterology 131:2, 478-484
CrossRef459
GianPiero Benetti, Mauro Borzio, Giuliano Ramella, Giorgio Bellati, Silvia Fargion, Alberto Colombo, Guido Croce, Carlo Iamoletti, Federico Balzola, Mario Rizzetto, . (2006) Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study. Internal and Emergency Medicine 1:2, 113-118
CrossRef460
S. Ramia, J. Eid-Fares. (2006) Distribution of hepatitis C virus genotypes in the Middle East. International Journal of Infectious Diseases 10:4, 272-277
CrossRef461
Masahiko Tomimatsu, Yoshio Aizawa, Yoshimichi Chuganji, Hideo Ishizuka, Yoshiyuki Fujita, Ryouichi Aizawa, Hiroshi Abe, Takako Matsuda, Yumi Itou, Hiroyuki Nakanishi, Hisashi Ushiyama, Teruhisa Higuchi, Tomoko Fujimoto, Hitoshi Endou, Daijiro Iga, Kazuki Ohta, Hiroyuki Kuroda. (2006) Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 21:7, 1177-1183
CrossRef462
C. Berg, F. L. Goncales, D. E. Bernstein, H. Sette, J. Rasenack, M. Diago, D. M. Jensen, P. Graham, G. Cooksley. (2006) Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. Journal of Viral Hepatitis 13:7, 435-440
CrossRef463
Jean-Pierre Bronowicki. (2006) Traitements antiviraux au cours de la cirrhose virale C. Gastroentérologie Clinique et Biologique 30:6-7, 899-902
CrossRef464
Lindsay Mollison, Leanne Totten, James Flexman, Miles Beaman, Robert Batey. (2006) Randomized double blind placebo-controlled trial of a Chinese herbal therapy (CH100) in chronic hepatitis C. Journal of Gastroenterology and Hepatology 21:7, 1184-1188
CrossRef465
Esther Voigt, Christian Schulz, Gerd Klausen, Joerg Goelz, Stefan Mauss, Guenther Schmutz, Heiko Jessen, Lutwin Weitner, Antonius Mutz, Dietmar Schranz, Juergen K. Rockstroh, for the KAAD study group. (2006) Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Journal of Infection 53:1, 36-42
CrossRef466
B. Meyer-Wyss, P. Rich, Hp Egger, B. Helbling, B. Mullhaupt, C. Rammert, J.-J. Gonvers, C. Oneta, D. Criblez, L. Rossi, J. Borovicka, C. Meyenberger, M. Arn, E. L. Renner, . (2006) Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 mug/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. Journal of Viral Hepatitis 13:7, 457-465
CrossRef467
Kiminori Uka, Fumitaka Suzuki, Norio Akuta, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada. (2006) Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. Journal of Gastroenterology 41:5, 470-475
CrossRef468
Valérie Paradis, Tarik Asselah, Delphine Dargere, Marie–Pierre Ripault, Michèle Martinot, Nathalie Boyer, Dominique Valla, Patrick Marcellin, Pierre Bedossa. (2006) Serum Proteome to Predict Virologic Response in Patients With Hepatitis C Treated by Pegylated Interferon Plus Ribavirin. Gastroenterology 130:7, 2189-2197
CrossRef469
Mitsuhiko Moriyama, Yasuyuki Arakawa. (2006) Treatment of interferon-α for chronic hepatitis C. Expert Opinion on Pharmacotherapy 7:9, 1163-1179
CrossRef470
Keiichi Fujiwara, Osamu Yokosuka, Fumihiko Komine, Mitsuhiko Moriyama, Naoya Kato, Haruhiko Yoshida, Naohide Tanaka, Fumio Imazeki, Yasushi Shiratori, Yasuyuki Arakawa, Masao Omata, . (2006) Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1. Liver International 26:5, 520-528
CrossRef471
Dominique Thabut, Sophie Le Calvez, Vincent Thibault, Julien Massard, Mona Munteanu, Vincent Di Martino, Vlad Ratziu, Thierry Poynard. (2006) Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease?. The American Journal of Gastroenterology 101:6, 1260-1267
CrossRef472
S. Zeuzem. (2006) Individualisierte Behandlung der chronischen Hepatitis C. Der Internist 47:S01, S20-S25
CrossRef473
D Scott Bowden, Mark D Berzsenyi. (2006) Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiology 1:1, 103-112
CrossRef474
C. P. Desmond, S. K. Roberts, F. Dudley, J. Mitchell, C. Day, S. Nguyen, S. Pianko. (2006) Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. Journal of Viral Hepatitis 13:5, 311-315
CrossRef475
Bhupinder S. Anand, Sue Currie, Eric Dieperink, Edmund J. Bini, Hui Shen, Samuel B. Ho, Teresa Wright. (2006) Alcohol Use and Treatment of Hepatitis C Virus: Results of a National Multicenter Study. Gastroenterology 130:6, 1607-1616
CrossRef476
R. S. Brown. (2006) Evaluating the evidence from clinical trials in chronic hepatitis C. Journal of Viral Hepatitis 13:s1, 15-25
CrossRef477
C. O'Brien. (2006) Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C. Journal of Viral Hepatitis 13:s1, 6-14
CrossRef478
Gary L. Davis. (2006) Tailoring antiviral therapy in hepatitis C. Hepatology 43:5, 909-911
CrossRef479
Gil Weitzman, Ira Jacobson. (2006) Peginterferon α-2b in the treatment of hepatitis C. Future Virology 1:3, 279-292
CrossRef480
B. R. Bacon. (2006) Assessing evidence from clinical trials in chronic hepatitis C. Journal of Viral Hepatitis 13:s1, 1-5
CrossRef481
Vijayan Balan. (2006) Albumin-interferon-α in the treatment of chronic hepatitis C. Future Virology 1:3, 269-278
CrossRef482
Gloria Taliani, Giulia Gemignani, Carlo Ferrari, Antonio Aceti, Dario Bartolozzi, Pier Luigi Blanc, Marco Capanni, Francesco Esperti, Paolo Forte, Vincenzo Guadagnino, Terenzio Mari, Nicoletta Marino, Stefano Milani, Caterina Pasquazzi, Floriano Rosina, Danilo Tacconi, Mario Toti, Anna Linda Zignego, Luca Messerini, Tommaso Stroffolini. (2006) Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients. Gastroenterology 130:4, 1098-1106
CrossRef483
Gregory M. Asnis, Richard De La Garza. (2006) Interferon-Induced Depression in Chronic Hepatitis C: A Review of Its Prevalence, Risk Factors, Biology, and Treatment Approaches. Journal of Clinical Gastroenterology 40:4, 322-335
CrossRef484
Claire Wartelle-Bladou, Jean-Pierre Arpurt, Christophe Renou, Alexandre Pariente, Didier Pillon, Bernard Nalet, Magali Picon, André Glibert, Michel Chousterman, Denis Grasset, Thierry Morin, Pierre Bernard, Daniel Fischer, Mohamed Ramdani, Evelyne Lagier, Michel Rotily, Michel Rotily. (2006) High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique 30:4, 525-532
CrossRef485
A. Moghaddam, N. Reinton, O. Dalgard. (2006) A rapid real-time PCR assay for determination of hepatitis C virus genotypes 1, 2 and 3a. Journal of Viral Hepatitis 13:4, 222-229
CrossRef486
Eva Herrmann, Stefan Zeuzem. (2006) The kinetics of hepatitis C virus. European Journal of Gastroenterology & Hepatology 18:4, 339-342
CrossRef487
N. Brau, E. J. Bini, S. Currie, H. Shen, W. N. Schmidt, P. D. King, S. B. Ho, R. C. Cheung, K.-Q. Hu, B. S. Anand, F. R. Simon, A. Aytaman, D. P. Johnson, J. A. Awad, J. Ahmad, C. L. Mendenhall, M. C. Pedrosa, R. H. Moseley, C. H. Hagedorn, B. Waters, K.-M. Chang, T. R. Morgan, S. J. Rossi, L. J. Jeffers, T. L. Wright, . (2006) Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*. Journal of Viral Hepatitis 13:4, 242-249
CrossRef488
Robert J. Fontana. (2006) Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified?. Gastroenterology 130:4, 1357-1362
CrossRef489
M. Friedrich-Rust, S. Zeuzem. (2006) Therapie der Hepatitis C. Der Gastroenterologe 1:2, 126-132
CrossRef490
S. Chainuvati, S. K. Khalid, S. Kancir, M. Shea, J. Edwards, M. Sernyak, S. Wongcharatrawee, G. Garcia-Tsao. (2006) Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders+. Journal of Viral Hepatitis 13:4, 235-241
CrossRef491
Thomas Berg, Michael von Wagner, Samer Nasser, Christoph Sarrazin, Tobias Heintges, Tilman Gerlach, Peter Buggisch, Tobias Goeser, Jens Rasenack, Gerd R. Pape, Wolfgang E. Schmidt, Birgit Kallinowski, Hartwig Klinker, Ulrich Spengler, Peter Martus, Ulrich Alshuth, Stefan Zeuzem. (2006) Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin. Gastroenterology 130:4, 1086-1097
CrossRef492
U. MIHM, E. HERRMANN, C. SARRAZIN, S. ZEUZEM. (2006) Review article: predicting response in hepatitis C virus therapy. Alimentary Pharmacology and Therapeutics 23:8, 1043-1054
CrossRef493
Cristina M. Rocha, Renata M. Perez, Adalgisa P. Ferreira, Roberto J. Carvalho-Filho, Fabio H. Pace, Ivonete S. Silva, Jose O. M. Pestana, Valeria P. Lanzoni, Antonio E. Silva, Maria Lucia G. Ferraz. (2006) Efficacy and tolerance of interferon-alpha in the treatment of chronic Hepatitis C in end-stage renal disease patients on hemodialysis. Liver International 26:3, 305-310
CrossRef494
Chun-Jen Liu, Ming-Yang Lai, You-Chen Chao, Li-Ying Liao, Sien-Sing Yang, Tun-Jen Hsiao, Tsai-Yuan Hsieh, Chih-Lin Lin, Jui-Ting Hu, Chi-Ling Chen, Per-Jer Chen, Jia-Horng Kao, Ding-Shinn Chen. (2006) Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study. Hepatology 43:4, 742-749
CrossRef495
Dawn A. Fishbein, Yungtai Lo, Dale Netski, David L. Thomas, Robert S. Klein. (2006) Predictors of Hepatitis C Virus RNA Levels in a Prospective Cohort Study of Drug Users. JAIDS Journal of Acquired Immune Deficiency Syndromes 41:4, 471-476
CrossRef496
L. A. Mistler. (2006) Hepatitis C Treatment for People With Severe Mental Illness. Psychosomatics 47:2, 93-107
CrossRef497
J GLENN. (2006) Molecular Virology of the Hepatitis C Virus: Implication for Novel Therapies. Infectious Disease Clinics of North America 20:1, 81-98
CrossRef498
N. Fujita, M. Kaito, H. Tanaka, S. Horiike, N. Urawa, R. Sugimoto, M. Konishi, S. Watanabe, Y. Adachi. (2006) Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients. Journal of Viral Hepatitis 13:3, 190-198
CrossRef499
E. J. BINI, S. MEHANDRU. (2006) Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Alimentary Pharmacology and Therapeutics 23:6, 777-785
CrossRef500
Furqaan Ahmed, Ira M. Jacobson. (2006) Treatment of Relapsers after Combination Therapy for Chronic Hepatitis C. Infectious Disease Clinics of North America 20:1, 137-153
CrossRef501
C. d'Arondel, M. Munteanu, J. Moussalli, V. Thibault, S. Naveau, A. Simon, D. Messous, R. Morra, C. Blot, T. Poynard. (2006) A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. Journal of Viral Hepatitis 13:3, 182-189
CrossRef502
Anne Boulestin, Nassim Kamar, Karine Sandres-Sauné, Florence Legrand-Abravanel, Laurent Alric, Jean-Pierre Vinel, Lionel Rostaing, Jacques Izopet. (2006) Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. Journal of Medical Virology 78:3, 365-371
CrossRef503
S OH, N AFDHAL. (2006) Antiviral Therapy for Treatment Naïve Patients with Hepatitis C Virus. Infectious Disease Clinics of North America 20:1, 99-113
CrossRef504
Amrita Sethi, Mitchell L. Shiffman. (2006) Approach to the Management of Patients with Chronic Hepatitis C Who Failed to Achieve Sustained Virologic Response. Infectious Disease Clinics of North America 20:1, 115-135
CrossRef505
Srikanth Venkatraman, F. George Njoroge, Wanli Wu, Viyyoor Girijavallabhan, Andrew J. Prongay, Nancy Butkiewicz, John Pichardo. (2006) Novel inhibitors of hepatitis C NS3–NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid. Bioorganic & Medicinal Chemistry Letters 16:6, 1628-1632
CrossRef506
Norio Hayashi, Tetsuo Takehara. (2006) Antiviral therapy for chronic hepatitis C: past, present, and future. Journal of Gastroenterology 41:1, 17-27
CrossRef507
C. Bradley Hare, Jonathan A. Morris, Alice Chu, Vincent Gotz, Jacqueline J. Loveland, David Hodes, Winslow Klaskala. (2006) Comparison of characteristics of treated and non-treated patients with Hepatitis C infection. Pharmacoepidemiology and Drug Safety 15:2, 71-76
CrossRef508
Konstantinos Papastathopoulos, Evridiki Bouzas, George Naoum, Ioannis Vergados, Sotirios Tsiodras. (2006) Vogt–Koyanagi–Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection. Journal of Infection 52:2, e59-e61
CrossRef509
Ming-Lung Yu, Chia-Yen Dai, Zu-Yau Lin, Li-Po Lee, Nei-Jen Hou, Ming-Yen Hsieh, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang. (2006) A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver International 26:1, 73-81
CrossRef510
Yifei Liu, Christine Xu, Rongzi Yan, Charmaine Lim, Li-Tain Yeh, Chin-chung Lin. (2006) Sensitive and specific LC–MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma. Journal of Chromatography B 832:1, 17-23
CrossRef511
L. Alric, S. Thebault, J.-M. Peron, P. Balard, S. Metivier, B. Pipy, J. Izopet, J.-P. Vinel. (2006) Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1. Journal of Viral Hepatitis 13:2, 139-144
CrossRef512
Yasuko Murakami, Ayako Nagai, Takayo Kawakami, Keisuke Hino, Akira Kitase, Yuh-ichi Hara, Michiari Okuda, Kiwamu Okita, Misako Okita. (2006) Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon α-2b and ribavirin. Nutrition 22:2, 114-122
CrossRef513
Noriyoshi Kuzushita, Stephen H. Gregory, Nola A. Monti, Rolf Carlson, Stephan Gehring, Jack R. Wands. (2006) Vaccination With Protein-Transduced Dendritic Cells Elicits a Sustained Response to Hepatitis C Viral Antigens. Gastroenterology 130:2, 453-464
CrossRef514
K. YAMAMOTO, T. HONDA, T. MATSUSHITA, T. KOJIMA, J. TAKAMATSU. (2006) Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin. Journal of Thrombosis and Haemostasis 4:2, 469-470
CrossRef515
Jean-Michel Pawlotsky. (2006) Therapy of hepatitis C: From empiricism to eradication. Hepatology 43:S1, S207-S220
CrossRef516
Jie-Hyun Kim, Kwang-Hyub Han, Kwan Sik Lee, Young Nyun Park, Sang Hoon Ahn, Chae Yoon Chon, Young Myoung Moon. (2006) Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea. Yonsei Medical Journal 47:6, 793
CrossRef517
Hiroshi Kohno, Shiomi Aimitsu, Mikiya Kitamoto, Yasuyuki Aisaka, Hiroiku Kawakami, Kazuaki Chayama. (2006) Prolonged Negative HCV-RNA Status Led to a Good Outcome in Chronic Hepatitis C Patients with Genotype 1b and Super-High Viral Load. Intervirology 49:6, 362-369
CrossRef518
Keiko Arataki, Hiromitsu Kumada, Kiyomi Toyota, Waka Ohishi, Shoichi Takahashi, Susumu Tazuma, Kazuaki Chayama. (2006) Evolution of Hepatitis C Virus Quasispecies during Ribavirin and Interferon-Alpha-2b Combination Therapy and Interferon-Alpha-2b Monotherapy. Intervirology 49:6, 352-361
CrossRef519
Wang-Long Chuang, Ming-Lung Yu, Chia-Yen Dai, Wen-Yu Chang. (2006) Treatment of Chronic Hepatitis C in Southern Taiwan. Intervirology 49:1-2, 99-106
CrossRef520
M. Moreno, R. Perez-Alvarez, L. Rodrigo, R. Perez-Lopez, P. Suarez-Leiva. (2006) Long-term evolution of serum and liver viral markers in patients treated for chronic hepatitis C and sustained response. Journal of Viral Hepatitis 13:1, 28-33
CrossRef521
Rikako Koyama, Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi, Norio Akuta, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Mariko Kobayashi, Hiromitsu Kumada. (2006) Efficacy of Interferon Therapy in Elderly Patients with Chronic Hepatitis C. Intervirology 49:3, 121-126
CrossRef522
Shintaro Abe, Ryoichi Narita, Takeshi Oto, Akinari Tabaru, Makoto Otsuki. (2006) Effect of combination therapy with ribavirin and high-dose interferon-α2b for 24 weeks in chronic hepatitis C. Journal of Gastroenterology and Hepatology 21:1, 308-312
CrossRef523
Chuan-Mo Lee, Chao-Hung Hung, Sheng-Nan Lu, Jing-Houng Wang, Hung-Da Tung, Wu-Shiung Huang, Chao-Long Chen, Wei-Jen Chen, Chi-Sin Changchien. (2006) Viral Etiology of Hepatocellular Carcinoma and HCV Genotypes in Taiwan. Intervirology 49:1-2, 76-81
CrossRef524
Ming-Yang Lai. (2006) Combined Interferon and Ribavirin Therapy for Chronic Hepatitis C in Taiwan. Intervirology 49:1-2, 91-95
CrossRef525
Ming Gao, Hai-Ping Wang, Yan-Ning Wang, Yong Zhou, Quan-Li Wang. (2006) Target HCV NS3 CD4+ Th1 Epitope to Major Histocompatibility Complex Class II Pathway. Biotechnology Letters 28:1, 3-8
CrossRef526
P. Sarobe, J.-J. Lasarte, N. Garcia, M. P. Civeira, F. Borras-Cuesta, J. Prieto. (2006) Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins. Journal of Viral Hepatitis 13:1, 47-55
CrossRef527
Aiko HAYASHI, Yoshiaki INUI, Chie WATANABE, Yumi MATSUMOTO, Naoe YOSHIDA, Yuichi YASUNAGA, Masahiro NISHIKAWA. (2006) Chorea induced by PEG-IFN and rivabirin therapy for type C chronic hepatitis. Kanzo 47:3, 129-133
CrossRef528
Man-Fung Yuen, Ching-Lung Lai. (2006) Response to Combined Interferon and Ribavirin Is Better in Patients Infected with Hepatitis C Virus Genotype 6 than Genotype 1 in Hong Kong. Intervirology 49:1-2, 96-98
CrossRef529
Markus Cornberg, Michael P Manns. (2006) Future trends in hepatitis C therapy. Future Virology 1:1, 99-107
CrossRef530
Olav Dalgard, Alessandra Mangia. (2006) Short-Term Therapy for Patients with Hepatitis C Virus Genotype??2??or??3 Infection. Drugs 66:14, 1807-1815
CrossRef531
2006. Ribavirin. , 3036-3039.
CrossRef532
Kanji Sugihara, Etsuro Orito, Yasuhito Tanaka, Takanobu Kato, Johnson Y.N. Lau, Tomoyoshi Ohno, Katsuo Hayashi, Masataka Ogino, Noboru Hirashima, Kenji Sakakibara, Yoshiki Mizuno, Hideaki Kato, Seiji Suzuki, Ryuzo Ueda, Masashi Mizokami. (2006) Variations in the Viral NS5B Region in Japanese Patients with Chronic Hepatitis C Virus Genotype 1b Infection. Intervirology 49:6, 319-326
CrossRef533
Yoshiaki Iwasaki, Hiroshi Ikeda, Yasuyuki Araki, Toshiya Osawa, Keiji Kita, Masaharu Ando, Toshinari Shimoe, Kouichi Takaguchi, Noriaki Hashimoto, Toshitsugu Kobatake, Minoru Tomita, Mitsuhiko Kawaguchi, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori. (2006) Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 43:1, 54-63
CrossRef534
Dragan Delic. (2006) Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection. Medicinski pregled 59:9-10, 415-419
CrossRef535
Amy L. Lazzarini, Robert A. Levine, Robert J. Ploutz-Snyder, Schuyler O. Sanderson. (2005) Advances in digital quantification technique enhance discrimination between mild and advanced liver fibrosis in chronic hepatitis C. Liver International 25:6, 1142-1149
CrossRef536
Andreas Baranyi, Hans-Bernd Rothenhäusler. (2005) Interferon – alpha-induzierte Depressionen bei Patienten mit chronischen Hepatitis C-Infektionen. Psychiatrie und Psychotherapie 1:2, 51-56
CrossRef537
Stephanie A. Santos, Nickolas Kontorinis, Douglas T. Dieterich. (2005) Management of chronic Hepatitis C virus in patients with HIV. Current Treatment Options in Gastroenterology 8:6, 433-441
CrossRef538
Vinod K Rustgi. (2005) Thymalfasin for the treatment of chronic hepatitis C infection. Expert Review of Anti-infective Therapy 3:6, 885-892
CrossRef539
L. Brant, H. E. Harris, M. E. Ramsay, R. Grieve, J. Roberts, . (2005) Pathways of care and resource utilization in a national cohort of patients with transfusion-acquired hepatitis C. Journal of Viral Hepatitis 12:6, 618-626
CrossRef540
Nafiye Urganci, Seda Geylani Gulec, Mujde Arapoglu, Sema Vural, Asiye Nuho??. (2005) The Effect of Ribavirin on Bone Density in Patients with Chronic Hepatitis C Treated with Interferon-Ribavirin Therapy. Journal of Pediatric Gastroenterology and Nutrition 41:5, 650-652
CrossRef541
J. Encke, J. Findeklee, J. Geib, E. Pfaff, W. Stremmel. (2005) Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clinical and Experimental Immunology 142:2, 362-369
CrossRef542
Abdel-Rahman El-Zayadi, Mohy Attia, Eman M. F. Barakat, Hanaa M. Badran, Hassan Hamdy, Ahmed El-Tawil, Adham El-Nakeeb, Osaima Selim, Ahmed Saied. (2005) Response of Hepatitis C Genotype-4 Naive Patients to 24 Weeks of Peg-Interferon-alpha2b/Ribavirin or Induction-Dose Interferon-alpha2b/Ribavirin/Amantadine: A Non-Randomized Controlled Study. The American Journal of Gastroenterology 100:11, 2447-2452
CrossRef543
Regino P. González-Peralta, Deirdre A. Kelly, Barbara Haber, Jean Molleston, Karen F. Murray, Maureen M. Jonas, Mark Shelton, Giorgina Mieli-Vergani, Yoav Lurie, Steven Martin, Thomas Lang, Andrew Baczkowski, Michael Geffner, Samir Gupta, Mark Laughlin, . (2005) Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics. Hepatology 42:5, 1010-1018
CrossRef544
Hiroshi Sakamoto, Koichi Okamoto, Masahiro Aoki, Hideyuki Kato, Asao Katsume, Atsunori Ohta, Takuo Tsukuda, Nobuo Shimma, Yuko Aoki, Mikio Arisawa, Michinori Kohara, Masayuki Sudoh. (2005) Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nature Chemical Biology 1:6, 333-337
CrossRef545
J. Lubbe, K. Kerl, F. Negro, J-H. Saurat. (2005) Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. British Journal of Dermatology 153:5, 1088-1090
CrossRef546
J. Itakura, K. Nagayama, N. Enomoto, K. Hamano, N. Sakamoto, L. J. Fanning, E. Kenny-Walsh, F. Shanahan, M. Watanabe. (2005) Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin*. Journal of Viral Hepatitis 12:6, 594-603
CrossRef547
Chuan-Qing Wang, Yuan Li, Steven D. Douglas, Xu Wang, David S. Metzger, Ting Zhang, Wen-Zhe Ho. (2005) Morphine Withdrawal Enhances Hepatitis C Virus Replicon Expression. The American Journal of Pathology 167:5, 1333-1340
CrossRef548
Srikanta Dash, Salima Haque, Virendra Joshi, Ramesh Prabhu, Sidhartha Hazari, Cesar Fermin, Robert Garry. (2005) HCV-hepatocellular carcinoma: New findings and hope for effective treatment. Microscopy Research and Technique 68:3-4, 130-148
CrossRef549
SHI-MING LIN, CHIA-MING CHU. (2005) Secondary prevention of hepatitis C virus-related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 20:10, 1475-1477
CrossRef550
CHAO-HUNG HUNG, CHUAN-MO LEE, JING-HOUNG WANG, HUNG-DA TUNG, CHIEN-HUNG CHEN, SHENG-NAN LU. (2005) Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. Journal of Gastroenterology and Hepatology 20:10, 1553-1559
CrossRef551
Ramsey C. Cheung, Sue Currie, Hui Shen, Samuel B. Ho, Edmund J. Bini, Bhupinderjit S. Anand, Norbert Brau, Teresa L. Wright, . (2005) Chronic Hepatitis C in Latinos: Natural History, Treatment Eligibility, Acceptance, and Outcomes. The American Journal of Gastroenterology 100:10, 2186-2193
CrossRef552
Harlan Wright, Philip Alex, Thuan Nguyen, Teddy Bader, Ahmet Gurakar, Anthony Sebastian, Liberty Gonzales, Gemma Wallis, Mark Naylor, Igor Dozmorov, Michael Centola, Bakr Nour. (2005) Multiplex Cytokine Profiling of Initial Therapeutic Response in Patients with Chronic Hepatitis C Virus Infection. Digestive Diseases and Sciences 50:10, 1793-1803
CrossRef553
Shruti H Mehta, David L Thomas, Mark S Sulkowski, Mahboobeh Safaein, David Vlahov, Steffanie A Strathdee. (2005) A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS 19:Suppl 3, S179-S189
CrossRef554
Elena Rodríguez-Iñigo, Juan Manuel López-Alcorocho, Javier Bartolomé, Nuria Ortiz-Movilla, Margarita Pardo, Vicente Carreño. (2005) Percentage of Hepatitis C Virus-Infected Hepatocytes Is a Better Predictor of Response Than Serum Viremia Levels. The Journal of Molecular Diagnostics 7:4, 535-543
CrossRef555
Alan S. Perelson, Eva Herrmann, Florence Micol, Stefan Zeuzem. (2005) New kinetic models for the hepatitis C virus. Hepatology 42:4, 749-754
CrossRef556
Nickolas Kontorinis, Kaushik Agarwal, Douglas T Dieterich. (2005) Treatment of hepatitis C virus in HIV patients: a review. AIDS 19:Suppl 3, S166-S173
CrossRef557
Diana L. Sylvestre, Alain H. Litwin, Barry J. Clements, Marc N. Gourevitch. (2005) The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment 29:3, 159-165
CrossRef558
Abraham Reichenberg, Jack M Gorman, Douglas T Dieterich. (2005) Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 19:Suppl 3, S174-S178
CrossRef559
Patrice Cacoub, David Saadoun, Nicolas Limal, Jean Marc Léger, Thierry Maisonobe. (2005) Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications. AIDS 19:Suppl 3, S128-S134
CrossRef560
Akira Matsumori. (2005) Emerging treatments for viral myocarditis. Future Cardiology 1:5, 683-692
CrossRef561
KOSEI HAMANO, NAOYA SAKAMOTO, NOBUYUKI ENOMOTO, NAMIKI IZUMI, YASUHIRO ASAHINA, MASAYUKI KUROSAKI, ERI UEDA, YOKO TANABE, SHINYA MAEKAWA, JUN ITAKURA, HIDEKI WATANABE, SEI KAKINUMA, MAMORU WATANABE. (2005) Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. Journal of Gastroenterology and Hepatology 20:9, 1401-1409
CrossRef562
Masaru Enomoto, Shuhei Nishiguchi, Akihiro Tamori, Modoka Kohmoto, Daiki Habu, Hiroki Sakaguchi, Tadashi Takeda, Norifumi Kawada, Shuichi Seki, Susumu Shiomi. (2005) Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-α2b and ribavirin therapy in patients with genotype 1 and high viral loads. Journal of Medical Virology 77:1, 77-82
CrossRef563
V. Sypsa, G. Touloumi, G. V. Papatheodoridis, N. C. Tassopoulos, I. Ketikoglou, I. Vafiadis, G. Hatzis, D. Tsantoulas, E. Akriviadis, S. Koutsounas, A. Hatzakis. (2005) Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. Journal of Viral Hepatitis 12:5, 543-550
CrossRef564
Yvonne C Gilleece, Rita E Browne, David Asboe, Mark Atkins, Sundhiya Mandalia, Mark Bower, Brian G Gazzard, Mark R Nelson. (2005) Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin. JAIDS Journal of Acquired Immune Deficiency Syndromes 40:1, 41-46
CrossRef565
S. P. Savvas, J. Koskinas, C. Sinani, A. Hadziyannis, F. Spanou, S. J. Hadziyannis. (2005) Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. Journal of Viral Hepatitis 12:5, 551-557
CrossRef566
Guy A. Farber, Tomer Levin, Craig A. White. (2005) A cognitive therapy conceptualization of panic disorder exacerbated by interferon treatment. General Hospital Psychiatry 27:5, 329-337
CrossRef567
Sharon J. Hutchinson, Sheila M. Bird, David J. Goldberg. (2005) Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 42:3, 711-723
CrossRef568
N. A. Terrault, J-M. Pawlotsky, J. McHutchison, F. Anderson, M. Krajden, S. Gordon, I. Zitron, R. Perrillo, R. Gish, M. Holodniy, M. Friesenhahn. (2005) Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. Journal of Viral Hepatitis 12:5, 465-472
CrossRef569
J. K. Lim, D. Wooten, R. Siegel, R. C. Cheung. (2005) Amantadine in treatment of chronic hepatitis C virus infection?. Journal of Viral Hepatitis 12:5, 445-455
CrossRef570
Bonnie Kolor. (2005) Patient Education and Treatment Strategies Implemented at a Pharmacist-Managed Hepatitis C Virus Clinic. Pharmacotherapy 25:9, 1230-1241
CrossRef571
Michael von Wagner, Miriam Huber, Thomas Berg, Holger Hinrichsen, Jens Rasenack, Tobias Heintges, Alexandra Bergk, Christine Bernsmeier, Dieter Häussinger, Eva Herrmann, Stefan Zeuzem. (2005) Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C. Gastroenterology 129:2, 522-527
CrossRef572
Gary L Davis, Karen L Lindsay. (2005) Treatment of chronic hepatitis C infection: one step at a time. The Lancet Infectious Diseases 5:8, 524-526
CrossRef573
Chia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, Shinn-Cherng Chen, Li-Po Lee, Ming-Yen Hsieh, Nei-Jen Hou, Zu-Yau Lin, Ming-Yuh Hsieh, Liang-Yen Wang, Ming-Lung Yu. (2005) Polymorphisms in the interferon-γ gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-α and ribavirin. Antiviral Research 67:2, 93-97
CrossRef574
Akihiro Tamori, Shuhei Nishiguchi, Susumu Shiomi, Takehiro Hayashi, Sawako Kobayashi, Daiki Habu, Tadashi Takeda, Shuichi Seki, Kazuhiro Hirohashi, Hiromu Tanaka, Shoji Kubo. (2005) Hepatitis B Virus DNA Integration in Hepatocellular Carcinoma After Interferon-Induced Disappearance of Hepatitis C Virus. The American Journal of Gastroenterology 100:8, 1748-1753
CrossRef575
Valérie A. McLin, William F. Balistreri. (2005) Advances in the treatment of hepatitis C in children and adolescents. Current Hepatitis Reports 4:3, 97-103
CrossRef576
Ana Luc??a Rend??n, Marina N????ez, Miriam Romero, Pablo Barreiro, Luz Mart??n-Carbonero, Javier Garc??a-Samaniego, Inmaculada Jim??nez-N??cher, Juan Gonz??lez-Lahoz, Vincent Soriano. (2005) Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 39:4, 401-405
CrossRef577
Ramesh Prabhu, Padmaja Vittal, Qinyan Yin, Erik Flemington, Robert Garry, William H. Robichaux, Srikanta Dash. (2005) Small interfering RNA effectively inhibits protein expression and negative strand RNA synthesis from a full-length hepatitis C virus clone. Journal of Medical Virology 76:4, 511-519
CrossRef578
Edmund J. Bini, Norbert Brau, Sue Currie, Hui Shen, Bhupinderjit S. Anand, Ke-Qin Hu, Lennox Jeffers, Samuel B. Ho, David Johnson, Warren N. Schmidt, Paul King, Ramsey Cheung, Timothy R. Morgan, Joseph Awad, Marcos Pedrosa, Kyong-Mi Chang, Ayse Aytaman, Franz Simon, Curt Hagedorn, Richard Moseley, Jawad Ahmad, Charles Mendenhall, Bradford Waters, Doris Strader, Anna W. Sasaki, Stephen Rossi, Teresa L. Wright. (2005) Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection. The American Journal of Gastroenterology 100:8, 1772-1779
CrossRef579
Jin-Ching Lee, Ming-Chen Yu, Tzu-Wen Lien, Ching-Fung Chang, John T.-A. Hsu. (2005) High-Throughput Cell-Based Screening for Hepatitis C Virus NS3/4A Protease Inhibitors. ASSAY and Drug Development Technologies 3:4, 385-392
CrossRef580
Kazue Sasaki, Nobuto Minowa, Hiroyuki Kuzuhara, Shoji Nishiyama. (2005) Preventive effects of soyasapogenol B derivatives on liver injury in a concanavalin A-induced hepatitis model. Bioorganic & Medicinal Chemistry 13:16, 4900-4911
CrossRef581
Karen Weck. (2005) Molecular methods of hepatitis C genotyping. Expert Review of Molecular Diagnostics 5:4, 507-520
CrossRef582
C. Payan, F. Roudot-Thoraval, P. Marcellin, N. Bled, G. Duverlie, I. Fouchard-Hubert, P. Trimoulet, P. Couzigou, D. Cointe, C. Chaput, C. Henquell, A. Abergel, J. M. Pawlotsky, C. Hezode, M. Coude, A. Blanchi, S. Alain, V. Loustaud-Ratti, P. Chevallier, C. Trepo, V. Gerolami, I. Portal, P. Halfon, M. Bourliere, M. Bogard, E. Plouvier, C. Laffont, G. Agius, C. Silvain, V. Brodard, G. Thiefin, C. Buffet-Janvresse, G. Riachi, F. Grattard, T. Bourlet, F. Stoll-Keller, M. Doffoel, J. Izopet, K. Barange, M. Martinot-Peignoux, M. Branger, A. Rosenberg, P. Sogni, M. L. Chaix, S. Pol, V. Thibault, P. Opolon, A. Charrois, L. Serfaty, B. Fouqueray, J. D. Grange, J. J. Lefrere, F. Lunel-Fabiani. (2005) Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. Journal of Viral Hepatitis 12:4, 405-413
CrossRef583
Anja Schulze-Krebs, Dorothee Preimel, Yury Popov, Ralf Bartenschlager, Volker Lohmann, Massimo Pinzani, Detlef Schuppan. (2005) Hepatitis C Virus-Replicating Hepatocytes Induce Fibrogenic Activation of Hepatic Stellate Cells. Gastroenterology 129:1, 246-258
CrossRef584
Fu-Chin Huang, Min-Hsiu Shih, Sung-Huei Tseng, Shih-Chin Lin, Ting-Tsung Chang. (2005) Tear Function Changes During Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C. Cornea 24:5, 561-566
CrossRef585
B. McGovern, J. Fiore, A. Wurcel, P. Taglienti, M. Bradley, S. Galvin, G. Libone, J. Ramsey, V. Molinaro-Gudas, S. Drewniak, C. Amick, A. Andalkar, H. Scheft, I. Bica. (2005) Delivering Therapy for Hepatitis C Virus Infection to Incarcerated HIV-Seropositive Patients. Clinical Infectious Diseases 41:Supplement 1, S56-S62
CrossRef586
Atsushi Hokari, Mikio Zeniya, Hiroyasu Esumi, Tomohisa Ishikawa, Yukiko Kurasima, Gotaro Toda. (2005) Role of nitric oxide (NO) in interferon-alpha therapy for hepatitis C. Journal of Infection 51:1, 47-53
CrossRef587
TAKASHI ISHIKAWA, YASUSHI FUKUSHIMA, YUJIRO SHIOBARA, TSUYOSHI KISHIMOTO, SAKIKO TANNO, IKUO SHOJI, TETSURO SUZUKI, TAMANO MATSUI, YASUSHI SHIMADA, TAKAAKI OHYAMA, RYOZO NAGAI, TATSUO MIYAMURA. (2005) Outbreak of hepatitis C virus infection in an outpatient clinic. Journal of Gastroenterology and Hepatology 20:7, 1087-1093
CrossRef588
D. L. Sylvestre. (2005) Approaching Treatment for Hepatitis C Virus Infection in Substance Users. Clinical Infectious Diseases 41:Supplement 1, S79-S82
CrossRef589
F. Marrache, Y. Consigny, M. P. Ripault, D. Cazals-Hatem, M. Martinot, N. Boyer, C. Degott, D. Valla, P. Marcellin. (2005) Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. Journal of Viral Hepatitis 12:4, 421-428
CrossRef590
Wang-Sheng Ko, Chih-Hung Guo, Guoo-Shyng W. Hsu, Ya-Ling Chiou, Maw-Sheng Yeh, Shyu-Rong Yaun. (2005) The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin. Clinical Biochemistry 38:7, 614-620
CrossRef591
N. J. Shire, K. E. Sherman. (2005) Clinical Trials of Treatment for Hepatitis C Virus Infection in HIV-Infected Patients: Past, Present, and Future. Clinical Infectious Diseases 41:Supplement 1, S63-S68
CrossRef592
Uwe Siebert, Gaby Sroczynski, Jürgen Wasem, Wolfgang Greiner, Ulrike Ravens-Sieberer, Pamela Aidelsburger, Bärbel M. Kurth, Monika Bullinger, J.-Matthias Schulenburg, John B. Wong, Siegbert Rossol. (2005) Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. The European Journal of Health Economics 6:2, 112-123
CrossRef593
Zhi Hong. (2005) Ribavirin mutagenesis: Hidden clues in mathematical models. Hepatology 41:6, 1399-1402
CrossRef594
Tami Daugherty, Maurizio Bonacini. (2005) Therapy of hepatitis C in patients with HIV infection. Expert Review of Anti-infective Therapy 3:3, 375-384
CrossRef595
Anastasia M. Rivkin, Sweta Chawla. (2005) Epoetin alfa for the Treatment of Combination Therapy–Induced Hemolytic Anemia in Patients Infected with Hepatitis C Virus. Pharmacotherapy 25:6, 862-875
CrossRef596
HAJIME TOKITA, HIDEO FUKUI, AKIHISA TANAKA, HIROSHI KAMITSUKASA, MICHIYASU YAGURA, HIDEHARU HARADA, HIROAKI OKAMOTO. (2005) Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. Journal of Gastroenterology and Hepatology 20:5, 752-758
CrossRef597
S.-D. Lee, M.-L. Yu, P.-N. Cheng, M.-Y. Lai, Y.-C. Chao, S.-J. Hwang, W.-Y. Chang, T.-T. Chang, T.-Y. Hsieh, C.-J. Liu, D.-S. Chen. (2005) Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis 12:3, 283-291
CrossRef598
CHAO-HUNG HUNG, CHUAN-MO LEE, SHENG-NAN LU, JING-HOUNG WANG, HUNG-DA TUNG, CHIEN-HUNG CHEN, CHI-SIN CHANGCHIEN. (2005) Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. Journal of Gastroenterology and Hepatology 20:5, 727-732
CrossRef599
Zobair M. Younossi, Arthur C. McCullough, David S. Barnes, Anthony Post, Janus P. Ong, Robert O’shea, Lisa M. Martin, Diane Bringman, Denise Farmer, Gavin Levinthal, Kevin D. Mullen, William D. Carey, Anthony S. Tavill, Roy Ferguson, Terry Gramlich. (2005) Pegylated Interferon α-2b, Ribavirin and Amantadine for Chronic Hepatitis C. Digestive Diseases and Sciences 50:5, 970-975
CrossRef600
Kazuhito Naka, Masanori Ikeda, Ken-ichi Abe, Hiromichi Dansako, Nobuyuki Kato. (2005) Mizoribine inhibits hepatitis C virus RNA replication: Effect of combination with interferon-α. Biochemical and Biophysical Research Communications 330:3, 871-879
CrossRef601
Furqaan Ahmed, Ira M. Jacobson. (2005) Management of hematologic side effects: Impact on compliance and efficacy. Current Hepatitis Reports 4:2, 56-60
CrossRef602
Fred Shapiro, Viviane Smeets, Jean-Christophe Donck, Wim Ottevaere. (2005) Innogenetics NV. Personalized Medicine 2:2, 127-133
CrossRef603
D. Posthouwer, I. Plug, J. G. van der Bom, K. Fischer, F. R. Rosendaal, E. P. Mauser-Bunschoten. (2005) Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia 11:3, 270-275
CrossRef604
Gregory T. Everson. (2005) Antiviral therapy in the liver transplant candidate and recipient. Current Hepatitis Reports 4:2, 75-82
CrossRef605
Graham R. Foster, Abid R. Suddle. (2005) Treatment of HCV infection with pegylated interferons. Current Hepatitis Reports 4:2, 49-55
CrossRef606
Harvey U Fracht, Todd J Harvey, Timothy J Bennett. (2005) Transient Corneal Microcysts Associated With Interferon Therapy. Cornea 24:4, 480-481
CrossRef607
Jesper Brok, Lise Lotte Gluud, Christian Gluud, Jesper Brok. 2005. Ribavirin plus interferon versus interferon for chronic hepatitis C. .
CrossRef608
Olav Dalgard. (2005) Follow‐Up Studies of Treatment for Hepatitis C Virus Infection among Injection Drug Users. Clinical Infectious Diseases 40:s5, S336-S338
CrossRef609
Gail Matthews, Ian J. Kronborg, Gregory J. Dore. (2005) Treatment for Hepatitis C Virus Infection among Current Injection Drug Users in Australia. Clinical Infectious Diseases 40:s5, S325-S329
CrossRef610
David L. Veenstra. 2005. The clinical and economic implications of pharmacogenomics. .
CrossRef611
Diana L. Sylvestre. (2005) Treating Hepatitis C Virus Infection in Active Substance Users. Clinical Infectious Diseases 40:s5, S321-S324
CrossRef612
Benigno Rodriguez, David A. Bobak. (2005) Management of hepatitis C in HIV-infected patients. Current Infectious Disease Reports 7:2, 91-102
CrossRef613
Adeel A Butt. (2005) Hepatitis C virus infection: the new global epidemic. Expert Review of Anti-infective Therapy 3:2, 241-249
CrossRef614
FRANCISCO JORQUERA, MARIA J MONTE, JOSE GUERRA, SONIA SANCHEZ-CAMPOS, JOSE A MERAYO, JOSE L OLCOZ, JAVIER GONZALEZ-GALLEGO, JOSE J G MARIN. (2005) Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. Journal of Gastroenterology and Hepatology 20:4, 547-554
CrossRef615
Beth A. Plunkett, William A. Grobman. (2005) Routine hepatitis C virus screening in pregnancy: A cost-effectiveness analysis. American Journal of Obstetrics and Gynecology 192:4, 1153-1161
CrossRef616
Kevin M. Korenblat, Paul D. Berk. (2005) Hyperbilirubinemia in the setting of antiviral therapy. Clinical Gastroenterology and Hepatology 3:4, 303-310
CrossRef617
N. Grancher, F. Kedzierewicz, V. Venard, A. Marsura, C. Finance, A. Le. Faou. (2005) Physicochemical Study of Ribavirin Complexes with α-, β- and γ-Cyclodextrins. Journal of Inclusion Phenomena 51:3-4, 149-157
CrossRef618
C. A. Benson, J. E. Kaplan, H. Masur, A. Pau, K. K. Holmes. (2005) Treating Opportunistic Infections among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clinical Infectious Diseases 40:Supplement 3, S131-S235
CrossRef619
Michael J Grace, David L Cutler, Ronald W Bordens. (2005) Pegylated IFNs for chronic hepatitis C: an update. Expert Opinion on Drug Delivery 2:2, 219-226
CrossRef620
K. Imanaka, S. Tamura, K. Fukui, N. Ito, S. Kiso, Y. Imai, T. Naka, T. Kishimoto, S. Kawata, Y. Shinomura, . (2005) Enhanced expression of suppressor of cytokine signalling-1 in the liver of chronic hepatitis C: possible involvement in resistance to interferon therapy. Journal of Viral Hepatitis 12:2, 130-138
CrossRef621
Oliver G. Pybus, Alexandra Cochrane, Edward C. Holmes, Peter Simmonds. (2005) The hepatitis C virus epidemic among injecting drug users. Infection, Genetics and Evolution 5:2, 131-139
CrossRef622
Samuel Daniel. (2005) Chronic Hepatitis C Treatment Patterns in African American Patients: An Update. The American Journal of Gastroenterology 100:3, 716-722
CrossRef623
G. Y. Minuk, A. J. Cohen, N. Assy, M. Moser. (2005) Viral hepatitis and the surgeon. HPB: Official Journal of The International Hepato Pancreato Biliary Association 7:1, 56-64
CrossRef624
Martine Neau-Cransac, Juliette Foucher, Victor De Ledinghen, Pierre-Henri Bernard, Elisabeth Legrand, Marie-Edith Lafon. (2005) Modifications of T-Lymphocyte Subsets before and during Interferon and Ribavirin Treatment for Chronic Hepatitis C Infection. Viral Immunology 18:1, 197-204
CrossRef625
Jess F. Armor, Javid Fazili, Nagib Toubia, William Kern, Rammurti Kamble, Mohamed A. Kharfan-Dabaja. (2005) Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy. American Journal of Hematology 78:3, 212-215
CrossRef626
Calogero Cammà, Anna Licata, Giuseppe Cabibbo, Federica Latteri, Antonio Craxì. (2005) Treatment of hepatitis C: critical appraisal of the evidence. Expert Opinion on Pharmacotherapy 6:3, 399-408
CrossRef627
Stephen J. Rulyak, Sue C. Eng, Keyur Patel, John G. McHutchison, Stuart C. Gordon, Kris V. Kowdley. (2005) Relationships between Hepatic Iron Content and Virologic Response in Chronic Hepatitis C Patients Treated with Interferon and Ribavirin. The American Journal of Gastroenterology 100:2, 332-337
CrossRef628
A. Scalori, M. Pozzi, V. Bellia, P. Apale, G. Santamaria, T. Bordoni, A. Redaelli, A. Avolio, P. Parravicini, P. Pioltelli, L. Roffi. (2005) Interferon-induced depression: prevalence and management. Digestive and Liver Disease 37:2, 102-107
CrossRef629
Wolf Peter Hofmann, Stefan Zeuzem, Christoph Sarrazin. (2005) Hepatitis C virus-related resistance mechanisms to interferon α-based antiviral therapy. Journal of Clinical Virology 32:2, 86-91
CrossRef630
Richard K. Sterling, Robert S. Brown, Charlotte M. Hofmann, Velimir A. Luketic, R. Todd Stravitz, Arun J. Sanyal, Melissa J. Contos, A. Scott Mills, Vernon Smith, Mitchell L. Shiffman. (2005) The Spectrum of Chronic Hepatitis C Virus Infection in the Virginia Correctional System: Development of a Strategy for the Evaluation and Treatment of Inmates with HCV. The American Journal of Gastroenterology 100:2, 313-321
CrossRef631
Masao Honda, Takeo Shimazaki, Shuichi Kaneko. (2005) La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation. Gastroenterology 128:2, 449-462
CrossRef632
Rasa Bertuzis, Alison Hardie, Barbara Hottentraeger, Jacques Izopet, Wolfgang Jilg, Barbara Kaesdorf, Gregor Leckie, Jean Leete, Luc Perrin, Chunfu Qiu, Iris Ran, George Schneider, Peter Simmonds, John Robinson. (2005) Clinical performance of the LCx® HCV RNA quantitative assay. Journal of Virological Methods 123:2, 171-178
CrossRef633
Masanori BABA. (2005) Advances in antiviral chemotherapy. Uirusu 55:1, 69-75
CrossRef634
ROBIN C. HILSABECK, TAREK I. HASSANEIN, ELIZABETH A. ZIEGLER, MEGHAN D. CARLSON, WILLIAM PERRY. (2005) Effect of Interferon-[alpha] on cognitive functioning in patients with chronic hepatitis C. Journal of the International Neuropsychological Society 11:01,
CrossRef635
Koichi WATASHI, Kunitada SHIMOTOHNO. (2005) Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents. Uirusu 55:1, 105-110
CrossRef636
Yukako Ito, Biranchinarayan Tosh, Yusuke Togashi, Kikuko Amagase, Tsunao Kishida, Tsunataro Kishida, Nobuyuki Sugioka, Nobuhito Shibata, Kanji Takada. (2005) Absorption of interferon alpha from patches in rats. Journal of Drug Targeting 13:6, 383-390
CrossRef637
Akihito Tsubota, Yasuji Arase, Takashi Someya, Yoshiyuki Suzuki, Fumitaka Suzuki, Satoshi Saitoh, Kenji Ikeda, Norio Akuta, Tetsuya Hosaka, Masahiro Kobayashi, Hiromitsu Kumada. (2005) Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for na
CrossRef638
L Gallelli, M Ferraro, G F Mauro, G De Sarro. (2005) Generalised Dermatitis Induced by Pegylated Interferon-??-2b in a Patient Infected with Genotype-1 Hepatitis C Virus. Clinical Drug Investigation 25:4, 281-284
CrossRef639
Joji TOYOTA, Yosiyasu KARINO, Jun AKAIKE, Takumi OHMURA, Takahiro SATO, Katsu YAMAZAKI, Yasuaki KUWATA, Shiro IINO. (2005) Total clearance (CL/F) of ribavirin is the factor most influencing incidence of hemolytic anemia in interferon .ALPHA. plus ribavirin combination therapy. Kanzo 46:3, 107-118
CrossRef640
Takaji WAKITA. (2005) Kanzo 46:12, 691-702
CrossRef641
T. Barry Kelleher, Nezam H. Afdhal. (2005) Maintenance therapy for chronic hepatitis C. Current Gastroenterology Reports 7:1, 50-53
CrossRef642
Chiaki Okuse, Jo Ann Rinaudo, Kristine Farrar, Frances Wells, Brent E. Korba. (2005) Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Research 65:1, 23-34
CrossRef643
Tae Hun Kim, Kyung A. Kim, Young Seok Lim, Geum-youn Gwak, Jung-Hwan Yoon, Gyeong Hoon Kang, Hyo-Suk Lee. (2005) Prediction of Treatment Outcome in Chronic Hepatitis C Patients Based on Early Viral Dynamics during High-Dose Induction Interferon and Ribavirin Therapy. Intervirology 48:4, 230-238
CrossRef644
Michael R. Charlton, K.V. Narayanan Menon. 2005. Late Complications of Liver Transplantation and Recurrence of Disease. , 995-1017.
CrossRef645
Michel Tod, Muriel Farcy-Afif, Jeanick Stocco, Nathalie Boyer, Val??rie Bouton, Martine Sin??gre, Patrick Marcellin. (2005) Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C. Clinical Pharmacokinetics 44:4, 417-428
CrossRef646
R. Moreno-Otero. (2005) Therapeutic modalities in hepatitis C: challenges and development. Journal of Viral Hepatitis 12:1, 10-19
CrossRef647
Yasuji Arase, Kenji Ikeda, Akihito Tsubota, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi, Norio Akuta, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Mariko Kobayashi, Hiromitsu Kumada. (2005) Significance of Serum Ribavirin Concentration in Combination Therapy of Interferon and Ribavirin for Chronic Hepatitis C. Intervirology 48:2-3, 138-144
CrossRef648
Charles L Raison, Marina Demetrashvili, Lucile Capuron, Andrew H Miller. (2005) Neuropsychiatric Adverse Effects of Interferon-??. CNS Drugs 19:2, 105-123
CrossRef649
James F. Calvert, Paula C. Goldenberg, Cathy Schock. (2005) Chronic Hepatitis C Infection in a Rural Medicaid HMO. The Journal of Rural Health 21:1, 74-78
CrossRef650
M. Raptopoulou, D. Tsantoulas, I. Vafiadi, I. Ketikoglou, E. Paraskevas, T. Vassiliadis, S. Kanatakis, G. Hatzis, L. Sidiropoulos, E. Akriviadis. (2005) The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. Journal of Viral Hepatitis 12:1, 91-95
CrossRef651
Uwe Siebert, Gaby Sroczynski, . (2005) Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security. International Journal of Technology Assessment in Health Care 21:01,
CrossRef652
Namiki Izumi, Asahina Yasuhiro, Masayuki Kurosaki, Yuko Onuki, Yuki Nishimura, Kazunari Inoue, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Masakatsu Uchihara, Shozo Miyake. (2005) Development of Hepatocellular Carcinoma after Interferon Therapy in Chronic Hepatitis C. Intervirology 48:1, 59-63
CrossRef653
Shinya NAKAJIMA. (2005) Effective use of minute quantities of IFN for hard-to-cure cirrhosis of the liver with hepatitis C virus infection. Kanzo 46:5, 257-261
CrossRef654
A. A. Butt, M. Wagener, A. O. Shakil, J. Ahmad. (2005) Reasons for non-treatment of hepatitis C in veterans in care. Journal of Viral Hepatitis 12:1, 81-85
CrossRef655
Dragan Delic, Zorica Nesic, Milica Prostran, Nebojsa Maksic, Milisav Cutovic, Jasmina Simonovic, Neda Svirtlih. (2005) The relationship of serum aminotransferase levels to viral load and genotype in chronic hepatitis C. Jugoslovenska medicinska biohemija 24:4, 247-252
CrossRef656
Andrew F. Angelino, Glenn J. Treisman. (2005) Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. International Review of Psychiatry 17:6, 471-476
CrossRef657
Mirabel Pai, Ramesh Prabhu, Alfredo Panebra, Sarah Nangle, Salima Haque, Frank Bastian, Robert Garry, Krishna Agrawal, Steve Goodbourn, Srikanta Dash. (2005) Activation of Interferon-Stimulated Response Element in Huh-7 Cells Replicating Hepatitis C Virus Subgenomic RNA. Intervirology 48:5, 301-311
CrossRef658
Narendra M. Dixit, Jennifer E. Layden-Almer, Thomas J. Layden, Alan S. Perelson. (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432:7019, 922-924
CrossRef659
T. Watkins-Riedel, P. Ferenci, P. Steindl-Munda, M. Gschwantler, C. Mueller, M. Woegerbauer. (2004) Early Prediction of Hepatitis C Virus (HCV) Infection Relapse in Nonresponders to Primary Interferon Therapy by means of HCV RNA Whole-Blood Analysis. Clinical Infectious Diseases 39:12, 1754-1760
CrossRef660
Eric J. Lawitz, Matthew J. Hepburn, Thomas J. Casey. (2004) A Pilot Study of Interleukin-11 in Subjects with Chronic Hepatitis C and Advanced Liver Disease Nonresponsive to Antiviral Therapy. The American Journal of Gastroenterology 99:12, 2359-2364
CrossRef661
Wan-Long Chuang, Chia-Yen Dai, Shinn-Cherng Chen, Li-Po Lee, Zu-Yau Lin, Ming-Yuh Hsieh, Liang-Yen Wang, Ming-Lung Yu, Wen-Yu Chang. (2004) Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. Liver International 24:6, 595-602
CrossRef662
(2004) Hepatitis and reproduction. Fertility and Sterility 82:6, 1754-1764
CrossRef663
Derek T. O’Hagan, Manmohan Singh, Christine Dong, Mildred Ugozzoli, Kim Berger, Edward Glazer, Mark Selby, Mark Wininger, Philip Ng, Kevin Crawford, Xavier Paliard, Steven Coates, Michael Houghton. (2004) Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23:5, 672-680
CrossRef664
Regino P. González-Peralta. (2004) Treatment of chronic hepatitis C in children. Pediatric Transplantation 8:6, 639-643
CrossRef665
EVA HERRMANN, CHRISTOPH SARRAZIN. (2004) Hepatitis C viral kinetics. Journal of Gastroenterology and Hepatology 19:s7, S133-S137
CrossRef666
James R. Jacob, Brent E. Korba, Jung Eun You, Bud C. Tennant, Young-Ho Kim. (2004) Korean Medicinal Plant Extracts Exhibit Antiviral Potency Against Viral Hepatitis. The Journal of Alternative and Complementary Medicine 10:6, 1019-1026
CrossRef667
MATTHIAS J BAHR, MICHAEL P MANNS. (2004) Treatment of chronic HCV infection in compensated and decompensated cirrhosis. Journal of Gastroenterology and Hepatology 19:s7, S94-S98
CrossRef668
Arun Chakrabarty, Karl Beutner. (2004) Therapy of other viral infections: herpes to hepatitis. Dermatologic Therapy 17:6, 465-490
CrossRef669
ERWIN SABLON, FRED SHAPIRO. (2004) Hepatitis B and C genotyping: methodologies and implications for patient management. Journal of Gastroenterology and Hepatology 19:s7, S329-S337
CrossRef670
Amany Zekry, Keyur Patel, Andrew Muir, John G. McHutchison. (2004) Tinkering and tailoring with HCV therapy: Can we get away with less?. Hepatology 40:6, 1249-1251
CrossRef671
A. Airoldi, C. Zavaglia, E. Silini, C. Tinelli, M. Martinetti, M. Asti, A. Rossini, M. Vangeli, L. Salvaneschi, G. Pinzello. (2004) Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to alpha-interferon treatment in patients with chronic hepatitis C. European Journal of Immunogenetics 31:6, 259-265
CrossRef672
Yoshiaki Iwasaki, Kouichi Takaguchi, Hiroshi Ikeda, Yasuhiro Makino, Yasuyuki Araki, Masaharu Ando, Haruhiko Kobashi, Toshitsugu Kobatake, Ryoji Tanaka, Minoru Tomita, Tomonori Senoh, Mitsuhiko Kawaguchi, Toshinari Shimoe, Koji Manabe, Keiji Kita, Junnosuke Shimamura, Kohsaku Sakaguchi, Yasushi Shiratori. (2004) Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver International 24:6, 603-610
CrossRef673
A. Vallejo, S. Molina-Pinelo, M. A. Abad, G. G
CrossRef674
G. Fattovich, I. Zagni, M. L. Ribero, E. Castagnetti, E. Minola, L. Lomonaco, C. Scattolini, P. Fabris, S. Boccia, M. Giusti, G. Abbati, M. Felder, P. Rovere, A. Redaelli, A. Tonon, A. Tomba, R. Montanari, C. Paternoster, M. Distasi, G. Fornaciari, G. Tositti, C. Rizzo, S. Suppressa, M. Pantalena, F. Noventa, A. Tagger. (2004) A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. Journal of Viral Hepatitis 11:6, 543-551
CrossRef675
HIDEYUKI NOMURA, HIRONORI TANIMOTO, EIJI KAJIWARA, JUNYA SHIMONO, TOSHIHIRO MARUYAMA, NOBUYUKI YAMASHITA, MASANORI NAGANO, MASASHI HIGASHI, TAMOTSU MUKAI, YUTAKA MATSUI, JUN HAYASHI, SEIZABURO KASHIWAGI, HIROMI ISHIBASHI. (2004) Factors contributing to ribavirin-induced anemia. Journal of Gastroenterology and Hepatology 19:11, 1312-1317
CrossRef676
Sandrine Castelain, Véronique Descamps, Vincent Thibault, Catherine François, Dorine Bonte, Virginie Morel, Jacques Izopet, Dominique Capron, Patricia Zawadzki, Gilles Duverlie. (2004) TaqMan amplification system with an internal positive control for HCV RNA quantitation. Journal of Clinical Virology 31:3, 227-234
CrossRef677
Lorna M Dove. (2004) Management of hepatitis C after transplantation. European Journal of Gastroenterology & Hepatology 16:11, 1131-1133
CrossRef678
Naoki Fujita, Masahiko Kaito, Hideaki Tanaka, Shinichiro Horiike, Yukihiko Adachi. (2004) Reduction of Serum HCV RNA Titer by Bezafibrate Therapy in Patients with Chronic Hepatitis C. The American Journal of Gastroenterology 99:11, 2280-2280
CrossRef679
M.D. Tanamly, F. Tadros, S. Labeeb, H. Makld, M. Shehata, N. Mikhail, M. Abdel-Hamid, M. Shehata, L. Abu-Baki, A. Medhat, L.S. Magder, N.H. Afdhal, G.T. Strickland. (2004) Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Digestive and Liver Disease 36:11, 752-759
CrossRef680
Armand Abergel, Claude Darcha, Michèle Chevallier, Sylvie Ughetto, Cécile Henquell, Stanislas Pol, Victor de Ledinghen, Valérie Canva, Jean Pierre Bronowicki, Albert Tran, Nathalie Martineau, Hélène Lafeuille, Pierre Dechelotte, Gilles Bommelaer, Corinne Bonny. (2004) Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. European Journal of Gastroenterology & Hepatology 16:11, 1219-1227
CrossRef681
Natsuko Tsuda, Nobukazu Yuki, Kiyoshi Mochizuki, Takayuki Nagaoka, Masatoshi Yamashiro, Masao Omura, Kazumasa Hikiji, Michio Kato. (2004) Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. Journal of Medical Virology 74:3, 406-413
CrossRef682
Jian-Qiu Han, Greggory Wroblewski, Zan Xu, Robert H. Silverman, David J. Barton. (2004) Sensitivity of Hepatitis C Virus RNA to the Antiviral Enzyme Ribonuclease L Is Determined by a Subset of Efficient Cleavage Sites. Journal of Interferon & Cytokine Research 24:11, 664-676
CrossRef683
AYMAN A ABDO, SAMUEL S LEE. (2004) Management of hepatitis C virus genotype 4. Journal of Gastroenterology and Hepatology 19:11, 1233-1239
CrossRef684
R. J. Aspinall, P. J. Pockros. (2004) The management of side-effects during therapy for hepatitis C. Alimentary Pharmacology and Therapeutics 20:9, 917-929
CrossRef685
Naglaa H. Shoukry, Andrew G. Cawthon, Christopher M. Walker. (2004) CELL-MEDIATED IMMUNITY AND THE OUTCOME OF HEPATITIS C VIRUS INFECTION. Annual Review of Microbiology 58:1, 391-424
CrossRef686
Piero R Bianco. (2004) Hepatitis C NS3 helicase unwinds RNA in leaps and bounds. The Lancet 364:9443, 1385-1387
CrossRef687
Yi-Wei Tang, Haijing Li, Ann Roberto, Diane Warner, Belinda Yen-Lieberman. (2004) Detection of hepatitis C virus by a user-developed reverse transcriptase-PCR and use of amplification products for subsequent genotyping. Journal of Clinical Virology 31:2, 148-152
CrossRef688
A. Alberti, L. Benvegnù, S. Boccato, A. Ferrari, G. Sebastiani. (2004) Natural history of initially mild chronic hepatitis C. Digestive and Liver Disease 36:10, 646-654
CrossRef689
Ewa Orlewska. (2004) Cost-effectiveness of pegylated IFN-α 2b and - 2a and ribavirin for chronic hepatitis C treatment. Expert Review of Pharmacoeconomics & Outcomes Research 4:5, 495-504
CrossRef690
Katsuyuki Namba, Kazuhito Naka, Hiromichi Dansako, Akito Nozaki, Masanori Ikeda, Yasushi Shiratori, Kunitada Shimotohno, Nobuyuki Kato. (2004) Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype. Biochemical and Biophysical Research Communications 323:1, 299-309
CrossRef691
G. R. Foster. (2004) Pegylated interferons: chemical and clinical differences. Alimentary Pharmacology and Therapeutics 20:8, 825-830
CrossRef692
Y. Wang, J. R. Jacob, S. Menne, C. A. Bellezza, B. C. Tennant, J. L. Gerin, P. J. Cote. (2004) Interferon-gamma-associated responses to woodchuck hepatitis virus infection in neonatal woodchucks and virus-infected hepatocytes. Journal of Viral Hepatitis 11:5, 404-417
CrossRef693
Beth A. Plunkett, William A. Grobman. (2004) Elective cesarean delivery to prevent perinatal transmission of hepatitis C virus: A cost-effectiveness analysis. American Journal of Obstetrics and Gynecology 191:3, 998-1003
CrossRef694
Robert J. Fontana. (2004) Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. Gastroenterology Clinics of North America 33:3, 527-547
CrossRef695
P.-N. Cheng, P. Marcellin, B. Bacon, G. Farrell, I. Parsons, T. Wee, T.-T. Chang. (2004) Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients. Journal of Viral Hepatitis 11:5, 418-426
CrossRef696
Furqaan Ahmed, Ira M. Jacobson. (2004) Treatment of relapsers after combination therapy for chronic hepatitis C. Gastroenterology Clinics of North America 33:3, 513-526
CrossRef697
Fuad Hasan, Haifa Asker, Jameela Al-Khaldi, Iqbal Siddique, Misfer Al-Ajmi, Salim Owaid, Rosh Varghese, Basil Al-Nakib. (2004) Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C Genotype 4. The American Journal of Gastroenterology 99:9, 1733-1737
CrossRef698
Montserrat Laguno, Javier Murillas, Jos?? Luis Blanco, Esteban Mart??nez, Rosa Miquel, Jos?? M S??nchez-Tapias, Xavier Bargallo, Angeles Garc??a-Criado, Elisa de Lazzari, Mar??a Larrousse, Agathe Le??n, Montserrat Lonc??, Ana Milinkovic, Josep M Gatell, Josep Mallolas. (2004) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18:13, 27-36
CrossRef699
Martin Schaefer, Andreas Heinz, Markus Backmund. (2004) Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. Addiction 99:9, 1167-1175
CrossRef700
Bruce R. Bacon. (2004) Chronic Hepatitis C and Normal ALT: Considerations for Treatment. The American Journal of Gastroenterology 99:9, 1706-1707
CrossRef701
Sangik Oh, Nezam H. Afdhal. (2004) Antiviral therapy for treatment naı̈ve patients with hepatitis C virus. Gastroenterology Clinics of North America 33:3, 497-511
CrossRef702
Tim D. Jones, Marian Hanlon, Beverley J. Smith, Charles T. Heise, Prakash D. Nayee, Deborah A. Sanders, Anita Hamilton, Clive Sweet, Esther Unitt, Graeme Alexander, Kin-Ming Lo, Stephen D. Gillies, Frank J. Carr, Matthew P. Baker. (2004) The Development of a Modified Human IFN-α2b Linked to the Fc Portion of Human IgG1 as a Novel Potential Therapeutic for the Treatment of Hepatitis C Virus Infection. Journal of Interferon & Cytokine Research 24:9, 560-572
CrossRef703
Ira M. Jacobson, Furqaan Ahmed, Mark W Russo, Edward Lebovics, Douglas T. Dieterich, Stephen P. Esposito, Nancy Bach, Franklin Klion, Hillel Tobias, Louis Antignano, Robert S. Brown, David Gabbaizadeh, Jane Geders, Hulya Levendoglu. (2004) Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT. The American Journal of Gastroenterology 99:9, 1700-1705
CrossRef704
M. Enomoto, S. Nishiguchi, M. Kohmoto, A. Tamori, D. Habu, T. Takeda, S. Seki, S. Shiomi. (2004) Effects of ribavirin combined with interferon-alpha2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. Journal of Viral Hepatitis 11:5, 448-454
CrossRef705
Roberta Soffredini, Maria Grazia Rumi, Maria Luisa Parravicini, Guido Ronchi, Ersilio Del Ninno, Antonio Russo, Massimo Colombo. (2004) Serum Levels of Hepatitis C Virus Core Antigen as a Marker of Infection and Response to Therapy. The American Journal of Gastroenterology 99:9, 1738-1743
CrossRef706
SIDHARTHA HAZARI, SUBRAT KUMAR PANDA, SIDDHARTH DATTA GUPTA, YOGESH BATRA, RAJBIR SINGH, SUBRAT KUMAR ACHARYA. (2004) Treatment of hepatitis C virus infection in patients of northern India. Journal of Gastroenterology and Hepatology 19:9, 1058-1065
CrossRef707
Juan I. Arenas, Hugo E. Vargas. (2004) Hepatitis C virus antiviral therapy in patients with cirrhosis. Gastroenterology Clinics of North America 33:3, 549-562
CrossRef708
S. Maekawa, N. Enomoto, N. Sakamoto, M. Kurosaki, E. Ueda, T. Kohashi, H. Watanabe, C.-H. Chen, T. Yamashiro, Y. Tanabe, N. Kanazawa, M. Nakagawa, C. Sato, M. Watanabe. (2004) Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficiently in Huh-7 cells. Journal of Viral Hepatitis 11:5, 394-403
CrossRef709
Angelo G. Coppola, Pietor C. Karakousis, David C. Metz, Mae F. Go, M Mhokashi, Colin W. Howden, Jean-Pierre Raufman, Virender K. Sharma. (2004) Hepatitis C Knowledge among Primary Care Residents: Is Our Teaching Adequate for the Times?. The American Journal of Gastroenterology 99:9, 1720-1725
CrossRef710
Alexander Monto. (2004) Alcohol and hepatitis C: Implications for disease progression and treatment. Current Hepatitis Reports 3:3, 105-111
CrossRef711
Eric J Gowans, Kathryn L Jones, Mandvi Bharadwaj, David C Jackson. (2004) Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. Journal of Clinical Virology 30:4, 283-290
CrossRef712
M.Lamine Mbow, Robert T. Sarisky. (2004) What is disrupting IFN-α's antiviral activity?. Trends in Biotechnology 22:8, 395-399
CrossRef713
Michael Stuart Forman, Alexandra Valsamakis. (2004) Increased Sensitivity of the Roche COBAS AMPLICOR HCV Test, Version 2.0, Using Modified Extraction Techniques. The Journal of Molecular Diagnostics 6:3, 225-230
CrossRef714
Pierre Pradat, Marianne Maynard, Maria Buti, Pascale Berthillon, Gaston Picchio, Hans L. Tillmann, Johannes Wiegand, Nicolas Voirin, Michael P. Manns, Juan-Ignacio Esteban, Mich
CrossRef715
G. V. Papatheodoridis, E. Cholongitas. (2004) Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. Journal of Viral Hepatitis 11:4, 287-296
CrossRef716
Javad Behravan, Hassan Ahmadpour. (2004) Cloning and characterization of directly amplified antiviral gene interferon alpha-2b (hulfnα-2b) from human leukocytes chromosomal DNA. Archives of Pharmacal Research 27:7, 776-780
CrossRef717
Kenneth L. Smith, Vicky C.H. Lai, Brett J. Prigaro, Yili Ding, Esmir Gunic, Jean-Luc Girardet, Weidong Zhong, Zhi Hong, Stanley Lang, Haoyun An. (2004) Synthesis of new 2′-β-C-methyl related triciribine analogues as anti-HCV agents. Bioorganic & Medicinal Chemistry Letters 14:13, 3517-3520
CrossRef718
T. Griga, W. Schmiegel, H. Henke. (2004) Prognostic value of soluble interleukin-2 receptor plasma levels in non-responders with chronic hepatitis C treated with pegylated interferon alpha 2b and ribavirin / Der prognostische Wert von Plasmaspiegeln des löslichen Interleukin-2-Rezeptors in mit pegyliertem Interferon alpha 2b und Ribavirin behandelten Non-Respondern mit chronischer Hepatitis C. LaboratoriumsMedizin 28:3, 288-292
CrossRef719
Jill P. Smith, Thomas R. Riley, Sandra Bingaman, David T. Mauger. (2004) Amantadine Therapy for Chronic Hepatitis C: A Dose Escalation Study. The American Journal of Gastroenterology 99:6, 1099-1104
CrossRef720
Kuo-Hsiung Shu, Joung-Liang Lan, Ming-Ju Wu, Chi-Hung Cheng, Chen-Hsu Chen, Wen-Chin Lee, Horng-Rong Chang, Jong-Da Lian. (2004) ULTRALOW-DOSE ALPHA-INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF ACTIVE HEPATITIS C IN RENAL TRANSPLANT RECIPIENTS. Transplantation 77:12, 1894-1896
CrossRef721
Mark A. Virtue, Julie K. Furne, Samuel B. Ho, Michael D. Levitt. (2004) Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival. American Journal of Hematology 76:2, 107-113
CrossRef722
Natalie Stieltjes, Nadra Ounnoughene, Emilie Sava, Patricia Paugy, Valerie Roussel-Robert, Arielle R. Rosenberg, Benoit Terris, Dominique Salmon-Ceron, Philippe Sogni. (2004) Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus. British Journal of Haematology 125:6, 769-776
CrossRef723
M SORESI, G BONFISSUTO, R SESTI, A RIILI, G DIGIOVANNI, A CARROCCIO, S TRIPI, G MONTALTO. (2004) Perihepatic lymph nodes and antiviral response in chronic HCV-associated hepatitis. Ultrasound in Medicine & Biology 30:6, 711-717
CrossRef724
Clodoveo Ferri, Marco Sebastiani, Dilia Giuggioli, Massimiliano Cazzato, Giovanni Longombardo, Alessandro Antonelli, Rodolfo Puccini, Claudio Michelassi, Anna Linda Zignego. (2004) Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Seminars in Arthritis and Rheumatism 33:6, 355-374
CrossRef725
Lennox J. Jeffers, William Cassidy, Charles D. Howell, Sylvia Hu, K. Rajender Reddy. (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39:6, 1702-1708
CrossRef726
Eric Dieperink, Samuel B. Ho, Lori Tetrick, Paul Thuras, Kulwinder Dua, Mark L. Willenbring. (2004) Suicidal ideation during interferon-α2b and ribavirin treatment of patients with chronic hepatitis C. General Hospital Psychiatry 26:3, 237-240
CrossRef727
Emiliano Giostra, Gerd A. Kullak-Ublick, Walter Keller, Ronald Fried, Claire Vanlemmens, Stephan Kraehenbuhl, Sandrine Locher, Hans-Peter Egger, Pierre-Alain Clavien, Antoine Hadengue, Gilles Mentha, Philippe Morel, Francesco Negro. (2004) Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transplant International 17:4, 169-176
CrossRef728
GERRY C MACQUILLAN, XIANWA NIU, DAVID SPEERS, SUZANNE ENGLISH, GEORGE GARAS, GERRY B HARNETT, WILLIAM D REED, JANE E ALLAN, GARY P JEFFREY. (2004) Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?. Journal of Gastroenterology and Hepatology 19:5, 551-557
CrossRef729
R. T. Marinho, R. Pinto, M. L. Santos, I. V. Lobos, M. C. Moura. (2004) Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. Journal of Viral Hepatitis 11:3, 206-216
CrossRef730
MASAAKI SHIINA, KOJU KOBAYASHI, HIROKO SATOH, HIROFUMI NIITSUMA, YOSHIYUKI UENO, TOORU SHIMOSEGAWA. (2004) Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C. Journal of Gastroenterology and Hepatology 19:5, 558-564
CrossRef731
Richard K. Sterling, Charlotte M. Hofmann, Velimir A. Luketic, Arun J. Sanyal, Melissa J. Contos, A. Scott Mills, Mitchell L. Shiffman. (2004) Treatment of Chronic Hepatitis C Virus in the Virginia Department of Corrections: Can Compliance Overcome Racial Differences to Response?. The American Journal of Gastroenterology 99:5, 866-872
CrossRef732
M. S. Sulkowski, R. Wasserman, L. Brooks, L. Ball, R. Gish. (2004) Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Journal of Viral Hepatitis 11:3, 243-250
CrossRef733
N. Kumagai, N. Takahashi, M. Kinoshita, S. Tsunematsu, K. Tsuchimoto, H. Saito, H. Ishii. (2004) Polymorphisms of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: a pilot study. Journal of Viral Hepatitis 11:3, 225-235
CrossRef734
H.G. Hass, C. Kreysel, O. Nehls, M. Gregor, S. Kaiser. (2004) Correspondence. Digestive and Liver Disease 36:5, 367-368
CrossRef735
E. Santagostino, F. De Filippi, M. G. Rumi, M. Rivi, M. Colombo, P. M. Mannucci, . (2004) Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. Transfusion 44:5, 790-794
CrossRef736
N. Brau. (2004) Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. Journal of Viral Hepatitis 11:3, 191-197
CrossRef737
Megan J Brooks, Joseph J Sasadeusz, Gregory A Tannock. (2004) Antiviral chemotherapeutic agents against respiratory viruses. Current Opinion in Pulmonary Medicine 10:3, 197-203
CrossRef738
Edward P. Armstrong, Scott L. Charland. (2004) Burden of illness of hepatitis C from a managed care organization perspective. Current Medical Research and Opinion 20:5, 671-679
CrossRef739
F. Suzuki, Y. Arase, Y. Suzuki, A. Tsubota, N. Akuta, T. Hosaka, T. Someya, M. Kobayashi, S. Saitoh, K. Ikeda, M. Kobayashi, M. Matsuda, K. Takagi, J. Satoh, H. Kumada. (2004) Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. Journal of Viral Hepatitis 11:3, 271-276
CrossRef740
Mark S. Sulkowski, Franco Felizarta, Cheryl Smith, Jidah Slim, Ruth Berggren, Russell Goodman, Lisa Ball, Mandana Khalili, Douglas T. Dieterich. (2004) Daily Versus Thrice-Weekly Interferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Persons: A Multicenter Randomized Controlled Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes 35:5, 464-472
CrossRef741
Doris B. Strader, Teresa Wright, David L. Thomas, Leonard B. Seeff. (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:4, 1147-1171
CrossRef742
Norbert Bräu, Maribel Rodriguez-Torres, Dale Prokupek, Maurizio Bonacini, Carol A. Giffen, Jeffery J. Smith, Kevin R. Frost, Jay R. Kostman. (2004) Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs. 16-week delayed ribavirin. Hepatology 39:4, 989-998
CrossRef743
Jacqueline O’Leary, Raymond T Chung. (2004) New antiviral therapies for hepatitis C. Expert Review of Anti-infective Therapy 2:2, 235-243
CrossRef744
Oluwatoyin M. Adeyemi, Donald Jensen, Bashir Attar, Rony Ghaoui, Maureen Gallagher, Deborah Wolen, Scott J. Cotler. (2004) Hepatitis C Treatment Eligibility in an Urban Population with and without HIV Coinfection. AIDS Patient Care and STDs 18:4, 239-245
CrossRef745
Susan Zickmund, Stephen L. Hillis, Mitchell J. Barnett, Laura Ippolito, Douglas R. LaBrecque. (2004) Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 39:4, 999-1007
CrossRef746
Brian L. Pearlman. (2004) Hepatitis C Infection: A Clinical Review. Southern Medical Journal 97:4, 365-373
CrossRef747
Brian R. Edlin. (2004) Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. International Journal of Drug Policy 15:2, 81-91
CrossRef748
Keyur Patel, Anouk T. Dev. (2004) Adherence to antiviral therapy in chronic hepatitis C. Current Hepatitis Reports 3:1, 10-15
CrossRef749
Ayumu Kurimoto, Tetsuhiro Ogino, Shinji Ichii, Yoshiaki Isobe, Masanori Tobe, Haruhisa Ogita, Haruo Takaku, Hironao Sajiki, Kosaku Hirota, Hajime Kawakami. (2004) Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. Bioorganic & Medicinal Chemistry 12:5, 1091-1099
CrossRef750
Michael P Manns. (2004) Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterology Clinics of North America 33:1, 11-24
CrossRef751
J Lee. (2004) A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells. Journal of Virological Methods 116:1, 27-33
CrossRef752
Paul J. Pockros. (2004) Current status of immunomodulatory therapies in HCV infection. Current Hepatitis Reports 3:1, 16-22
CrossRef753
S. Pol, P. Lebra, A. Vallet-Pichard. (2004) HIV Infection and Hepatic Enzyme Abnormalities: Intricacies of the Pathogenic Mechanisms. Clinical Infectious Diseases 38:Supplement 2, S65-S72
CrossRef754
P. Lebray, H. Zylberberg, S. Hue, B. Poulet, F. Carnot, S. Martin, Y. Chretien, S. Pol, S. Caillat-Zuckman, C. Brechot, B. Nalpas. (2004) Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. Journal of Viral Hepatitis 11:2, 175-182
CrossRef755
Eva Herrmann, Stefan Zeuzem. (2004) Update on viral kinetics and hcv antiviral therapy. Current Hepatitis Reports 3:1, 5-9
CrossRef756
Stephanos J. Hadziyannis, George V. Papatheodoridis. (2004) Recent peginterferon and ribavirin combination trials. Current Hepatitis Reports 3:1, 30-37
CrossRef757
Karan Emerick. (2004) TREATMENT OF HEPATITIS C IN CHILDREN. The Pediatric Infectious Disease Journal 23:3, 257-258
CrossRef758
Peter Hauser. (2004) Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFNα-induced depression. Gastroenterology Clinics of North America 33:1, 37-50
CrossRef759
Jean-Michel Pawlotsky, Harel Dahari, Avidan U. Neumann, Christophe Hezode, Georgios Germanidis, Isabelle Lonjon, Laurent Castera, Daniel Dhumeaux. (2004) Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126:3, 703-714
CrossRef760
Robert G. Gish. (2004) Treating hepatitis C: the state of the art. Gastroenterology Clinics of North America 33:1, 1-9
CrossRef761
Masao Omata, Haruhiko Yoshida. (2004) Prevention and treatment of hepatocellular carcinoma. Liver Transplantation 10:S2, S111-S114
CrossRef762
S Briolant, D Garin, N Scaramozzino, A Jouan, J.M Crance. (2004) In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-α and ribavirin combination. Antiviral Research 61:2, 111-117
CrossRef763
Amedeo Lonardo, Luigi E. Adinolfi, Paola Loria, Nicola Carulli, Giuseppe Ruggiero, Christopher P. Day. (2004) Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126:2, 586-597
CrossRef764
N.K. Sana ., I. Hossin ., E.M. Haque ., Ranajit Kumar Shaha .. (2004) Identification, Purification and Characterization of Lipase from Germinating Oil Seeds (Brassica napus L.). Pakistan Journal of Biological Sciences 7:2, 246-252
CrossRef765
Joseph Ahn, Steven Flamm. (2004) Peginterferon-α2b and ribavirin. Expert Review of Anti-infective Therapy 2:1, 17-25
CrossRef766
Gregor Leckie, George Schneider, Klara Abravaya, Robert Hoenle, Julie Johanson, John Lampinen, Reuben Ofsaiof, Lisa Rundle, Shruti Shah, Andrea Frank, Dan Toolsie, Roy Vijesurier, Hong Wang, John Robinson. (2004) Performance attributes of the LCx® HCV RNA quantitative assay. Journal of Virological Methods 115:2, 207-215
CrossRef767
Nelson Acosta-Rivero, Santiago Dueñas-Carrera, Liz Alvarez-Lajonchere, Juan Morales-Grillo. (2004) HCV core protein-expressing DNA vaccine induces a strong class I-binding peptide DTH response in mice. Biochemical and Biophysical Research Communications 314:3, 781-786
CrossRef768
A. Mangia, G. Spinzi, O. Vuturo, V. Pazienza, A. Iacobellis, M. Piattelli, A. Giacobbe, G. Leandro, V. Piermanni, G. Minoli, G. Montalto, A. Andriulli. (2004) Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. Alimentary Pharmacology and Therapeutics 19:3, 331-337
CrossRef769
Jason R. Stangl, Kathleen L. Carroll, Mitchell Illichmann, Robert Striker. (2004) EFFECT OF ANTIMETABOLITE IMMUNOSUPPRESSANTS ON FLAVIVIRIDAE, INCLUDING HEPATITIS C VIRUS. Transplantation 77:4, 562-567
CrossRef770
P. A. Gochee. (2004) Association Between Apolipoprotein E 4 and Neuropsychiatric Symptoms During Interferon Treatment for Chronic Hepatitis C. Psychosomatics 45:1, 49-57
CrossRef771
Stanislas Pol, Françoise Carnot, Bertrand Nalpas, Jean-Luc Lagneau, Héléne Fontaine, Jeanne Serpaggi, Lawrence Serfaty, Pierre Bedossa, Christian Bréchot. (2004) Reversibility of hepatitis C virus-related cirrhosis. Human Pathology 35:1, 107-112
CrossRef772
Mina Nakagawa, Naoya Sakamoto, Nobuyuki Enomoto, Yoko Tanabe, Nobuhiko Kanazawa, Tomoyuki Koyama, Masayuki Kurosaki, Shinya Maekawa, Tsuyoshi Yamashiro, Cheng-Hsin Chen, Yasuhiro Itsui, Sei Kakinuma, Mamoru Watanabe. (2004) Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochemical and Biophysical Research Communications 313:1, 42-47
CrossRef773
Peter Ferenci. (2004) Treatment of chronic viral hepatitis. Best Practice & Research Clinical Gastroenterology 18, 113-120
CrossRef774
Piero Luigi Almasio. (2004) Weight-based dosing: Which impact on efficacy and safety of therapy?. Digestive and Liver Disease 36, S349-S353
CrossRef775
Pascale Trimoulet, Victor de L
CrossRef776
K. Lindahl, R. Schvarcz, A. Bruchfeld, L. Stahle. (2004) Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. Journal of Viral Hepatitis 11:1, 84-87
CrossRef777
Antonio Craxi. (2004) Foreword. Digestive and Liver Disease 36, S333
CrossRef778
Yvonne Yip, Frantz Victor, Jason Lamar, Robert Johnson, Q.May Wang, Donna Barket, John Glass, Ling Jin, Lifei Liu, Daryl Venable, Mark Wakulchik, Congping Xie, Beverly Heinz, Elcira Villarreal, Joe Colacino, Nathan Yumibe, Mark Tebbe, John Munroe, Shu-Hui Chen. (2004) Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor. Bioorganic & Medicinal Chemistry Letters 14:1, 251-256
CrossRef779
Mark W. Russo, Michael W. Fried. (2004) Guidelines for stopping therapy in chronic hepatitis C. Current Gastroenterology Reports 6:1, 17-21
CrossRef780
Miriam Romero, Mayte P??rez-Olmeda, Javier Garc??a-Samaniego, Vicente Soriano. (2004) Management of Chronic Hepatitis C in Patients Co-Infected with HIV. Drug Safety 27:1, 7-24
CrossRef781
Misako UCHIDA, Akinobu HAMADA, Masafumi YAMASAKI, Shigetoshi FUJIYAMA, Yutaka SASAKI, Hideyuki SAITO. (2004) Assessment of Adverse Reactions and Pharmacokinetics of Ribavirin in Combination with Interferon α-2b in Patients with Chronic Hepatitis C. Drug Metabolism and Pharmacokinetics 19:6, 438-443
CrossRef782
Leonor Moreno, Carmen Quereda, Ana Moreno, María J Perez-Elías, Antonio Antela, José L Casado, Fernando Dronda, Maria L Mateos, Rafael Bárcena, Santiago Moreno. (2004) Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 18:1, 67-73
CrossRef783
Yasuji Arase, Kenji Ikeda, Akihito Tsubota, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi, Norio Akuta, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Mariko Kobayashi, Hiromitsu Kumada. (2004) Interferon Therapy for 2 Years or Longer Reduces the Incidence of Hepatocarcinogenesis in Patients with Chronic Hepatitis C Viral Infection. Intervirology 47:6, 355-361
CrossRef784
Anouk Dev, Keyur Patel, John G. McHutchison. (2004) New therapies for chronic hepatitis C virus infection. Current Gastroenterology Reports 6:1, 77-86
CrossRef785
Mariano Malaguarnera, Giovanni Pistone, Sergio Neri, Marcello Romano, Alfio Brogna, Salvatore Musumeci. (2004) Interleukin-2 Plus Ribavirin Versus Interferon-??-2b Plus Ribavirin in Patients with Chronic Hepatitis C Who Did Not Respond to Previous Interferon-??-2b Treatment. BioDrugs 18:6, 407-413
CrossRef786
S. Engler, C. Flechtenmacher, K. H. Wiedemann, R. Gugler, W. Stremmel, B. Kallinowski. (2004) Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. Journal of Viral Hepatitis 11:1, 60-68
CrossRef787
D. M. Jensen, S. J. Cotler, H. Lam, G. Harb, A. Shillington. (2004) A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres. Alimentary Pharmacology and Therapeutics 19:1, 69-77
CrossRef788
Osamu Yokosuka, Shosuke Iwama, Noriaki Suzuki, Motohide Takashi, Yasuo Hirai, Katsuo Uchiumi, Michio Kimura, Nobuaki Gotou, Shinichi Hino, Akira Hayasaka, Tatsuo Kanda, Shigenobu Kawai, Kenichi Fukai, Fumio Imazeki, Hiromitsu Saisho. (2004) High Sustained Virologic Response Rate after Interferon Monotherapy in Japanese Hepatitis C Patients with a Low HCV RNA Titer and/or HCV Genotype 2. Intervirology 47:6, 328-334
CrossRef789
P. Andreone, A. Gramenzi, C. Cursaro, F. Felline, E. Loggi, A. D'Errico, M. Spinosa, S. Lorenzini, M. Biselli, M. Bernardi. (2004) Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. Journal of Viral Hepatitis 11:1, 69-73
CrossRef790
Andre C. Lyra, Sunil Ramrakhiani, Bruce R. Bacon, Adrian M. Di Bisceglie. (2004) Infection with Hepatitis C Virus Genotype 4 in the United States. Journal of Clinical Gastroenterology 38:1, 68-71
CrossRef791
Antonio Craxi. (2004) Early virologic response with pegylated interferons. Digestive and Liver Disease 36, S340-S343
CrossRef792
Ichiro KONISHI, Norio HORIIKE, Kojiro MICHITAKA, Nobuko OCHI, Shinya FURUKAWA, Hisaka MINAMI, Morikazu ONJI. (2004) Renal Transplant Recipient with Chronic Hepatitis C Who Obtained Sustained Viral Response after Interferon-.BETA. Therapy. Internal Medicine 43:10, 931-934
CrossRef793
Thierry Poynard. (2004) Treatment of cirrhotic patients in the pegylated interferon era. Digestive and Liver Disease 36, S344-S348
CrossRef794
J. Puetz, M. Thrower, R. Kane, J. Bouhasin. (2004) Combination therapy with ribavirin and interferon in a cohort of children with hepatitis C and haemophilia followed at a pediatric haemophilia treatment center. Haemophilia 10:1, 87-93
CrossRef795
X. Jiao, R. Y.-H. Wang, Z. Feng, G. Hu, H. J. Alter, J. W.-K. Shih. (2004) DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response*. Journal of Viral Hepatitis 11:1, 18-26
CrossRef796
Hector Rodriguez-Luna, Amer Khatib, Pratima Sharma, Giovanni De Petris, James W. Williams, Jose Ortiz, Kathleen Hansen, David Mulligan, Adyr Moss, David D. Douglas, Vijayan Balan, Jorge Rakela, Hugo E. Vargas. (2004) Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon ??2b and ribavirin: an open-label series1. Transplantation 77:2, 190-194
CrossRef797
K. Meijer, E. B. Haagsma, J. Van Der Meer, . (2004) A randomized, double-blind, placebo-controlled clinical trial of high-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in hemophilia. Journal of Thrombosis and Haemostasis 2:1, 194-196
CrossRef798
Debbie M. Cheng, Stephen W. Lagakos. (2003) Use of incomplete post-treatment data in the analysis of viral eradication studies. Statistics in Medicine 22:23, 3611-3628
CrossRef799
F. Fabrizi, G. Dulai, V. Dixit, S. Bunnapradist, P. Martin. (2003) Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Alimentary Pharmacology and Therapeutics 18:11-12, 1071-1081
CrossRef800
Xin-Xin Zhang, Qiang Deng, Shen-Ying Zhang, Jing Liu, Qian Cai, Zhi-Meng Lu, Yuan Wang. (2003) Broadly cross-reactive mimotope of hypervariable region 1 of hepatitis C virus derived from DNA shuffling and screened by phage display library. Journal of Medical Virology 71:4, 511-517
CrossRef801
Markus Reiser, Peter Buggisch, Johannes Grossmann, Karsten Koop, Karsten Wursthorn, Wolff Schmiegel. (2003) First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C. European Journal of Gastroenterology & Hepatology 15:12, 1299-1304
CrossRef802
Mayte Pérez-Olmeda, Vincent Soriano, Victor Asensi, Dolores Morales, Miriam Romero, Anna Ochoa, Fausto Sánchez-Montero, Miguel Santin, Josep Guardiola, Jesús Blanch, Marina Núñez, Inmaculada Jiménez-Nácher, Javier García-Samaniego, The HCV/HIV Spanish Study Group. (2003) Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α -2b Plus Ribavirin. AIDS Research and Human Retroviruses 19:12, 1083-1089
CrossRef803
Michelle M. Lipman, Scott J. Cotler. (2003) Antiviral therapy for hepatitis C. Current Treatment Options in Gastroenterology 6:6, 445-453
CrossRef804
Edna Strauss, Hoel Sette Junior. (2003) Efficacy of hepatitis C treatment may be enhanced by a longer interferon administration. Liver International 23:6, 410-412
CrossRef805
G. Tarantino, P. Sorrentino, P. Conca, A. Perrella, P. Ragucci, O. Perrella. (2003) Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study. Liver International 23:6, 413-419
CrossRef806
Aijaz Ahmed, Emmet B. Keeffe. (2003) Upodate on chronic hepatitis C. Comprehensive Therapy 29:4, 224-232
CrossRef807
Jean-Michel Pawlotsky. (2003) The nature of interferon-?? resistance in hepatitis C virus infection. Current Opinion in Infectious Diseases 16:6, 587-592
CrossRef808
Thierry Poynard, Man-Fung Yuen, Vlad Ratzin, Ching Lung Lai. (2003) Viral hepatitis C. The Lancet 362:9401, 2095-2100
CrossRef809
Sheng-Shun Yang, Ming-Yang Lai, Ding-Shinn Chen, Gran-Hum Chen, Jia-Horng Kao. (2003) Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver International 23:6, 426-433
CrossRef810
Martin J. Slater, Elizabeth M. Amphlett, David M. Andrews, Paul Bamborough, Seb J. Carey, Martin R. Johnson, Paul S. Jones, Gail Mills, Nigel R. Parry, Alan J. Stewart, Tadeusz Skarzynski. (2003) Pyrrolidine-5,5- trans -lactams. 4. Incorporation of a P3/P4 Urea Leads to Potent Intracellular Inhibitors of Hepatitis C Virus NS3/4A Protease. Organic Letters 5:24, 4627-4630
CrossRef811
(2003) Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions. The American Journal of Gastroenterology 98:11, 2344-2347
CrossRef812
D. L. Sylvestre, A. R. Disston, D. P. Bui. (2003) Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. Journal of Viral Hepatitis 10:6, 467-470
CrossRef813
Douglas T. Dieterich, Ronald Wasserman, Norbert Brau, Tarek I. Hassanein, Edmund J. Bini, Peter J. Bowers, Mark S. Sulkowski. (2003) Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. The American Journal of Gastroenterology 98:11, 2491-2499
CrossRef814
R. Perez, M. Jimenez, J. Crespo, M. Diago, J. Enriquez, P. Vaquero, R. Sola, J. L. Olcoz, M. Romero, J. Salmeron, Ma I. Blanco, Ma Ona, S. Melon, L. Rodrigo, . (2003) Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C. Journal of Viral Hepatitis 10:6, 437-445
CrossRef815
PD Griffiths. (2003) The end of the needle is in sight. Reviews in Medical Virology 13:6, 343-345
CrossRef816
Norbert Br??u. (2003) Update on chronic hepatitis C in HIV/HCV-coinfected patients. AIDS 17:16, 2279-2290
CrossRef817
N. Kontorinis, G. Garas, J. Young, D. Speers, B. P. Chester, G. C. MacQuillan, B. De Boer, M. D. Chapman, E. Forster, G. P. Jeffrey. (2003) Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic. Internal Medicine Journal 33:11, 500-504
CrossRef818
H. Van Vlierberghe, G. Leroux-Roels, M. Adler, N. Bourgeois, F. Nevens, Y. Horsmans, J. Brouwer, I. Colle, J. Delwaide, R. Brenard, B. Bastens, J. Henrion, R. A. Vries, C. Galocsy, P. Michielsen, G. Robaeys, L. Bruckers. (2003) Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial *. Journal of Viral Hepatitis 10:6, 460-466
CrossRef819
Per Hoffmann, Maria Quasdorff, Maria Á González-Carmona, Wolfgang H Caselmann. (2003) Recent patents on experimental therapy for hepatitis C virus infection (1999 – 2002). Expert Opinion on Therapeutic Patents 13:11, 1707-1723
CrossRef820
Catherine Tamalet, Philippe Colson, Herv
CrossRef821
S. R. Knowles, E. J. Phillips, L. Dresser, L. Matukas. (2003) Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada. Clinical Infectious Diseases 37:8, 1139-1142
CrossRef822
Gerlinde Teuber, M Pascu, T Berg, M Lafrenz, J Pausch, F Kullmann, G Ramadori, R Arnold, H Weidenbach, E Musch, U Junge, K.H Wiedmann, E Herrmann, M Zankel, S Zeuzem. (2003) Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. Journal of Hepatology 39:4, 606-613
CrossRef823
Zhi Hong. (2003) The role of Ribavirin-induced mutagenesis in HCV therapy: A concept or a fact?. Hepatology 38:4, 807-810
CrossRef824
Philippe Halfon, Hacene Khiri, Albert Tran, Guillaume Pénaranda, Jerome Courcambeck, Hélene Joly, Denis Ouzan. (2003) Hepatitis C virus RNA load in relapsed patients. European Journal of Gastroenterology & Hepatology 15:10, 1067-1071
CrossRef825
Xiaotian Zheng, Minnie Pang, Amelia Chan, Ann Roberto, Diane Warner, Belinda Yen-Lieberman. (2003) Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods. Journal of Clinical Virology 28:2, 214-216
CrossRef826
Catherine M Meyers, Leonard B Seeff, Catherine O Stehman-Breen, Jay H Hoofnagle. (2003) Hepatitis C and renal disease: an update 1 1Summary of a workshop held October 21 to 22, 2002, in the Lister Hill Auditorium, The National Institutes of Health, Bethesda, MD.. American Journal of Kidney Diseases 42:4, 631-657
CrossRef827
A. Zaman, M. B. Fennerty, E. B. Keeffe. (2003) Peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Alimentary Pharmacology and Therapeutics 18:7, 661-670
CrossRef828
Kung-Chia Young, Karen L. Lindsay, Ki-Jeong Lee, Wen-Chun Liu, Jian-Wen He, Susan L. Milstein, Michael M. C. Lai. (2003) Identification of a Ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38:4, 869-878
CrossRef829
Jonathan C Anderson, Josephine Simonetti, Dennis G Fisher, James Williams, Yasuhiro Yamamura, Nayra Rodriguez, Daniel G Sullivan, David R Gretch, Brian McMahon, Kandace J Williams. (2003) Comparison of different HCV viral load and genotyping assays. Journal of Clinical Virology 28:1, 27-37
CrossRef830
Edmund J. Bini. (2003) Hepatitis C in veterans. Current Hepatitis Reports 2:3, 108-115
CrossRef831
Chihiro Morishima, Luwy Musey, Marnie Elizaga, Kersten Gaba, Megan Allison, Robert L Carithers, David R Gretch, M.Juliana McElrath. (2003) Hepatitis c virus-specific cytolytic t cell responses after antiviral therapy. Clinical Immunology 108:3, 211-220
CrossRef832
P. Halfon, A. U. Neumann, M. Bourliere, A. Rieu, S. Chadapaud, H. Khiri, D. Ouzan, P. Cacoub. (2003) Slow viral dynamics of hepatitis C virus genotype 4. Journal of Viral Hepatitis 10:5, 351-353
CrossRef833
Helen S. Yee, Teresa L. Wright. (2003) Hepatitis C antiviral treatment in special populations. Current Hepatitis Reports 2:3, 101-107
CrossRef834
Alexander Monto. (2003) Alcohol and hepatitis C: Implications for disease progression and treatment. Current Hepatitis Reports 2:3, 125-131
CrossRef835
N. C. Tassopoulos, I. Ketikoglou, D. Tsantoulas, M. Raptopoulou, G. Hatzis, I. Vafiadis, L. Sidiropoulos, S. Kanatakis, G. Anagnostopoulos, V. Sypsa, A. Hatzakis, . (2003) A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naive patients with chronic hepatitis C. Journal of Viral Hepatitis 10:5, 383-389
CrossRef836
P Ferenci. (2003) Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C. Digestive and Liver Disease 35:9, 601-606
CrossRef837
K. Kerl, F. Negro, J. Lubbe. (2003) Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin. British Journal of Dermatology 149:3, 656-656
CrossRef838
Wolfgang Vogel. (2003) Peginterferon-α 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection. Expert Review of Anti-infective Therapy 1:3, 423-431
CrossRef839
Yuan Li, Ting Zhang, Steven D. Douglas, Jian-Ping Lai, Wei-Dong Xiao, David E. Pleasure, Wen-Zhe Ho. (2003) Morphine Enhances Hepatitis C Virus (HCV) Replicon Expression. The American Journal of Pathology 163:3, 1167-1175
CrossRef840
D. T. Dieterich, J. L. Spivak. (2003) Hematologic Disorders Associated with Hepatitis C Virus Infection and Their Management. Clinical Infectious Diseases 37:4, 533-541
CrossRef841
G Rasi, P Pierimarchi, P Sinibaldi Vallebona, F Colella, E Garaci. (2003) Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. International Immunopharmacology 3:8, 1169-1176
CrossRef842
Eveline J Boucher, Sylvie Jacquelinet, Valerie Canva, Bruno Turlin, Christian Jacquelinet, Ronald Colimon, Yves Deugnier, Dominique Guyader, Pierre Brissot. (2003) High rate of long-term virological response after a 1-year course of interferon +- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial. Liver International 23:4, 255-261
CrossRef843
E. Schvoerer, M.C. Navas, C. Thumann, A. Fuchs, N. Meyer, F. Habersetzer, F. Stoll-Keller. (2003) Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy. Journal of Medical Virology 70:4, 588-593
CrossRef844
Petra Steindl-Munda, Peter Ferenci, Harald Brunner, Karin Nachbaur, Christian Datz, Michael Gschwantler, Harald Hofer, Rudolf Stauber, Franz Hackl, Wolfgang Jessner, Martha Rosenbeiger, Alfred Gangl, Wolfgang Vogel, . (2003) Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy. Liver International 23:4, 269-275
CrossRef845
B. McGovern, I. Bica. (2003) Should Treatment of Hepatitis C in HIV-Seropositive and HIV-Seronegative Patients with Hemophilia Include Induction Doses of Interferon?. Clinical Infectious Diseases 37:3, 463-464
CrossRef846
Yoshio Saito, Vanessa Escuret, David Durantel, Fabien Zoulim, Raymond F. Schinazi, Luigi A. Agrofoglio. (2003) Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon. Bioorganic & Medicinal Chemistry 11:17, 3633-3639
CrossRef847
Nassim Kamar, Karine Sandres-Saune, Janick Selves, David Ribes, Olivier Cointault, Dominique Durand, Jacques Izopet, Lionel Rostaing. (2003) Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. American Journal of Kidney Diseases 42:1, 184-192
CrossRef848
Junko Tanaka, Hiromitsu Kumada, Kenji Ikeda, Kazuaki Chayama, Masaaki Mizui, Kunihiko Hino, Keiko Katayama, Junko Kumagai, Yutaka Komiya, Yuzo Miyakawa, Hiroshi Yoshizawa. (2003) Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. Journal of Medical Virology 70:3, 378-386
CrossRef849
Megan L. Shaw, John McLauchlan, Peter R. Mills, Arvind H. Patel, Elizabeth A.B. McCruden. (2003) Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins. Journal of Medical Virology 70:3, 361-372
CrossRef850
P. Andreone, A. Gramenzi, C. Cursaro, M. Biselli, S. Lorenzini, E. Loggi, F. Felline, S. Fiorino, L. Di Giammarino, F. Porzio, S. Galli, M. Bernardi. (2003) Interferon-alpha combined with ketoprofen as treatment of naive patients with chronic hepatitis C: a randomized controlled trial. Journal of Viral Hepatitis 10:4, 306-309
CrossRef851
E. Formann, W. Jessner, L. Bennett, P. Ferenci. (2003) Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. Journal of Viral Hepatitis 10:4, 271-276
CrossRef852
J Vrolijk. (2003) A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. Journal of Virological Methods 110:2, 201-209
CrossRef853
Ramachandra S. Hosmane. 2003. Antiviral Agents. .
CrossRef854
D. Neau, P. Trimoulet, M. Winnock, A. Rullier, B. Le Bail, D. Lacoste, J.-M. Ragnaud, P. B. Sage, M.-E. Lafon, G. Chene, M. Dupon, . (2003) Comparison of 2 Regimens that Include Interferon- -2a plus Ribavirin for Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus--Coinfected Patients. Clinical Infectious Diseases 36:12, 1564-1571
CrossRef855
Jean-Michel Pawlotsky. (2003) Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Research 59:1, 1-11
CrossRef856
Paolo Rossi, Tullio Bertani, Piero Baio, Roberta Caldara, Patrizia Luliri, Francesca Tengattini, Piermario Bellavita, Gianna Mazzucco, Rocco Misiani. (2003) Hepatitis C virus-related cryoglobulinemic glomerulonephritis: Long-term remission after antiviral therapy. Kidney International 63:6, 2236-2241
CrossRef857
Dominique Salmon‐Ceron, Regis Lassalle, Alain Pruvost, Henri Benech, Magali Bouvier‐Alias, Christopher Payan, Cecile Goujard, Eric Bonnet, Fabien Zoulim, Philippe Morlat, Philippe Sogni, Sophie Perusat, Jean‐Marc Treluyer, Genevieve Chene, . (2003) Interferon‐Ribavirin in Association with Stavudine Has No Impact on Plasma Human Immunodeficiency Virus (HIV) Type 1 Level in Patients Coinfected with HIV and Hepatitis C Virus: A CORIST‐ANRS HC1 Trial. Clinical Infectious Diseases 36:10, 1295-1304
CrossRef858
David M. Andrews, Paul S. Jones, Gail Mills, S.Lucy Hind, Martin J. Slater, Naimisha Trivedi, Katrina J. Wareing. (2003) Design and synthesis of spiro-cyclopentenyl and spiro--dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease. Bioorganic & Medicinal Chemistry Letters 13:10, 1657-1660
CrossRef859
Mayte Pérez-Olmeda, Marina Núñez, Miriam Romero, Juan González, Angeles Castro, José Ramón Arribas, José Pedreira, Pablo Barreiro, Javier García-Samaniego, Luz Martín-Carbonero, Inmaculada Jiménez-Nácher, Vincent Soriano. (2003) Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 17:7, 1023-1028
CrossRef860
Stephen D Pickett, Bradley S Sherborne, Trevor Wilkinson, James Bennett, Neera Borkakoti, Michael Broadhurst, David Hurst, Ian Kilford, Murray McKinnell, Philip S Jones. (2003) Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. Bioorganic & Medicinal Chemistry Letters 13:10, 1691-1694
CrossRef861
T. Poynard, P. Marcellin, A. Bissery, R. P. Myers, J. Moussalli, F. Degos, D. Dhumeaux, G. Riachi, J. P. Bronowicki, P. Brissot, C. Buffet, L. Serfaty, S. Naveau, P. Sogni, M. Beaugrand, S. Gayno, D. Larrey, D. Samuel, C. Eugene, S. Pol, P. Bedossa, V. Daurat, P. Chaumet-Riffaud, . (2003) Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. Journal of Viral Hepatitis 10:3, 197-204
CrossRef862
Graham R Foster. (2003) Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. Expert Opinion on Pharmacotherapy 4:5, 685-691
CrossRef863
Zobair M. Younossi, Kevin D. Mullen, Sandra Hodnick, David S. Barnes, William D. Carey, Arthur C. McCullough, Kirk Easley, Terry Gramlich, Belinda Yen Liebermann. (2003) Triple Combination of Interferon Alpha-2b, Ribavirin, and Amantadine for Treatment of Chronic Hepatitis C. Journal of Clinical Gastroenterology 36:5, 427-430
CrossRef864
K Sandres-Sauné, P Deny, C Pasquier, V Thibaut, G Duverlie, J Izopet. (2003) Determining hepatitis C genotype by analyzing the sequence of the NS5b region. Journal of Virological Methods 109:2, 187-193
CrossRef865
Jayaprakash Sreenarasimhaiah, Andrés Jaramillo, Jeffrey Crippin, Mauricio Lisker-Melman, William C Chapman, T Mohanakumar. (2003) Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-α and ribavirin treatment for chronic hepatitis C virus infection. Human Immunology 64:5, 497-504
CrossRef866
W. Sievert, R. Batey, L. Mollison, S. Pianko, J. Mcdonald, G. Marinos, W. Reed, S. Warner, S. Bowden, R. De Solom, P. Bhathal, . (2003) Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone. Alimentary Pharmacology & Therapeutics 17:9, 1197-1204
CrossRef867
Tin-Yun Ho, Shih-Lu Wu, I-Lu Lai, Ken-Sheng Cheng, Shung-Te Kao, Chien-Yun Hsiang. (2003) An in vitro system combined with an in-house quantitation assay for screening hepatitis C virus inhibitors. Antiviral Research 58:3, 199-208
CrossRef868
N. C Tassopoulos, D. Tsantoulas, M. Raptopoulou, T. Vassiliadis, S. Kanatakis, E. Paraskevas, I. Vafiadis, A. Avgerinos, C. Tzathas, S. Manolakopoulos, I. Ketikoglou, P. Aggelis, K. Goritsas, G. Giannoulis, G. Hatzis G, K. Thomopoulos, E. Akriviadis, V. Sypsa, A. Hatzakis. (2003) A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1. Journal of Viral Hepatitis 10:3, 189-196
CrossRef869
Marina B Klein, Nadia Campeol, Richard G Lalonde, Bluma Brenner, Mark A Wainberg. (2003) Didanosine, interferon-alfa and ribavirin. AIDS 17:7, 1001-1008
CrossRef870
F Fred Poordad, Tram Tran, Paul Martin. (2003) Developments in hepatitis C therapy during 2000 – 2002. Expert Opinion on Emerging Drugs 8:1, 9-25
CrossRef871
J. M. Vrolijk, F. C. Bekkering, J. T. Brouwer, B. E. Hansen, S. W. Schalm. (2003) High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy. Journal of Viral Hepatitis 10:3, 205-209
CrossRef872
Diana L. Sylvestre. (2003) Hepatitis C and Addiction. Journal of Maintenance in the Addictions 2:3, 7-17
CrossRef873
Omar I. Massoud, Wael I. Yousef, Kevin D. Mullen. (2003) Hemoglobinuria With Ribavirin Treatment. Journal of Clinical Gastroenterology 36:4, 367-368
CrossRef874
Stephanos J Hadziyannis, George V Papatheodoridis. (2003) Peginterferon-α 2a (40 kDa) for chronic hepatitis C. Expert Opinion on Pharmacotherapy 4:4, 541-551
CrossRef875
Patrick Marcellin, Nathalie Boyer. (2003) Chronic viral hepatitis. Best Practice & Research Clinical Gastroenterology 17:2, 259-275
CrossRef876
Nicole Pavio, Michael M. C. Lai. (2003) The hepatitis C virus persistence: how to evade the immune system?. Journal of Biosciences 28:3, 287-304
CrossRef877
David M. Andrews, Helene M. Chaignot, Barry A. Coomber, Mike D. Dowle, S. Lucy Hind, Martin R. Johnson, Paul S. Jones, Gail Mills, Angela Patikis, Tony J. Pateman, J. Ed Robinson, Martin J. Slater, Naimisha Trivedi. (2003) The design of potent, non-peptidic inhibitors of hepatitis C protease. European Journal of Medicinal Chemistry 38:4, 339-343
CrossRef878
Zsófia Müller, Judith Deák, R.Stefan Ross, Elisabeth Nagy, László Kovács, M Roggendorf, Harald H Kessler. (2003) Hepatitis C virus genotypes in Hungarian and Austrian patients with chronic hepatitis C. Journal of Clinical Virology 26:3, 295-300
CrossRef879
Peter Borowski, Johanna Deinert, Sarah Schalinski, Maria Bretner, Krzysztof Ginalski, Tadeusz Kulikowski, David Shugar. (2003) Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. European Journal of Biochemistry 270:8, 1645-1653
CrossRef880
Renata M. Perez, Maria Lucia G. Ferraz, Mauro S. Figueiredo, Denilson Contado, Sandra Koide, Adalgisa P. Ferreira, Miguel Cendoroglo Neto, Jos
CrossRef881
YOSHIYASU KARINO, JOUJI TOYOTA, MASAAKI SUGAWARA, KAYO MIYAZAKI, YASUAKI KUWATA, KATSU YAMAZAKI, TAKAHIRO SATO, TAKUMI OHMURA, TAKASHI MATSUSHIMA. (2003) Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology 18:4, 404-410
CrossRef882
Akihito Tsubota, Yuichi Hirose, Namiki Izumi, Hiromitsu Kumada. (2003) Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. British Journal of Clinical Pharmacology 55:4, 360-367
CrossRef883
E. Dieperink. (2003) A Prospective Study of Neuropsychiatric Symptoms Associated With Interferon-alpha-2b and Ribavirin Therapy for Patients With Chronic Hepatitis C. Psychosomatics 44:2, 104-112
CrossRef884
Manuel Ramos-Casals, Mario García-Carrasco, Francisco López-Medrano, Olga Trejo, Xavier Forns, Armando López-Guillermo, Carles Muñoz, Miguel Ingelmo, Josep Font. (2003) Severe Autoimmune Cytopenias in Treatment-Naive Hepatitis C Virus Infection. Medicine 82:2, 87-96
CrossRef885
C.-H. Hung, C.-M. Lee, S.-N. Lu, J.-F. Lee, J.-H. Wang, H.-D. Tung, T.-M. Chen, T.-H. Hu, W.-J. Chen, C.-S. Changchien. (2003) Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. Journal of Viral Hepatitis 10:2, 87-94
CrossRef886
Mitchell L. Shiffman. (2003) Pegylated interferons: What role will they play in the treatment of chronic hepatitis C?. Current Hepatitis Reports 2:1, 17-23
CrossRef887
R. P. Myers, V. Thibault, T. Poynard. (2003) The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. Journal of Viral Hepatitis 10:2, 103-110
CrossRef888
CATHERINE CRONE, GEOFFREY M. GABRIEL. (2003) Comprehensive Review of Hepatitis C for Psychiatrists: Risks, Screening, Diagnosis, Treatment, and Interferon-Based Therapy Complications. Journal of Psychiatric Practice 9:2, 93-110
CrossRef889
G. Fattovich, I. Zagni, G. Fornaciari, E. Minola, P. Fabris, S. Boccia, M. Giusti, G. Abbati, M. Felder, P. Rovere, A. Redaelli, A. Tonon, R. Montanari, C. Paternoster, M. Distasi, E. Castagnetti, G. Tositti, C. Rizzo, S. Suppressa, M. Pantalena, L. Lomonaco, C. Scattolini, A. Tagger. (2003) Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. Journal of Viral Hepatitis 10:2, 111-117
CrossRef890
Tram T. Tran, Fred Poordad, Paul Martin. (2003) Treatment of hepatitis C. Current Hepatitis Reports 2:1, 3-8
CrossRef891
R. San Miguel, J. Mar, J. M. Cabases, F. GuilleN-Grima, M. Buti. (2003) Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon. Alimentary Pharmacology and Therapeutics 17:6, 765-773
CrossRef892
Mazen Alsatie, Paul Y. Kwo. (2003) Treatment of chronic hepatitis C in patients who have failed to respond to IFN or IFN and ribavirin combination therapy. Current Hepatitis Reports 2:1, 32-39
CrossRef893
S. S. Lee. (2003) Indicators and predictors of response to anti-viral therapy in chronic hepatitis C. Alimentary Pharmacology and Therapeutics 17:5, 611-621
CrossRef894
Jean Marc Crance, Natale Scaramozzino, Alain Jouan, Daniel Garin. (2003) Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Research 58:1, 73-79
CrossRef895
Gary L. Davis. (2003) Treatment of chronic hepatitis C: Improved combination therapy. Current Hepatitis Reports 2:1, 40-46
CrossRef896
M. Buti, M. Medina, M. A. Casado, J. B. Wong, L. Fosbrook, R. Esteban. (2003) A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics 17:5, 687-694
CrossRef897
Markus Cornberg, Heiner Wedemeyer, Michael P. Manns. (2003) Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. Current Hepatitis Reports 2:1, 24-31
CrossRef898
Gregory J Dore, Matthew Law, Margaret MacDonald, John M Kaldor. (2003) Epidemiology of hepatitis C virus infection in Australia. Journal of Clinical Virology 26:2, 171-184
CrossRef899
Brendon Y Chua, Anne Healy, Paul U Cameron, Owen Stock, Michael Rizkalla, Weiguang Zeng, Joseph Torresi, Lorena E Brown, Nina L Fowler, Eric J Gowans, David C Jackson. (2003) Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunology and Cell Biology 81:1, 67-72
CrossRef900
Uichiro Fuchizaki, Shuichi Kaneko, Yasunari Nakamoto, Yoshihiro Sugiyama, Kenichi Imagawa, Mikio Kikuchi, Kenichi Kobayashi. (2003) Synergistic antiviral effect of a combination of mouse interferon-? and interferon-? on mouse hepatitis virus. Journal of Medical Virology 69:2, 188-194
CrossRef901
Sandrine Loubiere, Jean-Paul Moatti. (2003) Cost-effectiveness of hepatitis C screening of blood donations. Expert Review of Pharmacoeconomics & Outcomes Research 3:1, 47-55
CrossRef902
(2003) Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C. New England Journal of Medicine 348:3, 259-260
Full Text903
Sun-Lung Tsai, I-Shyan Sheen, Rong-Nan Chien, Chia-Min Chu, Hsiu-Chu Huang, Yen-Ling Chuang, Tzong-Hsien Lee, Shuen-Kuei Liao, Chen-Lung Lin, George C. Kuo, Yun-Fan Liaw. (2003) Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: Tetramer assay and therapeutic implications. Journal of Biomedical Science 10:1, 120-135
CrossRef904
Sukanya Raghuraman, R.V Shaji, Gopalan Sridharan, Sujatha Radhakrishnan, George Chandy, B.S Ramakrishna, Priya Abraham. (2003) Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India. Journal of Clinical Virology 26:1, 61-69
CrossRef905
Jens Rasenack, Stefan Zeuzem, S. Victor Feinman, E. Jenny Heathcote, Michael Manns, Eric M. Yoshida, Mark G. Swain, Edward Gane, Moises Diago, Dennis A. Revicki, Amy Lin, Neil Wintfeld, Jesse Green. (2003) Peginterferon ??-2a (40kD) [Pegasys??] Improves HR-QOL Outcomes Compared with Unmodified Interferon ??-2a [Roferon??-A]. PharmacoEconomics 21:5, 341-349
CrossRef906
Andrea Moser, Herwig Lackner, Johann Deutsch, Reinhold Kerbl, Wolfgang Schwinger, Hans Jürgen Dornbusch, Harald H. Kessler, Christian Urban. (2003) Doppelinfektion mit Hepatitis B und C. Spontanverlauf und Ansprechen auf virostatische Therapie bei Kindern nach onkologischen Erkrankungen. Wiener Klinische Wochenschrift 115:1-2, 66-70
CrossRef907
W. Jessner, R. Stauber, F. Hackl, C. Datz, T. Watkins-Riedel, H. Hofer, A. Gangl, H. Kessler, P. Ferenci. (2003) Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection*. Journal of Viral Hepatitis 10:1, 37-42
CrossRef908
Silvio Tripi, Maurizio Soresi, Giuseppa Di Gaetano, Antonio Carroccio, Lydia Giannitrapani, Onofrio Vuturo, Gaetana Di Giovanni, Giuseppe Montalto. (2003) Leucocyte Interferon-alpha for Patients with Chronic Hepatitis C Intolerant to Other alpha-Interferons. BioDrugs 17:3, 201-205
CrossRef909
Todd E. Dantzler, Eric J. Lawitz. (2003) Treatment of chronic hepatitis C in nonresponders to previous therapy. Current Gastroenterology Reports 5:1, 78-85
CrossRef910
Gillian M Keating, Monique P Curran. (2003) Peginterferon-??-2a (40kD) Plus Ribavirin. Drugs 63:7, 701-730
CrossRef911
P. J. Pockros, R. Reindollar, J. McHutchinson, R. Reddy, T. Wright, D.G. Boyd, L.B. Wilkes. (2003) The safety and tolerability of daily infergen plus ribavirin in the treatment of naiive chronic hepatitis C patients. Journal of Viral Hepatitis 10:1, 55-60
CrossRef912
R. P. Myers, K. Patel, S. Pianko, T. Poynard, J. G. McHutchison. (2003) The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. Journal of Viral Hepatitis 10:1, 16-22
CrossRef913
Volker Meier, Erik B
CrossRef914
Carole Gilling-Smith, Paula Almeida. (2003) HIV, hepatitis B and hepatitis C and infertility: Reducing risk. Human Fertility 6:3, 106-112
CrossRef915
S. J. Cotler, J. E. Layden, A. U. Neumann, D. M. Jensen. (2003) First phase hepatitis c viral kinetics in previous nonresponders patients. Journal of Viral Hepatitis 10:1, 43-49
CrossRef916
Gaetano Scotto, Fausto Campanozzi, Antonio D??Adduzio, Maria Grimaldi, Vincenzina Fazio. (2003) Interferon-?? (IFN??) Daily Dose Versus IFN?? Plus Ribavirin for Treatment-Naive Chronic Hepatitis??? C Patients Infected by Genotype 1b. BioDrugs 17:4, 281-286
CrossRef917
Hideji Hanabusa. (2002) Efficacy of Induction Therapy with High‐Dose Interferon for Patients with Hemophilia and Human Immunodeficiency Virus–Hepatitis C Virus Coinfection. Clinical Infectious Diseases 35:12, 1527-1533
CrossRef918
Martin J. Slater, David M. Andrews, Graham Baker, Susanne S. Bethell, Seb Carey, Helene Chaignot, Berwyn Clarke, Barry Coomber, Malcolm Ellis, Andrew Good, Norman Gray, George Hardy, Paul Jones, Gail Mills, Ed Robinson. (2002) Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease. Bioorganic & Medicinal Chemistry Letters 12:23, 3359-3362
CrossRef919
S.M.L Waugh, D Pillay, D Carrington, W.F Carman. (2002) Antiviral prophylaxis and treatment (excluding HIV therapy). Journal of Clinical Virology 25:3, 241-266
CrossRef920
Patrice Cacoub, Olivier Lidove, Thierry Maisonobe, Pierre Duhaut, Vincent Thibault, Pascale Ghillani, Robert P. Myers, Jean Marc Leger, J
CrossRef921
CHAO-HUNG HUNG, CHUAN-MO LEE, SHENG-NAN LU, JING-HOUNG WANG, HUNG-DA TUNG, TSUNG-MING CHEN, CHIEN-HUNG CHEN, CHI-SIN CHANGCHIEN. (2002) Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy?. Journal of Gastroenterology and Hepatology 17:12, 1307-1311
CrossRef922
Hugo E. Vargas, Jorge Rakela. (2002) Impact of hepatitis B and hepatitis C on solid organ transplantation. Current Opinion in Organ Transplantation 7:4, 325-331
CrossRef923
P.-N. Cheng, N.-H. Chow, S.-C. Hu, K.-C. Young, C.-Y. Chen, C.-M. Jen, T.-T. Chang. (2002) Clinical comparison of high-dose interferon-α2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C. Digestive and Liver Disease 34:12, 851-856
CrossRef924
Annette Bruchfeld, Karin Lindahl, Robert Schvarcz, Lars Ståhle. (2002) Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A Population Pharmacokinetic Analysis. Therapeutic Drug Monitoring 24:6, 701-708
CrossRef925
David M. Andrews, Helene Chaignot, Barry A. Coomber, Andrew C. Good, S. Lucy Hind, Martin R. Johnson, Paul S. Jones, Gail Mills, J. Ed Robinson, Tadeusz Skarzynski, Martin J. Slater, Donald O'N Somers. (2002) Pyrrolidine-5,5- trans -lactams. 2. The Use of X-ray Crystal Structure Data in the Optimization of P3 and P4 Substituents. Organic Letters 4:25, 4479-4482
CrossRef926
David M. Andrews, Seb J. Carey, Helene Chaignot, Barry A. Coomber, Norman M. Gray, S. Lucy Hind, Paul S. Jones, Gail Mills, J. Ed Robinson, Martin J. Slater. (2002) Pyrrolidine-5,5- trans -lactams. 1. Synthesis and Incorporation into Inhibitors of Hepatitis C Virus NS3/4A Protease. Organic Letters 4:25, 4475-4478
CrossRef927
HEINER WEDEMEYER, JOHANNES WIEGAND, MARKUS CORNBERG, MICHAEL P MANNS. (2002) Polyethylene glycol-interferon: Current status in hepatitis C virus therapy. Journal of Gastroenterology and Hepatology 17:s3, S344-S350
CrossRef928
H. Ullerich, W. Avenhaus, C. Poremba, W. Domschke, J. Menzel. (2002) High-dose interferon alpha-2a with ribavirin and amantadine in naive chronic hepatitis C patients - results of a randomized, prospective, pilot study. Alimentary Pharmacology and Therapeutics 16:12, 2107-2114
CrossRef929
Rinaldo Pellicano, Franco Palmas, Giuseppe Cariti, Gianfranco Tappero, Marco Boero, Marco Tabone, Renzo Suriani, Patrizia Pontisso, Michele Pitaro, Mario Rizzetto. (2002) Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection. European Journal of Gastroenterology & Hepatology 14:12, 1377-1382
CrossRef930
DANIEL LAVANCHY. (2002) Public health measures in the control of viral hepatitis: A World Health Organization perspective for the next millennium. Journal of Gastroenterology and Hepatology 17:s4, S452-S459
CrossRef931
ROBERT YM CHEN, PAUL V DESMOND, STEPHEN A LOCARNINI. (2002) Emerging therapies of hepatitis B and C. Journal of Gastroenterology and Hepatology 17:s4, S471-S481
CrossRef932
T MOATTER, A SHAHHUSSAINY, S HAMID, Z AHMAD, S SIDDIQUI. (2002) Comparative analysis of viral titers and histologic features of Pakistani patients infected with hepatitis C virus type 3. International Journal of Infectious Diseases 6:4, 272-276
CrossRef933
Wolfgang Jessner, Thomas Watkins-Riedel, Elisabeth Formann, Petra Steindl-Munda, Peter Ferenci. (2002) Hepatitis C viral dynamics: basic concept and clinical significance. Journal of Clinical Virology 25, 31-39
CrossRef934
Alan D. Tice. (2002) Bloodborne Pathogen Exposure and Recommendations for Management. Journal of Infusion Nursing 25:Supplement, S5-S9
CrossRef935
Anne Davoren, Annette D. Dillon, Joan P. Power, Joe Donnellan, Jacqueline M. Quinn, Joe W. Willis, Emer M. Lawlor, Joan M. O'Riordan. (2002) Outcome of an optional HCV screening program for blood transfusion recipients in Ireland. Transfusion 42:11, 1501-1506
CrossRef936
Shane Crotty, Raul Andino. (2002) Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes and Infection 4:13, 1301-1307
CrossRef937
Teresa L. Wright. (2002) Treatment of patients with hepatitis C and cirrhosis. Hepatology 36:S1, S185-S194
CrossRef938
Leonard B. Seeff. (2002) Natural history of chronic hepatitis C. Hepatology 36:S1, S35-S46
CrossRef939
David L. Thomas. (2002) Hepatitis C and human immunodeficiency virus infection. Hepatology 36:S1, S201-S209
CrossRef940
Mark S. Sulkowski. (2002) Hepatitis C virus infection in HIV-infected patients. Current Hepatitis Reports 1:1, 16-22
CrossRef941
Jonathan Moorman. (2002) Challenges in the HIV patient coinfected with hepatitis C. Current Hepatitis Reports 1:1, 9-15
CrossRef942
Jay H. Hoofnagle. (2002) Course and outcome of hepatitis C. Hepatology 36:S1, S21-S29
CrossRef943
P. Cacoub, Y. Benhamou. (2002) Place des interférons dans le traitement des infections par les virusde l'hépatite B et de l'hépatite C. La Revue de Médecine Interne 23, 459S-474S
CrossRef944
Gary L. Davis. (2002) Monitoring of viral levels during therapy of hepatitis C. Hepatology 36:S1, S145-S151
CrossRef945
Mitchell L. Shiffman. (2002) Retreatment of patients with chronic hepatitis C. Hepatology 36:S1, S128-S134
CrossRef946
Michael W. Fried. (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36:S1, S237-S244
CrossRef947
Karen L. Lindsay. (2002) Introduction to therapy of hepatitis C. Hepatology 36:S1, S114-S120
CrossRef948
Doris B. Strader. (2002) Understudied populations with hepatitis C. Hepatology 36:S1, S226-S236
CrossRef949
Shigenobu Kawai, Osamu Yokosuka, Fumio Imazeki, Hiromitsu Saisho, Chitose Mizuno. (2002) Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level. Journal of Medical Virology 68:3, 343-351
CrossRef950
Bruce R. Bacon. (2002) Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36:S1, S179-S184
CrossRef951
Thierry Poynard, Robert P Myers, Robert P Myers. 2002. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. .
CrossRef952
Elisa Scarselli, Helenia Ansuini, Raffaele Cerino, Rosa Maria Roccasecca, Stefano Acali, Gessica Filocamo, Cinzia Traboni, Alfredo Nicosia, Riccardo Cortese, Alessandra Vitelli. (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. The EMBO Journal 21:19, 5017-5025
CrossRef953
Claudia O Zein, Nizar N Zein. (2002) Advances in therapy for hepatitis C infection. Microbes and Infection 4:12, 1237-1246
CrossRef954
Carol F. Kwiatkowski, Karen Fortuin Corsi, Robert E. Booth. (2002) The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 97:10, 1289-1294
CrossRef955
Anne Boulestin, Karine Sandres-Saun
CrossRef956
Khalid S.A. Khabar, Stephen J. Polyak. (2002) Hepatitis C Virus-Host Interactions: The NS5A Protein and the Interferon/Chemokine Systems. Journal of Interferon & Cytokine Research 22:10, 1005-1012
CrossRef957
Curtis L. Cooper, D. William Cameron. (2002) Review of the Effect of Highly Active Antiretroviral Therapy on Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus and HCV Coinfection. Clinical Infectious Diseases 35:7, 873-879
CrossRef958
R. J. Fontana. (2002) Emotional Distress During Interferon-alpha-2B and Ribavirin Treatment of Chronic Hepatitis C. Psychosomatics 43:5, 378-385
CrossRef959
Fried, Michael W., Shiffman, Mitchell L., Reddy, K. Rajender, Smith, Coleman, Marinos, George, Gonçales, Fernando L. Jr., Häussinger, Dieter, Diago, Moises, Carosi, Giampiero, Dhumeaux, Daniel, Craxi, Antonio, Lin, Amy, Hoffman, Joseph, Yu, Jian, . (2002) Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. New England Journal of Medicine 347:13, 975-982
Full Text960
Y. Lurie, F. Nevens, Z. G. Aprosina, T. A. Fedorova, A. V. Kalinin, E. A. Klimova, Y. Ilan, M. V. Maevskaya, T. W. Warnes, N. D. Yuschuk, K. Hellstrand, K. R. Gehlsen. (2002) A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C. Journal of Viral Hepatitis 9:5, 346-353
CrossRef961
K. Hino, A. Kitase, Y. Satoh, D. Fujiwara, Y. Yamaguchi, M. Korenaga, Y. Shingai, T. Konishi, S. Yamashita, K. Uchida, K. Mori, H. Hanada, T. Kodama, K. Nukui, K. Okita. (2002) Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Journal of Viral Hepatitis 9:5, 370-376
CrossRef962
G. B. Gaeta, D. F. Precone, F. M. Felaco, R. Bruno, A. Spadaro, G. Stornaiuolo, M. Stanzione, T. Ascione, R. De Sena, A. Campanone, G. Filice, F. Piccinino. (2002) Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics 16:9, 1633-1639
CrossRef963
Y. Sugimoto, N. Kuzushita, T. Takehara, T. Kanto, T. Tatsumi, T. Miyagi, M. Jinushi, K. Ohkawa, M. Horimoto, A. Kasahara, M. Hori, Y. Sasaki, N. Hayashi. (2002) A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. Journal of Viral Hepatitis 9:5, 377-384
CrossRef964
R. San Miguel, F. Guillen, J. M. Cabases, M. Buti. (2002) Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. Alimentary Pharmacology and Therapeutics 16:9, 1611-1621
CrossRef965
G. Squadrito, G. Raffa, T. Restuccia, T. Pollicino, S. Brancatelli, G. Raimondo. (2002) Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?. Journal of Viral Hepatitis 9:5, 360-369
CrossRef966
Brent D Lemberg, Thomas A Shaw-Stiffel. (2002) Hepatic disease in injection drug users. Infectious Disease Clinics of North America 16:3, 667-679
CrossRef967
The English National Blood Service. (2002) Transfusion transmission of HCV infection before anti-HCV testing of blood donations in England: results of the national HCV lookback program. Transfusion 42:9, 1146-1153
CrossRef968
Shuichi Okada, Katsuaki Tanaka, Tosiya Sato, Hideki Ueno, Satoru Saito, Takuji Okusaka, Keiko Sato, Seiichiro Yamamoto, Tadao Kakizoe. (2002) Dose-response Trial of Lactoferrin in Patients with Chronic Hepatitis C. Cancer Science 93:9, 1063-1069
CrossRef969
Stefan Zeuzem, Eva Herrmann. (2002) First-phase parameters in hepatitis C viral kinetics. Journal of Viral Hepatitis 9:5, 332-333
CrossRef970
Peter Borowski, Sarah Schalinski, Herbert Schmitz. (2002) Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy. Antiviral Research 55:3, 397-412
CrossRef971
Bruce A. Luxon, Michael Grace, Diana Brassard, Ronald Bordens. (2002) Pegylated interferons for the treatment of chronic hepatitis C infection. Clinical Therapeutics 24:9, 1363-1383
CrossRef972
Jennifer E. Layden, Thomas J. Layden, K. Rajender Reddy, Rachel S Levy-Drummer, Jennifer Poulakos, Avidan U. Neumann. (2002) First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. Journal of Viral Hepatitis 9:5, 340-345
CrossRef973
C. H. Chang, K. Y. Chen, M. Y. Lai, K. A. Chan. (2002) Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics 16:9, 1623-1632
CrossRef974
Raymond T Chung, Scott R Evans, Yijun Yang, Dickens Theodore, Hernan Valdez, Rebecca Clark, Cecilia Shikuma, Thomas Nevin, Kenneth E Sherman. (2002) Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 16:14, 1915-1923
CrossRef975
V. Di Marco, D. Ferraro, P. Almasio, A. Vaccaro, P. Parisi, M. Cappello, N. Cino, R. Di Stefano, Antonio Craxi. (2002) Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. Journal of Viral Hepatitis 9:5, 354-359
CrossRef976
Thomas J. Layden, Jennifer E. Layden, K. Rajender Reddy, Rachel S. Levy-Drummer, Jennifer Poulakos, Avidan U. Neumann. (2002) Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. Journal of Viral Hepatitis 9:5, 334-339
CrossRef977
Susanne Beckebaum, Vito R. Cicinnati, Guido Gerken. (2002) DNA-based immunotherapy: potential for treatment of chronic viral hepatitis?. Reviews in Medical Virology 12:5, 297-319
CrossRef978
J FRANCO, K SAEIAN. (2002) Role of Antiviral Therapy in the Prevention of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 13:9, S191-S196
CrossRef979
Carol A. Langford. (2002) Reply. Arthritis & Rheumatism 46:8, 2254-2255
CrossRef980
Roel E. Sentjens, Christine J. Weegink, Marcel G. Beld, Michel C. Cooreman, Henk W. Reesink. (2002) Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily. European Journal of Gastroenterology & Hepatology 14:8, 833-840
CrossRef981
Norbert Brau, Edmund J. Bini, Azra Shahidi, Ayse Aytaman, Peiying Xiao, Saray Stancic, Robert Eng, Sheldon T. Brown, Fiorenzo Paronetto. (2002) Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York city metropolitan area1. The American Journal of Gastroenterology 97:8, 2071-2078
CrossRef982
Norman Gitlin. (2002) Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases. European Journal of Gastroenterology & Hepatology 14:8, 883-885
CrossRef983
Mohamad Warda, Robert J Linhardt, Rory M Marks. (2002) Patents related to dengue virus infection. Expert Opinion on Therapeutic Patents 12:8, 1127-1143
CrossRef984
Christine Armbruster. (2002) Novel treatments for recurrent respiratory papillomatosis. Expert Opinion on Investigational Drugs 11:8, 1139-1148
CrossRef985
Diana L Sylvestre. (2002) Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug and Alcohol Dependence 67:2, 117-123
CrossRef986
Abraham Koshy, John P. Madda, Patrick Marcellin, Michele Martinot. (2002) Treatment of Hepatitis C Virus Genotype 4–Related Cirrhosis. Journal of Clinical Gastroenterology 35:1, 82-85
CrossRef987
Richard A. Willson. (2002) Nephrotoxicity of Interferon Alfa–Ribavirin Therapy for Chronic Hepatitis C. Journal of Clinical Gastroenterology 35:1, 89-92
CrossRef988
Rosa Di Stefano, Tommaso Stroffolini, Donatella Ferraro, Antonella Usticano, Lilli Mario Valenza, Luigi Montalbano, Giuseppina Pomara, Antonio Crax
CrossRef989
Barbara McGovern. (2002) Evaluation and Treatment of the HIV/HCV Coinfected Patient: A Case History and Discussion. AIDS Patient Care and STDs 16:7, 319-326
CrossRef990
AM Kesson. (2002) Diagnosis and management of paediatric hepatitis C virus infection. Journal of Paediatrics and Child Health 38:3, 213-218
CrossRef991
Vincent Wong, Angela Xi-Li Fu, Jacob George, N. Wah Cheung. (2002) Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clinical Endocrinology 56:6, 793-798
CrossRef992
Dirk J. Leeuwen. (2002) Liver biopsy: who should do it ... and who will show up in court?. The American Journal of Gastroenterology 97:6, 1285-1288
CrossRef993
M. R. Kraus, A. Schafer, H. Faller, H. Csef, M. Scheurlen. (2002) Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Alimentary Pharmacology and Therapeutics 16:6, 1091-1099
CrossRef994
K. Rajender Reddy, Marlene W. Modi, Simon Pedder. (2002) Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C. Advanced Drug Delivery Reviews 54:4, 571-586
CrossRef995
MICHAEL D. NISSEN, THEO P. SLOOTS. (2002) Rapid diagnosis in pediatric infectious diseases: the past, the present and the future. The Pediatric Infectious Disease Journal 21:6, 605-612
CrossRef996
R. Bruno, M. Puoti, P. Sacchi, G. Carosi, G. Filice. (2002) Management of hepatitis C in human immunodeficiency virus-infected patients. Digestive and Liver Disease 34:6, 452-459
CrossRef997
Yu-Sen Wang, Stephen Youngster, Michael Grace, James Bausch, Ronald Bordens, Daniel F. Wyss. (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Advanced Drug Delivery Reviews 54:4, 547-570
CrossRef998
Douglas T. Dieterich. (2002) Treatment of Hepatitis C and Anemia in Human Immunodeficiency Virus–Infected Patients. The Journal of Infectious Diseases 185:s2, S128-S137
CrossRef999
Scott J. Cotler, Teresa Craft, Mary Ferris, Mary Morrisey, Jonathan McCone, K. Raj Reddy, Andrew Conrad, Donald M. Jensen, Jeff Albrecht, Milton W. Taylor. (2002) Induction of IL-1Ra in Resistant and Responsive Hepatitis C Patients Following Treatment with IFN-con1. Journal of Interferon & Cytokine Research 22:5, 549-554
CrossRef1000
Jean-Michel Pawlotsky. (2002) Molecular diagnosis of viral hepatitis. Gastroenterology 122:6, 1554-1568
CrossRef1001
Peter M. Rosenberg. (2002) Hepatitis C: A Clinician???s View at the Turn of the Millennium. Infectious Diseases in Clinical Practice 11:4, 205-210
CrossRef1002
Geoffrey H. Haydon, David J. Mutimer. (2002) Genetically modified interferon: is there a consensus yet?. European Journal of Gastroenterology & Hepatology 14:5, 471-473
CrossRef1003
ZAIGHAM ABBAS, SAEED HAMID, SHAESTA TABASSUM. (2002) High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naive to therapy. Journal of Gastroenterology and Hepatology 17:5, 577-581
CrossRef1004
Marina Núñez, Pilar Ríos, Luz Martín-Carbonero, Mayte Pérez-Olmeda, Juan González-Lahoz, Vincent Soriano. (2002) Role of Hepatitis C Virus Genotype in the Development of Severe Transaminase Elevation After the Introduction of Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 30:1, 65-68
CrossRef1005
Giuseppe Barbaro, Giorgio Barbarini. (2002) Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. European Journal of Gastroenterology & Hepatology 14:5, 477-483
CrossRef1006
F. J. Castro, J. I. Esteban, A. Juarez, S. Sauleda, L. Viladomiu, M. Martell, F. Moreno, H. Allende, R. Esteban, J. Guardia. (2002) Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. Journal of Viral Hepatitis 9:3, 202-207
CrossRef1007
Robert P Myers, Corinne Regimbeau, Thierry Thevenot, Vincent Leroy, Philippe Mathurin, Pierre Opolon, Jean Pierre Zarski, Thierry Poynard, Robert P Myers. 2002. Interferon for interferon naive patients with chronic hepatitis C. .
CrossRef1008
Lise Lotte Gluud, Kim Krogsgaard, Christian Gluud, Lise Lotte Gluud. 2002. Ribavirin with or without alpha interferon for chronic hepatitis C. .
CrossRef1009
Paul J Pockros. (2002) Developments in the treatment of chronic hepatitis C. Expert Opinion on Investigational Drugs 11:4, 515-528
CrossRef1010
Gregory J Dore, Anthony J Freeman, Matthew Law, JohnM Kaldor. (2002) Is severe liver disease a common outcome for people with chronic hepatitisC?. Journal of Gastroenterology and Hepatology 17:4, 423-430
CrossRef1011
Kathleen Iosue. (2002) Chronic Hepatitis C: Latest Treatment Options. The Nurse Practitioner 27:4, 32-33
CrossRef1012
Shruti H Mehta, Andrea Cox, Donald R Hoover, Xiao-Hong Wang, Qing Mao, Stuart Ray, Steffanie A Strathdee, David Vlahov, David L Thomas. (2002) Protection against persistence of hepatitis C. The Lancet 359:9316, 1478-1483
CrossRef1013
William Sievert. (2002) Management issues in chronic viral hepatitis: Hepatitis C. Journal of Gastroenterology and Hepatology 17:4, 415-422
CrossRef1014
John G Mchutchison. (2002) Hepatitis C advances in antiviral therapy: What is accepted treatment now?. Journal of Gastroenterology and Hepatology 17:4, 431-441
CrossRef1015
Stephen Pianko, John G. McHutchison, Stuart C. Gordon, Shanon Heaton, Zachary D. Goodman, Keyur Patel, Cherise M. Cortese, Elizabeth M. Brunt, Bruce R. Bacon, Lawrence M. Blatt. (2002) Hepatic Iron Concentration Does Not Influence Response to Therapy with Interferon Plus Ribavirin in Chronic HCV Infection. Journal of Interferon & Cytokine Research 22:4, 483-489
CrossRef1016
K. E. Sherman, S. D. Rouster, R. T. Chung, N. Rajicic. (2002) Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group. Clinical Infectious Diseases 34:6, 831-837
CrossRef1017
Brenda Fredericksen, Giridhar R. Akkaraju, Eileen Foy, Chunfu Wang, Jill Pflugheber, Zhijian J. Chen, Michael Gale. (2002) Activation of the Interferon- β Promoter During Hepatitis C Virus RNA Replication. Viral Immunology 15:1, 29-40
CrossRef1018
S. SCHULMAN, N. KINNMAN, P. LINDMARKER, M. VON SYDOW. (2002) A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders. Haemophilia 8:2, 129-135
CrossRef1019
A. H. Malik, K. S. Kumar, P. F. Malet, G. Ostapowicz, G. Adams, M. Wood, K. Yarbrough, A. Jones, W. M. Lee. (2002) A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon. Alimentary Pharmacology and Therapeutics 16:3, 381-388
CrossRef1020
R Ross. (2002) Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. Journal of Virological Methods 101:1-2, 159-168
CrossRef1021
Andrew J. Muir, Dawn Provenzale. (2002) A Descriptive Evaluation of Eligibility for Therapy Among Veterans With Chronic Hepatitis C Virus Infection. Journal of Clinical Gastroenterology 34:3, 268-271
CrossRef1022
V. Carreno. (2002) Present treatment expectations and risks of chronic hepatitis C. Clinical Microbiology and Infection 8:2, 74-79
CrossRef1023
J. A. Moreno-Monteagudo, A. Castro, A. De Pedro, J. A. Lorenzo, M. Fernandez-Bermejo, S. Lopez, L. Garcia-Buey, M. J. Borque, J. D. Pedreira, R. Moreno-Otero. (2002) Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers. Alimentary Pharmacology and Therapeutics 16:2, 243-249
CrossRef1024
Markus Cornberg, Heiner Wedemeyer, Michael P. Manns. (2002) Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Current Gastroenterology Reports 4:1, 23-30
CrossRef1025
Dirk J. Leeuwen, Leland J. Yee, Rebecca G. Langner. (2002) 24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients. The American Journal of Gastroenterology 97:2, 497-498
CrossRef1026
Robert J. Fontana, John Walsh, Cheryl A. Moyer, Anna S.F. Lok, Steven Webster, Steven Klein. (2002) Results of a Prospective, Randomized, Controlled Trial. Journal of Clinical Gastroenterology 34:2, 177-182
CrossRef1027
Andrew H. Talal, P. Wilfredo Canchis, Ira M. Jacobson. (2002) The HCV and HIV coinfected patient: What have we learned about pathophysiology?. Current Gastroenterology Reports 4:1, 15-22
CrossRef1028
Mayte Pérez-Olmeda, Pilar Ríos, Marina Núñez, Javier García-Samaniego, Miriam Romero, Vincent Soriano. (2002) Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. AIDS 16:3, 493-495
CrossRef1029
Özlem D. Süoğlu, Berna Elkabes, Semra Sökücü, Günay Saner. (2002) Does Interferon and Ribavirin Combination Therapy Increase the Rate of Treatment Response in Children With Hepatitis C?. Journal of Pediatric Gastroenterology and Nutrition 34:2, 199-206
CrossRef1030
NANCY WY LEUNG. (2002) Management of viral hepatitis C. Journal of Gastroenterology and Hepatology 17, S146-S154
CrossRef1031
Jia-Horng Kao, Ding-Shinn Chen. (2002) Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma. International Journal of Cancer 97:3, 269-271
CrossRef1032
Maria Buti, Miguel A. Casado, Leslie Fosbrook, Rafael Esteban. (2002) Which is the Most Cost-Effective Combination Therapy Strategy Using Interferon ??-2b plus Ribavirin for Na??ve Patients with Chronic Hepatitis C?. Clinical Drug Investigation 22:1, 31-39
CrossRef1033
Paul R. Engstrom. 2002. Hepatocellular Carcinoma (HCC). , 363-371.
CrossRef1034
Mark Sulkowski, Robert Reindollar, David L. Thomas, Sherilyn Brinkley-Laughton, Martha Hudson, Jian Yu. (2002) Peginterferon-??-2a (40kD) and Ribavirin in Patients with Chronic Hepatitis C. BioDrugs 16:2, 105-109
CrossRef1035
G. Montalto, S. Tripi, O. Vuturo, G. Di Gaetano, M. Soresi, A. Spadaro, A. Aiello, M. Russello, R. Benigno, R. Siciliano. (2002) Randomised Trial of Two Different Daily Doses of Interferon-?? versus Classical Therapy in Treatment-Na??ve Patients with Chronic Hepatitis C. Clinical Drug Investigation 22:9, 623-631
CrossRef1036
M KAINUMA. (2002) The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-? for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study. Phytomedicine 9:5, 365-372
CrossRef1037
M. Bourliere, J. M. Barberin, M. Rotily, V. Guagliardo, I. Portal, L. Lecomte, S. Benali, C. Boustiere, H. Perrier, M. Jullien, G. Lambot, R. Loyer, O. LeBars, R. Daniel, H. Khiri, P. Halfon. (2002) Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. Journal of Viral Hepatitis 9:1, 62-70
CrossRef1038
Markus Sagmeister, Eberhard L. Renner, Beat Mullhaupt, John B. Wong. (2002) Simulation of hepatitis C based on a mandatory reporting system. European Journal of Gastroenterology & Hepatology 14:1, 25-34
CrossRef1039
I. K. Kuramoto, T. Moriya, V. Schoening, P. V. Holland. (2002) Fluctuation of serum HCV-RNA levels in untreated blood donors with chronic hepatitis C virus infection. Journal of Viral Hepatitis 9:1, 36-42
CrossRef1040
S. Pol, A. Vallet-Pichard, H. Fontaine. (2002) Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy. Journal of Viral Hepatitis 9:1, 1-8
CrossRef1041
Massimo Resti, Chiara Azzari, Flavia Bortolotti. (2002) Hepatitis C Virus Infection in Children Coinfected with HIV. Pediatric Drugs 4:9, 571-580
CrossRef1042
Anthony J Freeman, George Marinos, Rosemary A Ffrench, Andrew R Lloyd. (2001) Immunopathogenesis of hepatitis C virus infection. Immunology and Cell Biology 79:6, 515-536
CrossRef1043
Marie-Ange Thelu, Karen Brengel-Pesce, Vincent Leroy, Val
CrossRef1044
Scott J. Cotler, K. Rajender Reddy, Jon McCone, Darin L. Wolfe, Anguo Liu, Teresa R. Craft, Mary W. Ferris, Andrew J. Conrad, Jeff Albrecht, Mary Morrissey, Daniel R. Ganger, Howard Rosenblate, Lawrence M. Blatt, Donald M. Jensen, Milton W. Taylor. (2001) An Analysis of Acute Changes in Interleukin-6 Levels After Treatment of Hepatitis C with Consensus Interferon. Journal of Interferon & Cytokine Research 21:12, 1011-1019
CrossRef1045
Tram T. Tran, Paul Martin. (2001) Chronic hepatitis C. Current Treatment Options in Gastroenterology 4:6, 503-510
CrossRef1046
John M. O???Brien, Katarzyna E. Kruzel, Michael G. Wandell, Ilia V. Vinogradov, John N. Sheagren, Allan P. Frank. (2001) Detection of Hepatitis C Antibody With At-Home Collection Kits Using an Innovative Laboratory Algorithm. Infectious Diseases in Clinical Practice 10:9, 474-480
CrossRef1047
Tobias Heintges, Jens Encke, Jasper zu Putlitz, Jack R. Wands. (2001) Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. Journal of Medical Virology 65:4, 671-680
CrossRef1048
Marlene Modi, Nancy Martin, Jenny E Heathcote, Keith Nieforth, Stefan Zeuzem. (2001) Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opinion on Investigational Drugs 10:12, 2201-2213
CrossRef1049
Fabien Zoulim. (2001) Quantification and genotyping in management of chronic hepatitis B and C. Virus Research 82:1-2, 45-52
CrossRef1050
Rosamaria Roccasecca, Antonella Folgori, Bruno Bruni Ercole, Giulia Puntoriero, Armin Lahm, Silvia Zucchelli, Rosalba Tafi, Monica Pezzanera, Giovanni Galfre, Anna Tramontano, M.U. Mondelli, Antonello Pessi, Alfredo Nicosia, Riccardo Cortese, Annalisa Meola. (2001) Mimotopes of the hyper variable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. Molecular Immunology 38:6, 485-492
CrossRef1051
Thomas F. Smith. (2001) SUSCEPECPTIBILITY TESTING. Infectious Disease Clinics of North America 15:4, 1263-1294
CrossRef1052
Evangelista Sagnelli, Nicola Coppola, Carlo Scolastico, Anna Rita Mogavero, Maria Stanzione, Pietro Filippini, Francesca Maria Felaco, Felice Piccinino. (2001) Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. Journal of Medical Virology 65:4, 681-687
CrossRef1053
Gregory J. Dore, David A. Cooper. (2001) The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses. Current Opinion in Infectious Diseases 14:6, 749-755
CrossRef1054
A Pár. (2001) Therapy for chronic hepatitis C. Journal of Physiology-Paris 95:1-6, 399-405
CrossRef1055
Jaeckel, Elmar, Cornberg, Markus, Wedemeyer, Heiner, Santantonio, Teresa, Mayer, Julika, Zankel, Myrga, Pastore, Giuseppe, Dietrich, Manfred, Trautwein, Christian, Manns, Michael P., . (2001) Treatment of Acute Hepatitis C with Interferon Alfa-2b. New England Journal of Medicine 345:20, 1452-1457
Full Text1056
Hoofnagle, Jay H., . (2001) Therapy for Acute Hepatitis C. New England Journal of Medicine 345:20, 1495-1497
Full Text1057
Peter M. Rosenberg. (2001) Hepatitis C: A Hepatologist's Approach to an Infectious Disease. Clinical Infectious Diseases 33:10, 1728-1732
CrossRef1058
Donald K. Strickland, Jesse J. Jenkins, Melissa M. Hudson. (2001) Hepatitis C Infection and Hepatocellular Carcinoma After Treatment of Childhood Cancer. Journal of Pediatric Hematology/Oncology 23:8, 527-529
CrossRef1059
Pam Kimball, R.K. Elswick, Mitchell Shiffman. (2001) Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-? therapy. Journal of Medical Virology 65:3, 510-516
CrossRef1060
J. G. McHutchison, J. A. Shad, S. C. Gordon, T. R. Morgan, M.-H. Ling, J.-J. Garaud, J. K. Albrecht, J. L. Dienstag. (2001) Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. Journal of Viral Hepatitis 8:6, 414-420
CrossRef1061
Sandeep Rajan, Howard A. Liebman. (2001) Treatment of hepatitis C related thrombocytopenia with interferon alpha. American Journal of Hematology 68:3, 202-209
CrossRef1062
VINCENZO PURO, GABRIELLA CARLI, PAOLA SCOGNAMIGLIO, ROLANDO PORCASI, GIUSEPPE IPPOLITO, . (2001) Risk of HIV and Other Blood-Borne Infections in the Cardiac Setting. Annals of the New York Academy of Sciences 946:1, 291-309
CrossRef1063
Rafael Rodrı́guez-Rosado, Mayte Pérez-Olmeda, Javier Garcı́a-Samaniego, Vincente Soriano. (2001) Management of hepatitis C in HIV-infected persons. Antiviral Research 52:2, 189-198
CrossRef1064
D. G. Macejak, K. L. Jensen, P. A. Pavco, K. M. Phipps, B. A. Heinz, J. M. Colacino, L. M. Blatt. (2001) Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA. Journal of Viral Hepatitis 8:6, 400-405
CrossRef1065
Alain Landau, Dominique Batisse, Christophe Piketty, Jean Paul Duong Van Huyen, Francis Bloch, Laurent Belec, Patrick Bruneval, Laurence Weiss, Raymond Jian, Michel D. Kazatchkine. (2001) Long-term efficacy of combination therapy with interferon-α2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 15:16, 2149-2155
CrossRef1066
Shih-Hua Fang, Ming-Yang Lai, Lin-Hwa Hwang, Pei-Ming Yang, Pei-Jer Chen, Bor-Luen Chiang, Ding-Shinn Chen. (2001) Ribavirin enhances interferon-γ levels in patients with chronic hepatitis C treated with interferon-α. Journal of Biomedical Science 8:6, 484-491
CrossRef1067
Arno Kornberg, Merten Hommann, Andrea Tannapfel, Thomas Wagner, Thomas Grube, Uwe Schotte, Rigo Voigt, Johannes Scheele. (2001) Long-term Combination of Interferon Alfa-2b and Ribavirin for Hepatitis C Recurrence in Liver Transplant Patients. American Journal of Transplantation 1:4, 350-355
CrossRef1068
David Gretch. (2001) Mechanism of interferon resistance in hepatitis C. The Lancet 358:9294, 1662-1664
CrossRef1069
&NA;. (2001) Is pegylated interferon-?? plus ribavirin set to become the standard therapy for patients with hepatitis C?. Drugs & Therapy Perspectives 17:22, 5-8
CrossRef1070
Olaitan A. Adeniji, Jorge L. Herrera. (2001) Finally: changing the natural history of chronic hepatitis c!. Poynard T, McHutchison J, Davis GL, et al., Impact of Interferon Alfa-2b and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C, Hepatology 2000;32:1131-7. The American Journal of Gastroenterology 96:11, 3200-3201
CrossRef1071
Robert P Myers, Corinne Regimbeau, Thierry Thevenot, Vincent Leroy, Philippe Mathurin, Pierre Opolon, Jean Pierre Zarski, Thierry Poynard, Robert P Myers. 2001. Interferon for acute hepatitis C. .
CrossRef1072
M. Hirayama, T. Maruyama, H. Mitsui, H. Maekawa, H. Yamada, N. Hashimoto, K. Koike, S. Kimura, K. Yasuda, S. Iino, J. Green. (2001) IgG1 anti-P2 as a marker of response to interferon in patients with chronic hepatitis C. Clinical and Experimental Immunology 126:1, 92-100
CrossRef1073
Mark S. Sulkowski. (2001) Hepatitis C virus infection in HIV-infected patients. Current Infectious Disease Reports 3:5, 469-476
CrossRef1074
Vincent G. Bain. (2001) Effect of HCV viral dynamics on treatment design: lessons learned from HIV. The American Journal of Gastroenterology 96:10, 2818-2828
CrossRef1075
Anita Karim, Shahid Ahmed, Arfa Khan, Harry Steinberg, Joseph Mattana. (2001) Interstitial Pneumonitis in a Patient Treated with ??-Interferon and Ribavirin for Hepatitis C Infection. The American Journal of the Medical Sciences 322:4, 233-235
CrossRef1076
Yoshiyuki Suzuki, Takashi Gojobori. (2001) Positively selected amino acid sites in the entire coding region of hepatitis C virus subtype 1b. Gene 276:1-2, 83-87
CrossRef1077
Srikanta Dash, Gururaj Kalkeri, Hazel M. McClure, Robert F. Garry, Sanda Clejan, Swan N. Thung, Krishna K. Murthy. (2001) Transmission of HCV to a chimpanzee using virus particles produced in an RNA-transfected HepG2 cell culture. Journal of Medical Virology 65:2, 276-281
CrossRef1078
Aykut Ferhat Celik, Resat Ozaras, Gulsen Ozbay. (2001) Follow-up of a Patient With Chronic Hepatitis C–associated Cryoglobulinemia During Four and a Half Years of Maintenance Interferon Treatment. Journal of Clinical Gastroenterology 33:4, 327-329
CrossRef1079
Mindie H. Nguyen, Teresa L. Wright. (2001) Therapeutic advances in the management of hepatitis B and hepatitis C. Current Opinion in Infectious Diseases 14:5, 593-601
CrossRef1080
J. Sasadeusz. (2001) Human immunodeficiency virus-hepatitis C coinfection: swapping new problems for newer ones. Internal Medicine Journal 31:7, 418-421
CrossRef1081
E. Beth Devine, Kris V. Kowdley, David L. Veenstra, Sean D. Sullivan. (2001) Management Strategies for Ribavirin-Induced Hemolytic Anemia in the Treatment of Hepatitis C: Clinical and Economic Implications. Value in Health 4:5, 376-384
CrossRef1082
Francesc Puig-Basagoiti, Juan-Carlos S
CrossRef1083
Graziella Ogana, Andreina Tocco, Giovanni Garrucciu, Barbara Branca, Vittoria Azara, Noemi E. Manzoni, Angelo Deplano, Antonio Solinas. (2001) Patterns of Response During Therapy With Interferon and Outcome of Retreatment With Interferon Plus Ribavirin for Chronic Hepatitis C. Journal of Clinical Gastroenterology 33:3, 254-255
CrossRef1084
T. M. Shehab, S. S. Sonnad, A. S. F. Lok. (2001) Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. Journal of Viral Hepatitis 8:5, 377-383
CrossRef1085
Kenneth G. Hadlock, Robert Gish, Judy Rowe, Sonal S. Rajyaguru, Margaret Newsom, Ann Warford, Steven K.H. Foung. (2001) Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2). Journal of Medical Virology 65:1, 23-29
CrossRef1086
H. Takagi, T. Nagamine, T. Abe, H. Takayama, K. Sato, T. Otsuka, S. Kakizaki, Y. Hashimoto, T. Matsumoto, A. Kojima, J. Takezawa, K. Suzuki, S. Sato, M. Mori. (2001) Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. Journal of Viral Hepatitis 8:5, 367-371
CrossRef1087
Guglielmo Nasti, Giampiero Di Gennaro, Marcello Tavio, Lucia Cadorin, Rosa Maria Tedeschi, Renato Talamini, Antonino Carbone, Umberto Tirelli. (2001) Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. AIDS 15:14, 1783-1787
CrossRef1088
Michael P Manns, John G McHutchison, Stuart C Gordon, Vinod K Rustgi, Mitchell Shiffman, Robert Reindollar, Zachary D Goodman, Kenneth Koury, Mei-Hsiu Ling, Janice K Albrecht. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet 358:9286, 958-965
CrossRef1089
JEFFREY J. GERMER, NIZAR N. ZEIN. (2001) Advances in the Molecular Diagnosis of Hepatitis C and Their Clinical Implications. Mayo Clinic Proceedings 76:9, 911-920
CrossRef1090
J J Germer, N N Zein. (2001) Advances in the molecular diagnosis of hepatitis C and their clinical implications.. Mayo Clinic Proceedings 76:9, 911-920
CrossRef1091
John McHutchison, Keyur Patel. (2001) Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. Expert Opinion on Pharmacotherapy 2:8, 1307-1315
CrossRef1092
Max Arens. (2001) Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. Journal of Clinical Virology 22:1, 11-29
CrossRef1093
Tekla G.J. Rossum, Arnold G. Vulto, Wim C.J. Hop, Solko W. Schalm. (2001) Glycyrrhizin-induced reduction of alt in european patients with chronic hepatitis C. The American Journal of Gastroenterology 96:8, 2432-2437
CrossRef1094
Christopher B. O'Brien, Dilip K. Moonka, Barbara S. Henzel, Maureen Caufield, Michael F. DeBruin. (2001) A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-alpha. The American Journal of Gastroenterology 96:8, 2473-2479
CrossRef1095
Laura M. Lee, David K. Henderson. (2001) Emerging viral infections. Current Opinion in Infectious Diseases 14:4, 467-480
CrossRef1096
J Schinkel, A.C.M Kroes, M.J Wagtmans, C.B.H.W Lamers, B van Hoek. (2001) Monitoring response during a randomised controlled trial of escalating interferon dose for chronic hepatitis C infection: predictive value of quantitative and qualitative HCV RNA assays. Journal of Clinical Virology 22:1, 61-71
CrossRef1097
Nizar N Zein. (2001) Experimental and emerging therapies for chronic hepatitis C virus infection. Expert Opinion on Investigational Drugs 10:8, 1457-1469
CrossRef1098
Noel J C Snell. (2001) Ribavirin - current status of a broad spectrum antiviral agent. Expert Opinion on Pharmacotherapy 2:8, 1317-1324
CrossRef1099
Davis, Gary L., , Rodrigue, James R., . (2001) Treatment of Chronic Hepatitis C in Active Drug Users. New England Journal of Medicine 345:3, 215-217
Full Text1100
Edlin, Brian R., Seal, Karen H., Lorvick, JenniferKral, Alex H., Ciccarone, Daniel H., Moore, Lisa D., Lo, Bernard, . (2001) Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?. New England Journal of Medicine 345:3, 211-214
Full Text1101
M. Makris, T. Baglin, G. Dusheiko, P. L. F. Giangrande, C. A. Lee, C. A. Ludlam, F. E. Preston, H. G. Watson, J. T. Wilde, M. Winter, . (2001) Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 7:4, 339-345
CrossRef1102
Lauer, Georg M., Walker, Bruce D., . (2001) Hepatitis C Virus Infection. New England Journal of Medicine 345:1, 41-52
Full Text1103
G. Teuber, T. Berg, U. Naumann, J. Raedle, S. Brinkmann, U. Hopf, S. Zeuzem. (2001) Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. Journal of Viral Hepatitis 8:4, 276-283
CrossRef1104
E. Herrero Mart
CrossRef1105
Luigi Aurisicchio, Alessandra Ceccacci, Nicola La Monica, Fabio Palombo, Cinzia Traboni. (2001) Tamarin alpha-interferon is active in mouse liver upon intramuscular gene delivery. The Journal of Gene Medicine 3:4, 394-402
CrossRef1106
A. Bruchfeld, L. Stahle, J. Andersson, R. Schvarcz. (2001) Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. Journal of Viral Hepatitis 8:4, 287-292
CrossRef1107
V. Di Marco, A. Vaccaro, D. Ferraro, G. Alaimo, V. Rodolico, P. Parisi, S. Peralta, R. Di Stefano, P. L. Almasio, A. Craxi. (2001) High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C. Alimentary Pharmacology and Therapeutics 15:7, 953-958
CrossRef1108
J. L. Kinzie, P. H. Naylor, M. G. Nathani, R. R. Peleman, M. N. Ehrinpreis, M. Lybik, J. R. Turner, J. J. Janisse, M. Massanari, M. G. Mutchnick. (2001) African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. Journal of Viral Hepatitis 8:4, 264-269
CrossRef1109
Arie Regev, Eugene R. Schiff. (2001) LIVER DISEASE IN THE ELDERLY. Gastroenterology Clinics of North America 30:2, 547-563
CrossRef1110
Arturo Pereira. (2001) Health and economic consequences of HCV lookback. Transfusion 41:6, 832-839
CrossRef1111
Florence Komurian-Pradel, Gláucia Paranhos-Baccalà, Mireille Sodoyer, Philippe Chevallier, Bernard Mandrand, Vincent Lotteau, Patrice André. (2001) Quantitation of HCV RNA using real-time PCR and fluorimetry. Journal of Virological Methods 95:1-2, 111-119
CrossRef1112
H.M. Chapel, J.M.L. Christie, V. Peach, R.W.G. Chapman. (2001) Five-Year Follow-up of Patients with Primary Antibody Deficiencies Following an Outbreak of Acute Hepatitis C. Clinical Immunology 99:3, 320-324
CrossRef1113
Peter Ferenci, Rudolf Stauber, Petra Steindl-Munda, Michael Gschwantler, Peter Fickert, Christian Datz, Christian M??ller, Franz Hackl, Wolfgang Rainer, Thomas Watkins-Riedel, Werner Lin, G??nter J. Krejs, Alfred Gangl. (2001) Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. European Journal of Gastroenterology & Hepatology 13:6, 699-705
CrossRef1114
Jugnu Jain, Susan J. Almquist, Dina Shlyakhter, Matthew W. Harding. (2001) VX-497: A novel, selective IMPDH inhibitor and immunosuppressive agent. Journal of Pharmaceutical Sciences 90:5, 625-637
CrossRef1115
Markus Sagmeister, John B. Wong, Beat Mullhaupt, Eberhard L. Renner. (2001) A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. European Journal of Gastroenterology & Hepatology 13:5, 483-488
CrossRef1116
K. Katayama, A. Kasahara, Y. Sasaki, T. Kashiwagi, M. Naito, M. Masuzawa, M. Katoh, H. Yoshihara, T. Kamada, T. Mukuda, T. Hijioka, M. Hori, N. Hayashi. (2001) Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance. Journal of Viral Hepatitis 8:3, 180-185
CrossRef1117
Antoni Kozlowski, J. Milton Harris. (2001) Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. Journal of Controlled Release 72:1-3, 217-224
CrossRef1118
P. Andreone, C. Cursaro, A. Gramenzi, M. Margotti, E. Ferri, S. Talarico, M. Biselli, F. Felline, C. Tuthill, E. Martins, G. Gasbarrini, M. Bernardi. (2001) In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. Journal of Viral Hepatitis 8:3, 194-201
CrossRef1119
L. Mazzoran, F. Zorat, L. Chemello, L.S. Crocè, I. Rigato, L. Cavalletto, E. Bernardinello, C. Tiribelli, A. Alberti, G. Pozzato. (2001) Human leucocyte interferon-alpha in the treatment of chronic hepatitis C. Digestive and Liver Disease 33:4, 347-352
CrossRef1120
Laurent Castera, Isabelle Negre, Kamran Samii, Catherine Buffet. (2001) Patient-administered nitrous oxide/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: A randomized placebo-controlled trial. The American Journal of Gastroenterology 96:5, 1553-1557
CrossRef1121
S. Loubiere, M. Rotily, I. Durand-Zaleski, D. Costagliola. (2001) Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. Vox Sanguinis 80:4, 199-204
CrossRef1122
Samuel S. Lee, Morris Sherman. (2001) Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. Journal of Viral Hepatitis 8:3, 202-205
CrossRef1123
Umaprasanna S. Karnam, Ignacia Jaca, K. Rajender Reddy. (2001) Peginterferon is here to stay12. The American Journal of Gastroenterology 96:5, 1637-1638
CrossRef1124
G. V. Papatheodoridis, V. C. Papadimitropoulos, S. J. Hadziyannis. (2001) Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Alimentary Pharmacology and Therapeutics 15:5, 689-698
CrossRef1125
Giuliano Ramadori, Volker Meier. (2001) Hepatitis C virus infection: 10 years after the discovery of the virus. European Journal of Gastroenterology & Hepatology 13:5, 465-471
CrossRef1126
F. Capra, E. De Maria, M. Franchini, G. Gandini. (2001) Effective antiviral treatment for hepatitis C virus-related chronic active hepatitis in haemophiliac patients. Digestive and Liver Disease 33:4, 389
CrossRef1127
Sangik Oh, Nezam H. Afdhal. (2001) ARE THERE RACIAL DIFFERENCES IN THE RESPONSE TO THERAPY FOR HEPATITIS C?. Evidence-Based Gastroenterology 2:2, 88-89
CrossRef1128
Stefan Zeuzem. (2001) What is (cost) effective in patients with chronic hepatitis C virus infection?. European Journal of Gastroenterology & Hepatology 13:5, 473-476
CrossRef1129
A. S. Hadziyannis, C. Papaioannou, F. Spanou, E. K. Manesis, S. J. Hadziyannis. (2001) Induction interferon therapy in naive patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Alimentary Pharmacology and Therapeutics 15:4, 551-557
CrossRef1130
Brian W Dymock. (2001) Emerging therapies for hepatitis C virus infection. Expert Opinion on Emerging Drugs 6:1, 13-42
CrossRef1131
Jonathan P. Moorman. (2001) Issues in HIV/hepatitis C co-infection. Current Infectious Disease Reports 3:2, 131-136
CrossRef1132
Stefan Lethagen, Anders Widell, Erik Berntorp, Hans Verbaan, Stefan Lindgren. (2001) Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease. British Journal of Haematology 113:1, 87-93
CrossRef1133
Alfonso Paredes, Joan E. Zweben. (2001) The Hepatitis C Epidemic, Shall We Remain Silent?. Journal of Addictive Diseases 20:1, 1-7
CrossRef1134
Guglielmo Nasti, Giampiero di Gennaro, Giuliano Rizzardini, Lucia Cadorin, Umberto Tirelli. (2001) Chronic Hepatitis C in HIV-Coinfected Patients: Feasibility and Efficacy of Interferon-??2b and Ribavirin Combination Therapy. Journal of Acquired Immune Deficiency Syndromes299-300
CrossRef1135
Guglielmo Nasti, Giampiero di Gennaro, Giuliano Rizzardini, Lucia Cadorin, Umberto Tirelli. (2001) Chronic Hepatitis C in HIV-Coinfected Patients: Feasibility and Efficacy of Interferon-α2b and Ribavirin Combination Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 26:3, 299-300
CrossRef1136
Antje Knöll, Magdalena Helmig, Ove Peters, Wolfgang Jilg. (2001) Hepatitis C Virus Transmission in a Pediatric Oncology Ward: Analysis of an Outbreak and Review of the Literature. Laboratory Investigation 81:3, 251-262
CrossRef1137
Michael E. de Vera, Gregory A. Smallwood, Kathia Rosado, Laurel Davis, Enrique Martinez, Shobha Sharma, Andrei C. Stieber, Thomas G. Heffron. (2001) INTERFERON-?? AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION1. Transplantation 71:5, 678-686
CrossRef1138
F. Querenghi, Qiang Yu, G. Billaud, G. Maertens, C. Trépo, F. Zoulim. (2001) Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. Journal of Viral Hepatitis 8:2, 120-131
CrossRef1139
Richard C. Semelka, Jae-Joon Chung, Shahid M. Hussain, Hani B. Marcos, John T. Woosley. (2001) Chronic hepatitis: Correlation of early patchy and late linear enhancement patterns on gadolinium-enhanced MR images with histopathology initial experience. Journal of Magnetic Resonance Imaging 13:3, 385-391
CrossRef1140
J. L. Calleja, A. Albillos, I. Rossi, R. Moreno, F. Domper, J. L. MartInez, P. EscartIn. (2001) Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response. Alimentary Pharmacology and Therapeutics 15:2, 241-249
CrossRef1141
John Levis, Elizabeth Kenny-Walsh, Kathleen O'Sullivan, Mary Horgan, Michael Whelton, Fergus Shanahan, Liam Fanning. (2001) Strategy for the maximization of clinically relevant information from hepatitis C virus, RT-PCR quantification. Journal of Clinical Virology 20:3, 163-171
CrossRef1142
Giorgio Saracco, Alessia Ciancio, Valeria Ghisetti, Giuseppe Rocca, Giuseppe Cariti, Massimo Andreoni, Marco Tabone, Luigi Roffi, Guido Calleri, Marco Ballar??, Natalia Terreni, Massimo Sartori, Gian Franco Tappero, Antonio Traverso, Antonio Poggio, Annamaria Orani, Giovanni Maggi, Angelo Di Napoli, Arrigo Arrigoni, Mario Rizzetto. (2001) Treatment with interferon-??2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. European Journal of Gastroenterology & Hepatology 13:2, 149-155
CrossRef1143
Otto S. Lin, Emmet B. Keeffe. (2001) C
URRENT TREATMENT STRATEGIES FOR CHRONIC HEPATITIS BAND C. Annual Review of Medicine 52:1, 29-49
CrossRef1144
John G. McHutchison, Ryan Ponnudurai, David L. Bylund, Ariel Anguiano, Paul J. Pockros, Tony Mondala, Linda B. Wilkes. (2001) Prednisone Withdrawal Followed by Interferon Alpha for Treatment of Chronic Hepatitis C Infection. Journal of Clinical Gastroenterology 32:2, 133-137
CrossRef1145
Kenneth M Shermock, Mary E Temple, Zobair M Younossi. (2001) A pharmacoeconomic appraisal of therapies for hepatitis B and C. Expert Opinion on Pharmacotherapy 2:2, 205-211
CrossRef1146
Mitchell L.Shiffman. (2001) Pegylated interferons: What role will they play in the treatment of chronic hepatitis c?. Current Gastroenterology Reports 3:1, 30-37
CrossRef1147
Juan C??rdoba, Mar??a But??. (2001) PEGINTERFERON ALFA-2A IS MORE EFFECTIVE THAN INTERFERON ALFA-2A FOR HEPATITIS C. Evidence-Based Gastroenterology 2:1, 38-39
CrossRef1148
R. Cozzolongo, R. Cuppone, V. Giannuzzi, L. Amati, L. Caradonna, V. Tamborrino, E. Jirillo, O. G. Manghisi. (2001) Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon. Alimentary Pharmacology and Therapeutics 15:1, 129-135
CrossRef1149
Samuel B. Ho, Huy Nguyen, Lori L. Tetrick, Greg A. Opitz, Michael L. Basara, Eric Dieperink. (2001) Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. The American Journal of Gastroenterology 96:1, 157-164
CrossRef1150
T. Thevenot, C. Regimbeau, V. Ratziu, V. Leroy, P. Opolon, T. Poynard. (2001) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update. Journal of Viral Hepatitis 8:1, 48-62
CrossRef1151
Scott J. Cotler, Daniel R. Ganger, Suman Kaur, Howard Rosenblate, Shriram Jakate, Daniel G. Sullivan, Ka Wing Ng, David R. Gretch, and Donald M. Jensen. (2001) DAILY INTERFERON THERAPY FOR HEPATITIS C VIRUS INFECTION IN LIVER TRANSPLANT RECIPIENTS. Transplantation 71:2, 261-266
CrossRef1152
Mary L. Chavez. (2001) Treatment of Hepatitis C with Milk Thistle?. Journal of Herbal Pharmacotherapy 1:3, 79-90
CrossRef1153
Anne Gervais, Nathalie Boyer, Patrick Marcellin. (2001) Tolerability of Treatments for Viral Hepatitis. Drug Safety 24:5, 375-384
CrossRef1154
Deborah A. Payne, Susan L. Seifert, Brian A. Brody. (2001) Effects of storage and viral load on hepatitis C viral genotyping. Journal of Clinical Laboratory Analysis 15:6, 331-333
CrossRef1155
Thomas Morrow. (2001) Specialty Pharmacies. Disease Management and Health Outcomes 9:10, 531-538
CrossRef1156
Stuart C Gordon. (2001) Treatment of viral hepatitis - 2001. Annals of Medicine 33:6, 385-390
CrossRef1157
Antoni Kozlowski, Stephen A. Charles, J. Milton Harris. (2001) Development of Pegylated Interferons for the Treatment of Chronic Hepatitis C. BioDrugs 15:7, 419-429
CrossRef1158
C. Aguilar, J. F. Lucia, M. A. SimOn. (2001) An emerging role for interferon in haemophiliacs with chronic hepatitis C?. Haemophilia 7:1, 6-8
CrossRef1159
Raymond S. Koff. (2001) Disease Management Programs for Hepatitis C. Disease Management and Health Outcomes 9:8, 431-439
CrossRef1160
Makoto Nakamuta, Takayoshi Fukutomi, Naoya Shimohashi, Naoko Kinukawa, Koutaro Uchimura, Seiya Tada, Kenta Motomura, Munechika Enjoji, Masaki Kato, Hiroaki Iwamoto, Yuichi Tanabe, Yasuhisa Imari, Shigeru Sakamoto, Hironori Sakai, Hajime Nawata. (2001) Kinetics of the hepatitis C virus during interferon therapy as a marker of therapeutic response. Journal of Gastroenterology and Hepatology 16:1, 29-33
CrossRef1161
Ke-Qin Hu, John M. Vierling, Allan G. Redeker. (2001) Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. Journal of Viral Hepatitis 8:1, 1-18
CrossRef1162
Paul A Jorgensen, Paul D Neuwald. (2001) Standardized hepatitis C virus RNA panels for nucleic acid testing assays. Journal of Clinical Virology 20:1-2, 35-40
CrossRef1163
Rosamaria Roccasecca, Antonella Folgori, Bruno Bruni Ercole, Giulia Puntoriero, Armin Lahm, Silvia Zucchelli, Rosalba Tafi, Monica Pezzanera, Giovanni Galfre, Anna Tramontano, M. U. Mondelli, Antonello Pessi, Alfredo Nicosia, Riccardo Cortese, Annalisa Meola. (2001) Induction of Cross-reactive Humoral Immune Response by Immunization with Mimotopes of the Hypervariable Region 1 of the Hepatitis C Virus. International Reviews of Immunology 20:2, 289-300
CrossRef1164
Jane Collier, Roger Chapman. (2001) Combination Therapy with Interferon-?? and Ribavirin for Hepatitis C. BioDrugs 15:4, 225-238
CrossRef1165
Caroline M. Perry, Blair Jarvis. (2001) Peginterferon-??-2a (40kD). Drugs 61:15, 2263-2288
CrossRef1166
Schafer, Daniel F., Sorrell, Michael F., . (2000) Conquering Hepatitis C, Step by Step. New England Journal of Medicine 343:23, 1723-1724
Full Text1167
Heathcote, E. Jenny, Shiffman, Mitchell L., Cooksley, W. Graham E., Dusheiko, Geoffrey M., Lee, Samuel S., Balart, Luis, Reindollar, Robert, Reddy, Rajender K., Wright, Teresa L., Lin, Amy, Hoffman, Joseph, De Pamphilis, Jean, . (2000) Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis. New England Journal of Medicine 343:23, 1673-1680
Full Text1168
Zeuzem, Stefan, Feinman, S. Victor, Rasenack, Jens, Heathcote, E. Jenny, Lai, Ming-Yang, Gane, Edward, O'Grady, John, Reichen, Jürg, Diago, Moises, Lin, Amy, Hoffman, Joseph, Brunda, Michael J., . (2000) Peginterferon Alfa-2a in Patients with Chronic Hepatitis C. New England Journal of Medicine 343:23, 1666-1672
Full Text1169
G.W. McCaughan, A. Zekry. (2000) Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transplant Infectious Disease 2:4, 166-185
CrossRef1170
INGO JORDAN, THOMAS BRIESE, W. IAN LIPKIN. (2000) Discovery and Molecular Characterization of West Nile Virus NY 1999. Viral Immunology 13:4, 435-446
CrossRef1171
Travis W. Waldrep, Kimberly K. Summers, Philippe A. Chiliade. (2000) Coinfection with HIV and HCV: More Questions than Answers?. Pharmacotherapy 20:12, 1499-1507
CrossRef1172
G. W. McCaughan, S. I. Strasser. (2000) Emerging therapies for hepatitis C virus (HCV) infection: the importance of HCV genotype. Australian and New Zealand Journal of Medicine 30:6, 644-646
CrossRef1173
M. Angelico, M. Cepparulo, A. Barlattani, A. Liuti, S. Gentile, M. Hurtova, D. Ombres, P. Guarascio, G. Rocchi, F. Angelico. (2000) Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Alimentary Pharmacology and Therapeutics 14:11, 1459-1467
CrossRef1174
H. B. Krarup, J. M. Moller, P. B. Christensen, T. Fuglsang, J. Ingerslev, T. Arnfred, P. H. Madsen. (2000) Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups. Journal of Viral Hepatitis 7:6, 435-439
CrossRef1175
Mitchell L. Shiffman, Scott B. Verbeke, Pamela M. Kimball. (2000) Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes. Antiviral Research 48:2, 91-99
CrossRef1176
Fusao Ikeda, Hiroyuki Shimomura, Hiroshi Nakagawa, Yoshiaki Iwasaki, Masanobu Miyake, Hideyuki Tsuji, Shin-ichi Fukioka, Mamoru Itoh, Akira Takahashi, Takao Tsuji. (2000) Efficient Enhancement of Priming Effect by Intermittent Treatment with Interferon. Biochemical and Biophysical Research Communications 278:3, 599-603
CrossRef1177
Sandra Cerda, MD, Norris M. Keating, MD, Salah Elderiny, MD, Michael J. O'Brien, MD, Andrew P. Keaveny, MD, David P. Nunes, MD, Nezam H. Afdhal, MD. (2000) An Assessment of Digital Image Analysis to Measure Fibrosis in Liver Biopsy Specimens of Patients With Chronic Hepatitis C. American Journal of Clinical Pathology 114:5, 712-718
CrossRef1178
H. E. Harris, M. E. Ramsay, J. Heptonstall, K. Soldan, K. P. Eldridge, . (2000) The HCV National Register: towards informing the natural history of hepatitis C infection in the UK. Journal of Viral Hepatitis 7:6, 420-427
CrossRef1179
Delia Menozzi, Troy Udulutch, Augusto E. Llosa, Susan A. Galel. (2000) HCV lookback in the United States:effectiveness of an extended lookback program. Transfusion 40:11, 1393-1398
CrossRef1180
K. Hayashi, Y. Fukuda, I. Nakano, Y. Katano, S. Yokozaki, H. Toyoda, J. Takamatsu, T. Hayakawa. (2000) Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. Haemophilia 6:6, 677-681
CrossRef1181
K. Meijer, W. M. Smid, J. Van Der Meer. (2000) Treatment of chronic hepatitis C in haemophilia patients. Haemophilia 6:6, 605-613
CrossRef1182
C Mazzaro, G Panarello, S Carniello, A Faelli, G Mazzi, M Crovatto, S Baracetti, F Nascimben, F Zorat, G Pozzato, L Faccini, L Campanacci. (2000) Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Digestive and Liver Disease 32:8, 708-715
CrossRef1183
T. Carlsson, K. Lindahl, R. Schvarcz, R. Wejstal, I. Uhnoo, S. Shev, O. Reichard. (2000) HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin. Journal of Viral Hepatitis 7:6, 409-413
CrossRef1184
J. Enriquez, A. Gallego, X. Torras, T. Perez-Olmeda, M. Diago, V. Soriano, M.-S. Lujan, J. Garcia-Samaniego. (2000) Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. Journal of Viral Hepatitis 7:6, 403-408
CrossRef1185
Vincent Soriano, Rafael Rodr??guez-Rosado, Mayte P??rez-Olmeda, Miriam Romero, Javier Garc??a-Samaniego. (2000) Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 14:15, 2409-2410
CrossRef1186
Geoffrey W Mccaughan. (2000) Asian perspectives on viral hepatitis: Hepatitis C virus infection. Journal of Gastroenterology and Hepatology 15:s3, G90-G93
CrossRef1187
J. Frank Jen, Paul Glue, Samir Gupta, Demetris Zambas, Gerald Hajian. (2000) Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C. Therapeutic Drug Monitoring 22:5, 555-565
CrossRef1188
Mark Wright, Janice Main. (2000) The prevention and management of viral hepatitis. Current Opinion in Infectious Diseases 13:5, 489-494
CrossRef1189
E. Scott Priestley, Carl P. Decicco. (2000) 1-Aminocyclopropaneboronic Acid: Synthesis and Incorporation into an Inhibitor of Hepatitis C Virus NS3 Protease. Organic Letters 2:20, 3095-3097
CrossRef1190
P. Hauser. (2000) Prophylactic Treatment of Depression Induced by Interferon-alpha. Psychosomatics 41:5, 439-441
CrossRef1191
M. R. Kraus. (2000) Emotional State, Coping Styles, and Somatic Variables in Patients With Chronic Hepatitis C. Psychosomatics 41:5, 377-384
CrossRef1192
Laura Benson, Alice Birkel, Linda Caldwell, Valerie Stafford-Fox, Beverley Casarico. (2000) Advances in the Treatment of Hepatitis C: Combination Antiviral Therapy With Interferon alfa-2b and Ribavirin. Journal of the American Academy of Nurse Practitioners 12:9, 364-373
CrossRef1193
Zeuzem. (2000) Treatment of chronic hepatitis C virus infection in patients with cirrhosis. Journal of Viral Hepatitis 7:5, 327-334
CrossRef1194
Benjamin G Fanson, Patricia Osmack, Adrian M Di Bisceglie. (2000) A comparison between the phenol–chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of hepatitis C and GB virus-C/hepatitis G viral RNA from serum. Journal of Virological Methods 89:1-2, 23-27
CrossRef1195
Prati, Zanella, Zanuso, Vianello, E. Della Torre, Mozzi, Carriero, Zahm, Donato, Colombo, Sirchia, . (2000) Sustained response to interferon-alpha2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. Journal of Viral Hepatitis 7:5, 352-360
CrossRef1196
Fusao Ikeda, Hiroyuki Shimomura, Masanobu Miyake, Shin-Ichi Fujioka, Mamoru Itoh, Akira Takahashi, Yoshiaki Iwasaki, Kosaku Sakaguchi, Kazuhide Yamamoto, Toshihiro Higashi, Takao Tsuji. (2000) Early Clearance of Circulating Hepatitis C Virus Enhanced by Induction Therapy with Twice-a-Day Intravenous Injection of IFN-β. Journal of Interferon & Cytokine Research 20:9, 831-836
CrossRef1197
Sanjay Ramrakhiani, Bruce R. Bacon. (2000) HEPATOLOGY IN THE NEW MILLENNIUM. Medical Clinics of North America 84:5, 1085-1105
CrossRef1198
Catherine Petruff Cheney, Sanjiv Chopra, Camilla Graham. (2000) HEPATITIS C. Infectious Disease Clinics of North America 14:3, 633-667
CrossRef1199
Angela M. Caliendo. (2000) Molecular diagnostics in viral infections. Current Opinion in Organ Transplantation 5:3, 168-175
CrossRef1200
David L. Veenstra, Mitchell K. Higashi, Kathryn A. Phillips. (2000) Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2:3, 80-90
CrossRef1201
Thomas F. Imperiale, Areen T. Said, Oscar W. Cummings, Lawrence J. Born. (2000) Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. The American Journal of Gastroenterology 95:9, 2328-2332
CrossRef1202
Maria Erali, MS, Edward R. Ashwood, MD, David R. Hillyard, MD. (2000) Performance Characteristics of the COBAS AMPLICOR Hepatitis C Virus MONITOR Test, Version 2.0. American Journal of Clinical Pathology 114:2, 180-187
CrossRef1203
Kenneth A Alexander, William C Phelps. (2000) Recent advances in diagnosis and therapy of human papillomaviruses. Expert Opinion on Investigational Drugs 9:8, 1753-1765
CrossRef1204
Claude Souvignet, Jean-Pierre Zarski. (2000) Combination treatment for chronic hepatitis C: what is the role of ribavirin?. Fundamental & Clinical Pharmacology 14:4, 321-325
CrossRef1205
M. Wright, J. Main, H.C. Thomas. (2000) Drug-resistant Viral Hepatitis. Journal of Infection 41:1, 1-4
CrossRef1206
Giulia Morsica, Anna De Bona, Caterina Uberti Foppa, Giovanni Sitia, Renato Finazzi, Adriano Lazzarin. (2000) Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. AIDS 14:11, 1656-1658
CrossRef1207
Lee. (2000) Hepatitis C infection and its management. Haemophilia 6:s1, 133-137
CrossRef1208
Trepo. (2000) Genotype and viral load as prognostic indicators in the treatment of hepatitis C. Journal of Viral Hepatitis 7:4, 250-257
CrossRef1209
Héiène Fontaine, Marie-Laure Chaix, Jean-Luc Lagneau, Christian Bréchot, Stanislas Pol. (2000) Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. The Lancet 356:9223, 41
CrossRef1210
Al-Faleh, Aljumah, Rezeig, , Al-Otaibi, Alahdal, Al-Humayed, Mayet, Al-Juhani, Al-Karawi, George, Sbeih. (2000) Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. Journal of Viral Hepatitis 7:4, 287-291
CrossRef1211
Stephen Pianko, John G McHutchison. (2000) Treatment of hepatitis C with interferon and ribavirin. Journal of Gastroenterology and Hepatology 15:6, 581-586
CrossRef1212
Debbie M. Cheng, Stephen W. Lagakos. (2000) The One-Sample Problem from Eradication Studies of Chronic Viral Infections. Biometrics 56:2, 626-633
CrossRef1213
Garth E. Austin, Bette Jensen, Jean Leete, William De l???Aune, Julu Bhatnagar, Michele Racine, Joshua E. Braun. (2000) Prevalence of Hepatitis C Virus Seropositivity among Hospitalized US Veterans. The American Journal of the Medical Sciences 319:6, 353-359
CrossRef1214
John B. Wong, Thierry Poynard, Mei-Hsiu Ling, Janice K. Albrecht, Stephen G. Pauker, . (2000) Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis c. The American Journal of Gastroenterology 95:6, 1524-1530
CrossRef1215
Stephen Pianko, John McHutchison. (2000) Retreatment of hepatitis C patients who do not respond to interferon: the search continues. The American Journal of Gastroenterology 95:5, 1122-1124
CrossRef1216
C. McMahon, R. Pilkington, E. O. Shea, D. Kelleher, O. P. Smith. (2000) Liver biopsy in Irish hepatitis C-infected patients with inherited bleeding disorders. British Journal of Haematology 109:2, 354-359
CrossRef1217
Damien Mallat, Eugene Schiff. (2000) Viral hepatitis. Current Opinion in Gastroenterology 16:3, 255-261
CrossRef1218
Mandana Khalili, Cheryl Denham, Robert Perrillo. (2000) Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. The American Journal of Gastroenterology 95:5, 1284-1289
CrossRef1219
Michael D. Sintchak, Elmar Nimmesgern. (2000) The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 47:2-3, 163-184
CrossRef1220
Blatt, Mutchnick, Tong, Klion, Lebovics, Freilich, Bach, Smith, Herrera, Tobias, Conrad, Schmid, McHutchison. (2000) Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. Journal of Viral Hepatitis 7:3, 196-202
CrossRef1221
Anuchit Chutaputti. (2000) Adverse effects and other safety aspects of the hepatitis C antivirals. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E156-E163
CrossRef1222
Yasushi Shiratori, Masao Omata. (2000) Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course?. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E141-E151
CrossRef1223
Cotler, Wartelle, Larson, Gretch, Jensen, Carithers Jr. (2000) Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. Journal of Viral Hepatitis 7:3, 211-217
CrossRef1224
Edward Gane. (2000) Pre- and post-transplant treatment of hepatitis C. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E187-E193
CrossRef1225
Paul Glue, Steven Schenker, Samir Gupta, Robert P. Clement, Demetris Zambas, Margaret Salfi. (2000) The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. British Journal of Clinical Pharmacology 49:5, 417-421
CrossRef1226
Ming-Yang Lai. (2000) Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E130-E133
CrossRef1227
Wan-Cheng Chow. (2000) Hepatitis C: Retreatment and treatment of patients with renal failure. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E152-E155
CrossRef1228
Paul Desmond. (2000) Where does treatment fit into the strategy to control hepatitis C?. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E123-E125
CrossRef1229
G.R Foster, H.C Thomas. (2000) Therapeutic options for HCV—management of the infected individual. Best Practice & Research Clinical Gastroenterology 14:2, 255-264
CrossRef1230
Stephanos J Hadziyannis, Dimitrios Vassilopoulos. (2000) Complex management issues: management of HCV in the atypical patient. Best Practice & Research Clinical Gastroenterology 14:2, 277-291
CrossRef1231
George Webster, Eleanor Barnes, David Brown, Geoffrey Dusheiko. (2000) HCV genotypes—role in pathogenesis of disease and response to therapy. Best Practice & Research Clinical Gastroenterology 14:2, 229-240
CrossRef1232
Claudio Zavaglia, Aldo Airoldi, Giovambattista Pinzello. (2000) Antiviral Therapy of HBV- and HCV-induced Liver Cirrhosis. Journal of Clinical Gastroenterology 30:3, 234-241
CrossRef1233
Lo Iacono, Castro, Diago, Moreno, Fernandez-Bermejo, Vega, Garcia, Carbonell, Sanz, Borque, Garcia-Buey, Garcia-Monzon, Pedreira, Moreno-Otero. (2000) Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. Alimentary Pharmacology and Therapeutics 14:4, 463-469
CrossRef1234
Angelo deMattos, Hugo R. Rosen. (2000) Histopathological Features of Hepatitis C in Renal Transplant Candidates. Transplantation 2000; 69: 1479.. Transplantation 69:7, 1236-1237
CrossRef1235
Berwyn E. Clarke. (2000) New drugs for hepatitis C virus (HCV). Best Practice & Research Clinical Gastroenterology 14:2, 293-305
CrossRef1236
Jan-Olof Svensson, Annette Bruchfeld, Robert Schvarcz, Lars Ståhle. (2000) Determination of Ribavirin in Serum Using Highly Selective Solid-Phase Extraction and High-Performance Liquid Chromatography. Therapeutic Drug Monitoring 22:2, 215-218
CrossRef1237
Mark S. Sulkowski, Eric E. Mast, Leonard B. Seeff, David L. Thomas. (2000) Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases 30:s1, S77-S84
CrossRef1238
Orla M. Crosbie, Graeme J.M. Alexander. (2000) Liver transplantation for hepatitis C virus related cirrhosis. Best Practice & Research Clinical Gastroenterology 14:2, 307-325
CrossRef1239
W. Ray Kim, John J. Poterucha. (2000) Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C. Hepatology 31:3, 807-808
CrossRef1240
Robert J. Fontana, Jonathan Israel, Paula LeClair, Barbara F. Banner, Kristina Tortorelli, Norman Grace, Robert A. Levine, Gale Fiarman, Michael Thiim, Anthony S. Tavill, Herbert L. Bonkovsky. (2000) Iron reduction before and during interferon therapy of chronic hepatitis
CrossRef1241
David Gretch. (2000) Standardization of hepatitis C virus-RNA quantification: Advances and unfinished business. Hepatology 31:3, 788-789
CrossRef1242
B. Christensson, T. Wiebe, A. Akesson, A. Widell. (2000) Interferon- and Ribavirin Treatment of Hepatitis C in Children with Malignancy in Remission. Clinical Infectious Diseases 30:3, 585-586
CrossRef1243
Dennis G. Macejak, Kristi L. Jensen, Sharon F. Jamison, Kristal Domenico, Elisabeth C. Roberts, Nilabh Chaudhary, Ira von Carlowitz, Laurent Bellon, Myron J. Tong, Andrew Conrad, Pamela A. Pavco, Lawrence M. Blatt. (2000) Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 31:3, 769-776
CrossRef1244
Steedman A. Sarbah, Zobair M. Younossi. (2000) Hepatitis C. Journal of Clinical Gastroenterology 30:2, 125-143
CrossRef1245
Alice Birkel, Linda Caldwell, Valerie Stafford-Fox, Beverley Casarico, Laura Benson. (2000) Combination Interferon alfa-2b/Ribavirin Therapy for the Treatment of Hepatitis C: Nursing Implications. Gastroenterology Nursing 23:2, 55-62
CrossRef1246
Mich
CrossRef1247
Michael A. Poles, Douglas T. Dieterich. (2000) HIV and hepatitis virus infection. Current Infectious Disease Reports 2:2, 177-184
CrossRef1248
David W. Haas, James Lavelle, Jeffrey P. Nadler, Stephen B. Greenberg, Peter Frame, Norman Mustafa, Marty St. Clair, Ray McKinnis, Lynn Dix, Mary Elkins, James Rooney. (2000) A Randomized Trial of Interferon alpha Therapy for HIV Type 1 Infection. AIDS Research and Human Retroviruses 16:3, 183-190
CrossRef1249
Mark P. Epstein, Tamsin Knox. (2000) Current views on hepatitis C virus infection. Current Infectious Disease Reports 2:1, 55-60
CrossRef1250
Matthew E. Cramp, Siegbert Rossol, Shilpa Chokshi, Patrizia Carucci, Roger Williams, Nikolai V. Naoumov. (2000) Hepatitis C virus–specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118:2, 346-355
CrossRef1251
Shields, Mutimer, Muir, Skidmore, Britnell, Roberts, Wilde. (2000) Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders. British Journal of Haematology 108:2, 254-258
CrossRef1252
Gary L. Davis. (2000) Current therapy for chronic hepatitis C. Gastroenterology 118:2, S104-S114
CrossRef1253
P. Halfon, P. Cacoub. (2000) Quantification virale du virus de l'hépatite C : présent et avenir. La Revue de Médecine Interne 21:2, 174-181
CrossRef1254
Michael A. Poles, Douglas T. Dieterich. (2000) HIV and hepatitis virus infection. Current Infectious Disease Reports 2:1, 1-8
CrossRef1255
NOBUYUKI KATO. (2000) Genome of Human Hepatitis C Virus (HCV): Gene Organization, Sequence Diversity, and Variation. Microbial & Comparative Genomics 5:3, 129-151
CrossRef1256
Thierry Poynard, John McHutchison, Zachary Goodman, Mei-Hsiu Ling, Janice Albrecht. (2000) Is an ?
CrossRef1257
Clodoveo Ferri, Anna Linda Zignego. (2000) Relation between infection and autoimmunity in mixed cryoglobulinemia. Current Opinion in Rheumatology 12:1, 53-60
CrossRef1258
Masao Honda, Shuichi Kaneko, Eiki Matsushita, Kenichi Kobayashi, Geoffrey A. Abell, Stanley M. Lemon. (2000) Cell cycle regulation of hepatitis C virus internal ribosomal entry site–directed translation. Gastroenterology 118:1, 152-162
CrossRef1259
MADHUMITA SINHA, ANANYA DAS. (2000) Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. The Pediatric Infectious Disease Journal 19:1, 23-30
CrossRef1260
Robert L. Carithers. (2000) Liver transplantation. Liver Transplantation 6:1, 122-135
CrossRef1261
Alba Magalini, Massimo Puoti, Valeria Putzolu, Eugenia Quiros-Roldan, Maria Antonia Forleo, Stefania Rossi, Serena Zaltron, Angiola Spinetti, Barbara Zanini, Antonella Zonaro, Roberto Solfrini, Giampiero Carosi. (2000) Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month. Journal of Clinical Laboratory Analysis 14:3, 120-124
CrossRef1262
Gregory J. Moran. (2000) Emergency department management of blood and body fluid exposures. Annals of Emergency Medicine 35:1, 47-62
CrossRef1263
Masanori Ikeda, Akito Nozaki, Kazuo Sugiyama, Torahiko Tanaka, Atsushi Naganuma, Katsuaki Tanaka, Hisahiko Sekihara, Kunitada Shimotohno, Masaki Saito, Nobuyuki Kato. (2000) Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Research 66:1, 51-63
CrossRef1264
Paul Y. Kwo. (2000) Treatment of chronic hepatitis C in nonresponders to interferon monotherapy. Current Gastroenterology Reports 2:1, 11-17
CrossRef1265
Marcelo A. Costa, Eugene R. Schiff. (1999) Hepatitis C. Current Treatment Options in Gastroenterology 2:6, 481-489
CrossRef1266
Laurent Cast
CrossRef1267
M R Keating. (1999) Antiviral agents for non-human immunodeficiency virus infections.. Mayo Clinic Proceedings 74:12, 1266-1283
CrossRef1268
Cinda H. Clark, Reem H. Ghalib. (1999) Hepatitis C: Role of the Advanced Practice Nurse. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 10:4, 455-463
CrossRef1269
Zobair M. Younossi, Mendel E. Singer, John G. McHutchison, Kenneth M. Shermock. (1999) Cost effectiveness of interferon ?2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 30:5, 1318-1324
CrossRef1270
Andreas Ambrosch, Wolfgang König. (1999) Charakteristika des Hepatitis-C-Virus und virale Prädiktoren der therapeutischen Intervention. Medizinische Klinik 94:11, 626-632
CrossRef1271
Michael A. Walker. (1999) Hepatitis C virus: an overview of current approaches and progress. Drug Discovery Today 4:11, 518-529
CrossRef1272
J. G. McHutchison, G. Giannelli, L. Nyberg, L. M. Blatt, K. Waite, P. Mischkot, S. Pianko, A. Conrad, P. Grint. (1999) A Pilot Study of Daily Subcutaneous Interleukin-10 in Patients with Chronic Hepatitis C Infection. Journal of Interferon & Cytokine Research 19:11, 1265-1270
CrossRef1273
Dienstag, Jules L., Schiff, Eugene R., Wright, Teresa L., Perrillo, Robert P., Hann, Hie-Won L., Goodman, Zachary, Crowther, Lynn, Condreay, Lynn D., Woessner, Mary, Rubin, Marc, Brown, Nathaniel A., . (1999) Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. New England Journal of Medicine 341:17, 1256-1263
Full Text1274
Xavier Forns, Robert H Purcell, Jens Bukh. (1999) Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends in Microbiology 7:10, 402-410
CrossRef1275
Abdelmajid Sabile, Gabriel Perlemuter, Fulvia Bono, Kyoko Kohara, France Demaugre, Michinori Kohara, Yoshiharu Matsuura, Tatsuo Miyamura, Christian Br
CrossRef1276
Christian Trépo, Fabien Zoulim, Pierre Pradat. (1999) Viral hepatitis. Current Opinion in Infectious Diseases 12:5, 481-490
CrossRef1277
Etienne M. Sokal, Flavia Bortolotti. (1999) Update on prevention and treatment of viral hepatitis in children. Current Opinion in Pediatrics 11:5, 384-389
CrossRef1278
Vogt, Manfred, Lang, Thomas, Frösner, Gert, Klingler, ChristianeSendl, Anna F., Zeller, AnitaWiebecke, Baldur, Langer, Barbara, Meisner, Hans, Hess, John, . (1999) Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor Screening. New England Journal of Medicine 341:12, 866-870
Full Text1279
Nieves Ibarrola, José A. Moreno-Monteagudo, Margarita Sáiz, Carmelo García-Monzón, Francisco Sobrino, Luisa García-Buey, Oreste Lo Iacono, Ricardo Moreno-Otero, Encarnación Martínez-Salas. (1999) Response to retreatment with interferon-? plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence. The American Journal of Gastroenterology 94:9, 2487-2495
CrossRef1280
M. Gerotto, F. Dal Pero, D. G. Sullivan, L. Chemello, L. Cavalletto, S. J. Polyak, P. Pontisso, D. R. Gretch, A. Alberti. (1999) Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-α. Journal of Viral Hepatitis 6:5, 367-372
CrossRef1281
J. M. Pawlotsky, G. Germanidis. (1999) The non-structural 5A protein of hepatitis C virus. Journal of Viral Hepatitis 6:5, 343-356
CrossRef1282
K. Rajender Reddy, Jay H. Hoofnagle, Myron J. Tong, William M. Lee, Paul Pockros, E. Jenny Heathcote, Donald Albert, Tenshang Joh. (1999) Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 30:3, 787-793
CrossRef1283
Hugo R Rosen, David R Gretch. (1999) Hepatitis C virus: current understanding and prospects for future therapies. Molecular Medicine Today 5:9, 393-399
CrossRef1284
FF Poordad, RG Gish. (1999) Development in hepatitis C during 1997 - 1999. Expert Opinion on Therapeutic Patents 9:9, 1249-1262
CrossRef1285
Thomas M. Shehab, Seema S. Sonnad, Mark Jeffries, Naresh Gunaratnum, Anna S. Lok. (1999) Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology 30:3, 794-800
CrossRef1286
Alter, Miriam J., Kruszon-Moran, Deanna, Nainan, Omana V., McQuillan, Geraldine M., Gao, Fengxiang, Moyer, Linda A., Kaslow, Richard A., Margolis, Harold S., . (1999) The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994. New England Journal of Medicine 341:8, 556-562
Full Text1287
Nina Singh. (1999) Infections in solid organ transplant recipients. Current Opinion in Infectious Diseases 12:4, 365-370
CrossRef1288
Solko W. Schalm, Ola Weiland, Bettina E. Hansen, Michele Milella, Ming Y. Lai, Anna Hollander, Peter P. Michielsen, Antonio Bellobuono, Liliana Chemello, Giuseppe Pastore, Ding–Shinn Chen, Johannes T. Brouwer. (1999) Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Gastroenterology 117:2, 408-413
CrossRef1289
Dan Li, Scott Friedman. (1999) Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy. Journal of Gastroenterology and Hepatology 14:7, 618-633
CrossRef1290
Michael R. Beard, Geoffrey Abell, Masao Honda, Anthony Carroll, Margaret Gartland, Berwyn Clarke, Koyu Suzuki, Robert Lanford, David V. Sangar, Stanley M. Lemon. (1999) An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology 30:1, 316-324
CrossRef1291
Regino P González-Peralta, George J Galasso, Thierry Poynard, Solko Schalm, Howard C Thomas, Teresa L Wright. (1999) Summary of the first international symposium on viral hepatitis. Antiviral Research 42:2, 77-96
CrossRef1292
F Begemann, H Jablonowski. (1999) Enhancing the response to interferon-α. Journal of Clinical Virology 13:1-2, 1-7
CrossRef1293
Sammy Saab, Paul Martin. (1999) Hemolytic Anemia and the Treatment of Chronic Hepatitis C. Journal of Clinical Gastroenterology 28:4, 289-290
CrossRef1294
Arie Regev, Eugene R. Schiff. (1999) Viral hepatitis. Current Opinion in Gastroenterology 15:3, 234-239
CrossRef1295
Joanne Imperial. (1999) Natural history of chronic hepatitis B and C. Journal of Gastroenterology and Hepatology 14:5s, S1-S5
CrossRef1296
Harold J. Fallon. (1999) Hepatitis C: Implications for the general physician. Comprehensive Therapy 25:5, 253-257
CrossRef1297
(1999) Combination Therapy for Hepatitis C Infection. New England Journal of Medicine 340:15, 1207-1209
Full Text1298
F. Bricaire. (1999) Maladies infectieuses en 1998. La Revue de Médecine Interne 20:4, 365-368
CrossRef1299
Ince, Nedim, Wands, Jack R., . (1999) The Increasing Incidence of Hepatocellular Carcinoma. New England Journal of Medicine 340:10, 798-799
Full Text1300
D.R. Snydman. (1999) Infection in solid organ transplantation. Transplant Infectious Disease 1:1, 21-28
CrossRef1301
Gary L. Davis. (1999) Treatment of chronic hepatitis C: Impact of combination therapy. Current Gastroenterology Reports 1:1, 9-14
CrossRef1302
(1999) Public health, public trust, and public decision making: making hepatitis C virus lookback work. Transfusion 39:2, 123-127
CrossRef1303
Liang, T. Jake, . (1998) Combination Therapy for Hepatitis C Infection. New England Journal of Medicine 339:21, 1549-1550
Full Text
- Letters
